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SUMMARY
The principal aim of this study was to examine the feasibility and 
potential of an electrophoretically modulated constant current drug 
delivery device.
In addition to discussing the rationale for controlled drug delivery, 
the introduction reviews recent advances that have been made in this 
area. The skin is considered as a potential route for drug delivery, 
together with the properties and uses of poly(2-hydroxyethyl 
methacrylate) (PHEMA) as a material for use in drug delivery devices. 
The experimental work is divided into three sections, dealing with 
the characterization of materials and especially the properties of 
PHEMA polymer films; investigation of the use of low constant 
currents to control the transport of a model drug (propranolol HC1 
(PHC)) through films of PHEMA; and lastly an investigation of a model 
transdermal electrophoretic device.
PHEMA was prepared by chemically initiated polymerization and some of 
its physico-chemical properties examined. The diffusion of PHC 
through films of crosslinked PHEMA was investigated and found to be 
anomalous with respect to previously reported behaviour. The 
adsorption isotherm of PHC on PHEMA in aqueous solution indicated an 
interaction between PHC and PHEMA. The relationship between the 
anomalous diffusion behaviour of PHC through PHEMA films and the 
interaction between PHC and PHEMA was examined, in particular the 
involvement of negatively charged sites in PHEMA. It was found that 
charged ionic sites in PHEMA could only partly explain the anomalous
diffusion behaviour of PHC and the interaction in solution between 
PHC and PHEMA.
The use of low constant currents (0 to 2.4 mA) to control the
transport of PHC across films of PHEMA was examined. An automated 
model system was developed where flexible control over
electrophoresis and data collection was demonstrated. It was found 
that the transport of PHC through PHEMA films could be modulated 
predictably and reproducibly in a positive or negative manner. The 
degradation of PHC during electrophoresis was investigated. Several 
factors affecting the electrophoretic transport of PHC such as PHEMA 
crosslinker content, ionic strength and temperature were also 
investigated. Application of an electrophoretic current during the 
diffusion lag time was found to produce a different effect to that
found when electrophoresis was carried out during steady state
diffusion. It was demonstrated that feedback control could be used 
to effect the release of PHC using a computer-controlled model 
system.
The permeability coefficient of PHC through hairless mouse skin was 
determined and the effect of two permeation enhancers (sodium dodecyl 
sulphate and Azone) on the transport of PHC through hairless mouse 
skin examined. The information derived from these experiments was 
used to investigate an in vitro model of a transdermal 
electrophoretic device. The model used indicated that controlled drug 
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1.1 Evolution of Drug Delivery Devices
Drug delivery devices may be broadly subdivided into three 
categories, firstly, the conventional single dose or bolus medicine, 
secondly the constant release type of device which contain the 
equivalent of several single doses and where the drug delivery rate 
is a simple function of time (eg. t°, t-1/2 or t1), and finally the 
controlled drug delivery device where the rate may be modulated to 
provide an ever-changing drug delivery profile. The historical 
development of these groups of devices reflects the awareness that 
has developed regarding the therapeutic importance of dosage forms, 
the optimum therapeutic effect of many drugs is dependent on the form 
and delivery rate as much as on the intrinsic pharmacological 
activity of the drug [1], It has become clear that the use of 
conventional dosage forms has- resulted in many drugs not realizing 
their full therapeutic potential [1]. In addition to development of 
new dosage forms occurring exclusively as a result of therapeutic 
requirements, it is also the case that industry has invested heavily 
in a search for new dosage forms due to the enormous expense involved 
in developing new drug entities [2,3,4].
The route by which delivery devices administer drug to the 
body has also been an area of intense research interest [1,5,6]. The 
majority of present dosage forms are administered via the oral route; 
however other routes of administration are also used and these 
include ocular, rectal, nasal, pulmonary and transdermal applications 
[1]. Of these routes, a disproportionate research interest has been 
shown recently in the transdermal route, due to the significant 
potential advantages of transdermal delivery (section 1.5).
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Many controlled drug delivery devices rely on polymers as a 
major component [1,7,8]. New polymeric materials are continuously 
being developed to add to the extensive range of polymers which 
researchers in the field already have at their disposal [9,10,11].
The unique physico-chemical or biochemical properties' that individual 
polymeric materials offer have been exploited in the development of 
many drug delivery devices. A polymer that has been examined as a 
component in a number of drug delivery devices is poly(2-hydroxyethyl 
methacrylate) (PHEMA), this polymer will be discussed below in 
section 1.6.
1.2 Rationale for Controlled Drug Delivery
The most common types of drug delivery device currently used 
are based on the conventional repeated single dose or bolus type of 
delivery, the oral route of delivery being the primary route of 
administration of these devices. The most popular of these dosage 
forms are tablets, accounting for approximately 70% of all ethical 
pharmaceutical preparations produced [12]. However, included amongst 
the many other conventional dosage forms are solutions, suspensions, 
creams, ointments, inhalation aerosols, suppositories, pessaries and 
bolus injections. These conventional dosage forms can suffer from a 
number of therapeutic disadvantages [1,5,6,13-16]. A disadvantage 
which is also shared by most types of conventional medicines or newly 
developed drug delivery devices is that drug delivered by such dosage 
forms often acts systemically as well as on a specific target. 
Although the disadvantages associated with the use of non-targeted 
drug delivery are often not therapeutically significant and at worst 
result in the occurrence of only minor side effects, with certain
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drugs such as those with cytotoxic action, unwanted side effects are 
a major problem with non-targeted delivery [17], A number of 
approaches have been attempted as a means of targeting drugs to 
specific sites in order to avoid systemic side effects, some of these 
methods include the use of monoclonal antibodies [18,19], soluble 
polymers [20], and liposomes [21]. If research into drug targeting is 
successful, there will be an obvious need for suitable drug delivery 
devices. A major problem that is also shared by both conventional 
delivery devices and newly researched delivery devices concerns 
administration via the oral route. Orally administered drugs, once 
absorbed, pass through the hepatic system where they are susceptible 
to metabolism; this phenomenon is known as the first-pass effect. 
First-pass metabolism, as well as being potentially extensive, can 
result in a great variation in therapeutic drug concentrations 
between individuals and it is this major problem which has prompted 
workers to investigate other routes of administration, one of which, 
the transdermal route (section 1.5), has received widespread 
attention in recent years. A major problem with conventional delivery 
devices that has been recognised regards patient compliance with 
dosage regimes; an example of this concerns digoxin therapy where 
significant differences were found in plasma digoxin levels between 
compliant and non-compliant patients [22]. Examples can be found 
amongst drugs in common use which possess considerable therapeutic 
potential, yet frequently remain unused or underutilized when thqrapy 
would be too complex or burdensome for the patient [1],
Probably the main disadvantage associated with the use of 
existing medicines regards the plasma drug concentration profile 
produced by many of these conventional dosage forms. This problem has
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become a significant driving force for research focussing on new drug 
delivery methods. When a single oral dose is administered, an initial 
burst of plasma drug levels occurs which may exceed the toxic level 
of the drug, the plasma level of drug then decays to a value below 
the minimum effective concentration [1,13]. It is apparent that the 
plasma drug levels may therefore be within the optimum therapeutic 
levels, the so called therapeutic window, for a relatively short 
period of time compared to the total time of residence of drug within 
the body. In order to maintain therapeutic levels of drug, repeated 
administration of the dosage form is required. Depending on the 
pharmacokinetics of a drug, particularly its biological half life, 
repeated administration of a single dose can result in a 
characteristic see-saw variation of plasma drug levels. The plasma 
drug levels oscillate within the therapeutic window, but allowing 
periods when a toxic level may be maintained, and also periods where 
the concentration may be below the minimum effective concentration 
[13]. This has precluded the clinical use of many promising drugs 
with very short biological half-lives or very narrow therapeutic 
indices [23]. Constant release delivery devices were developed 
primarily to avoid this type of see-saw effect and thus maintain 
constant plasma levels within the therapeutic window [1], A review by 
Urquhart [23] considers the therapeutic consequences of having the 
see-saw type of variation in plasma drug levels found with most 
conventional delivery devices. It should be emphasized, however, that 
theoretically constant drug plasma levels may be obtained with 
conventional bolus dosage forms if the dose quantity and frequency 
were adjusted appropriately, but this would require dosing to be so 
frequent for most drugs that such an approach would be impractical
- 5 -
and disadvantageous [23]. Conventional drug delivery forms are often 
sensitive to environmental factors [6], for example, oral dosage 
forms, where the drug delivery rate may be affected by such factors 
as gastric motility and pH [6,24]. Constant release devices are 
designed to maintain constant plasma drug levels for periods of days, 
months or even years [25], and also to overcome some of the
disadvantages associated with conventional delivery devices, which 
have already been discussed. An example where decreased side effects 
may be produced by maintaining a steady plasma level is the
formulation of hyoscine hydrobromide as a transdermal delivery system 
known as the Scopoderm TTS device [1]. The side effects produced by 
conventional medicines containing hyoscine HBr such as dryness of the 
mouth, dizziness, tachycardia and drowsiness are found at a lower 
level of incidence with the transdermal device, although the TTS is
equally effective in the treatment of motion sickness [1,26]. The use 
of constant release devices could also lead to less wastage of drug 
as a result of more efficient drug delivery, which may be of 
particular importance with expensive drugs. However, it should be 
remembered that many novel constant delivery devices are expensive to 
fabricate which may be a limiting factor in their extensive 
therapeutic use. There are a number of potential problems however 
with constant release drug delivery devices. Many devices are based 
on polymeric materials, which may present problems due to low
biocompatibility, particularly with regard to their use in implant 
devices [27,28,29]. These devices will inevitably have a reservoir 
holding a potentially fatal dose of drug if accidentally released all 
at once. Prevention of such "dose dumping" from these devices must be 
guaranteed, as must be the reproducibility and predictability of drug
- 6 -
release [30]. Another problem, which applies particularly to 
implants, is that it will probably not be possible to reduce or 
terminate drug delivery immediately if so required.
Constant delivery devices offer considerable advantages over 
conventional drug delivery devices as has been described; however, 
for certain drugs, constant delivery rates may still not be the 
optimum manner of delivery. The advent of therapeutically potent 
peptides, polypeptides and proteins [31] suggest that these 
potential new drugs are likely to require delivery to the body in a 
precisely controlled manner which may be optimum when delivery 
mirrors physiological release profiles [31,32,33]. In addition 
peptides possess several properties which require special attention 
in the development of ■ delivery devices [34]. An example where 
controlled drug delivery may be desirable is with insulin therapy: 
normal human pancreatic beta-cells modulate the secretion of insulin 
into the hepatic portal vein, dependent on the bodies demands on 
glucose, in order to maintain normoglycaemia. Conventional 
subcutaneous therapy used in the treatment of diabetes cannot 
maintain such control and stability [35]. Many of the long term 
complications that diabetics are prone to such as cardiovascular 
problems and neuropathies have been associated with poor control over 
glucose levels that conventional therapy provides, and evidence 
suggests that these complications may be delayed or decreased by 
insulin delivery systems which normalise glucose levels over a 
narrower range [36-41]. In order to improve therapy for diabetics, 
true controlled drug delivery devices are required where insulin 
output can be modulated. There are already a number of infusion pumps 
used for insulin therapy (section 1.3.6), and other suitable devices
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are being investigated [42,43,44]. The ultimate goal must be for an 
artificial pancreas, where the output of a controlled delivery device 
is in response to feedback signals provided by a reliable glucose 
sensor.
The therapeutic benefits resulting from the use of true 
controlled delivery devices is also becoming evident from the results 
of current research which seems to indicate that the biological 
response to a given drug may vary according to the bodies circadian 
rhythms; a review by Pauly [45] presents the basis for research in 
this area of research, known as chronopharmacology. 
Chronopharmacologists have reported data which indicates that the 
absorption, metabolism and effects of various medicaments are likely 
to vary predictably with time, and it is being questioned whether 
constant plasma drug levels are necessarily the ideal for many drugs 
[45-48]. Controlled drug delivery devices able to respond to the 
bodies chronergy could result in drugs being used more effectively.
Propranolol HCl is a drug that may be a suitable candidate for 
a controlled drug delivery device. Conventional oral dosage forms of 
propranolol HCl are not entirely satisfactory due to low 
bioavailability and variability in plasma levels within individuals 
due to extensive first-pass metabolism [49,50,51]. Ideally a delivery 
route avoiding the hepatic circulation would thus be preferable. 
Controlled drug delivery of propranolol HCl may also be desirable as 
it has been reported that chronopharmacokinetic variations for 
propranolol HCl occur in man [52,53], as well as circadian 
rhythmicity in cardiovascular functions [46].
In 1971, the president of the Alza Corporation predicted that 
controlled drug delivery systems acting as artificial glands with
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their own sense detecting feedback control would be developed in 
about 10 years [54]. Whilst his prediction has not yet been fully 
realized due to technology restraints, advances have been made since 
the statement was made in 1971 and it can certainly be envisaged that 
feedback controlled delivery devices could be used clinically within 
the next decade.
1.3 Constant and Controlled Drug Delivery Devices
A number of different techniques have been examined as 
potential methods for producing constant and controlled drug delivery 
devices. In this section a comparison of some of the various systems 
that are being currently researched or that have been successfully 
utilised to provide constant and controlled drug delivery are 
examined; however, most of the systems which will be discussed are 
still largely experimental.
1.3.1 Polymer Reservoir Systems
Polymer reservoir devices were one of the first types of 
constant delivery devices to be developed, they are usually composed 
of a drug reservoir encapsulated by a rate controlling polymeric 
membrane of well defined thickness [1,5,15,25,55,56]. The release of 
drugs from reservoir devices is governed by Fick's first law of 
diffusion, the rate of release being theoretically zero-order given 
that the activity of drug in the reservoir remains constant. However, 
once the drug reservoir starts to deplete, then the delivery rate 
decreases in a manner similar to first-order release [55]. The 
factors affecting the release rate from this type of device include 
the chemical and physical nature of the polymer membrane selected and
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its thickness, the surface area of the device, and the solubility of 
the drug in the polymer membrane, assuming the diffusion coefficient 
of the drug is constant and that there are no stationary layers on 
the surface of the device [5,25,57]. There may be a 'burst' of drug 
release when these types of devices are used initially due to the 
rate controlling membrane being saturated with drug, however the 
delivery rate does subsequently stabilize and the release rate 
eventually becomes zero-order. A number of reservoir devices have 
been used clinically and these notably include the Progestasert 
device for the localized constant delivery of progesterone, the 
Transiderm Nitro patch for glyceryl trinitrate release, and the first 
clinically developed device, Ocusert [1,5,15,58]. The advantage of 
reservoir devices are that zero-order release kinetics are possible, 
however the disadvantages include the fact that these systems are 
generally not biodegradable and also leaks in the polymer membrane 
are potentially dangerous since "dose dumping" may occur [25]. A 
previously cited disadvantage of reservoir devices is that they are 
not suitable for the delivery of large molecules such as peptides 
[15,34], however, it has been reported that hydrogel copolymer 
membranes can be used as rate limiting membranes for the release of 
peptides [59].
1.3.2 Polymer Matrix Systems
Polymer matrix systems (monoliths) are constant delivery type 
devices, composed of a drug dispersed within an insoluble polymer 
matrix [5,15,25,30,60,61]. As with reservoir devices (section 1.3.1) 
the release of drugs is diffusion controlled and governed by Fick's 
first law of diffusion, however, whereas in the reservoir device the
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concentration across a unit thickness of membrane may be constant, 
with a matrix system the concentration gradient is time dependent. 
This can be seen if the flat surface on a rectangular slab of a 
monolith device is considered, in which the drug is immobilised. If 
the drug is considered to be eluted a layer at a time (the drug must 
first dissolve before diffusing out), then the outermost layer of the 
device elutes first, then once this layer becomes exhausted, drug in 
the next layer starts to be depleted, thus the path length of 
diffusion increases with time and the concentration gradient 
decreases progressively [62,63]. For this simple type of device the 
result is a time dependent release rate, which is linearly related to 
time-1/2 [62,64]. The actual equation describing release from matrix 
devices will depend on a number of factors [30,61], including the 
type of matrix device, the geometry and the initial drug loading. 
Examples of the types of matrix devices include dissolved matrix 
devices where the drug is dissolved in the matrix at a concentration 
below its saturation solubility, there is also the dispersed matrix 
device where the drug is dispersed as discrete solid particles within 
the polymer. A similar type of device to the dispersed matrix is the 
porous matrix where drug is also dispersed within the polymer at a 
concentration greater than its saturation solubility, however, in 
this type of device the drug particles form contiguous channels 
through the matrix. A final example of a matrix device are surface 
treated devices where a core of drug dispersed in polymer is 
surrounded by a surface layer which is of lower permeability to drug 
than the core. Reviews of the equations applicable to these systems 
and others can be found [15,30,62,64], however they are all based on 
the equation developed by Higuchi to describe the release of drugs
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from an ointment base [63]. A number of assumptions are made in the 
derivation of these equations [30,65], for example, it is assumed 
that the diffusion coefficient remains constant during release and 
that sink conditions prevail in the release medium which will not 
always be the case.
Some of the cited advantages of matrix devices include their 
ease of manufacture, and also the fact that on accidental rupture 
there is less chance of a potentially dangerous release of drug 
occurring unlike reservoir type devices [30]. One of the 
disadvantages of matrix devices is that the release rate is time 
dependent [30], however it is possible to get near zero-order release 
in certain cases. One approach is to use surface treated devices 
[30], another method involves the use of hemispherical devices coated 
with an impermeable coat except for an exposed cavity in the centre 
face of the device [66]. Zero-order release may also occur from 
matrix devices if the boundary layer around the matrix becomes the 
rate limiting step in drug release, which would occur for instance 
when the drug is more soluble in the device than in the dissolution 
medium, or when the diffusion coefficient in the boundary layer is 
very low [30,60].
Matrix devices can be engineered to enable the release of 
macromolecules such as insulin [43]. This has been demonstrated by 
the solvent casting of normally impermeable polymers such as 
ethylene-vinyl acetate copolymer in volatile solvents along with 
powdered macromolecules [67,68]. This results in the formation of a 
series of interconnecting channels large enough to permit 
macromolecular release over a prolonged period.
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Another type of matrix device is the so called 
swelling-controlled system where diffusion may not be the sole 
mechanism controlling release [15,69,70,71]. In this device drug is 
dispersed in a glassy polymer matrix, where no diffusion can occur in 
the solid phase. When a solvent such as water penetrates however the 
glass transition temperature is lowered and the swelling polymer 
becomes rubbery and allows drug diffusion outwards. Zero-order 
release may be obtained from this type of device.
1.3.3 Biodegradable Polymer Systems
Biodegradable devices are constant delivery type devices which 
employ the use of bioerodible polymers [5,72,73]. Polymer bioerosion 
can be defined as the conversion of a water insoluble material to 
one that is water soluble, this can be accomplished by hydrolysis, 
oxidation or other mechanisms of cleavage under enzymatic action 
[73]. The most obvious application for this type of device is as an 
implant. The mathematical treatment of the drug release from 
biodegradable matrix devices may be complex, since more than one 
mechanism can occur, such as the concurrent diffusion of drug out of 
the polymer matrix and release due to polymer degradation [5]. Other 
processes such as swelling may also occur which will further 
complicate any mathematical treatment of release kinetics [72,74].
The rates of polymer biodegradation can be varied, for example by 
copolymerization and by careful selection of polymer weight 
distribution [74,75]. Bioerosion may be classified according to three 
mechanisms [73], however in practice erosion is often a combination 
of these mechanisms. Type I erosion occurs when water-soluble 
polymers that have been insolubilized by covalent crosslinking
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undergo hydrolysis at either the crosslinks (Type IA erosion) or at 
the water-soluble backbone (Type IB erosion). Type II erosion occurs 
when water-insoluble macromolecules become water-soluble as a result 
of either hydrolysis, ionization or protonation of pendent groups.
Type III erosion occurs when high molecular weight water-insoluble 
macromolecules are converted to small water-soluble molecules by 
hydrolytic cleavage of labile bonds in the polymer backbone. The 
actual bioerosion process can be further defined as being either 
homogeneous or heterogeneous [76]. Heterogeneous erosion occurs only 
at the polymer surface and is sometimes termed surface erosion. 
Homogeneous erosion occurs throughout the bulk of the polymer matrix.
At least two approaches have been used in the development of 
implants based on biodegradable polymers [74,77]. The first is based 
on a reservoir device (section 1.3.1) where a drug reservoir is 
surrounded by a biodegradable rate controlling membrane. In order for 
the device to achieve zero-order drug release under diffusion 
control, significant bioerosion of the rate controlling membrane 
should not occur until the device has been depleted of drug. The 
second approach involves simply dispersing the drug in the 
biodegradable polymer matrix, from which drug is released as the 
result of bioerosion. Several reviews are available on release 
mechanisms from biodegradable devices and the various materials that 
have been examined, including polyesters and polyamides [3,74,76]. 
Many of the biomaterials used have been selected on the basis of 
their biocompatibility, furthermore these materials have tended to be 
hydrophilic and as a result homogeneous erosion may occur which tends 
to make the release process difficult to predict [15]. Zero-order 
release is theoretically possible from biodegradable devices if
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heterogeneous erosion is the only factor controlling drug release, 
and if the geometry used for the device is a slab [72]. In order to 
achieve zero-order release hydrophobic polyanhydrides have been 
investigated as potential biomaterials [78,79], and have recently 
been used clinically in the treatment of glioblastoma multiforme 
[80].
The advantages of biodegradable devices include those that 
polymer matrix devices possess (section 1.3.2), additionally, a major 
advantage is related to their use as implants since there is no need 
to remove the implant on exhaustion of the device, also adverse 
tissue reactions caused by foreign implants are less likely than a 
normal matrix device [5]. The disadvantages associated with the use 
of biodegradable devices include potential problems with 
biocompatibility of the non degraded polymer, the possible need for 
surgical implantation, and also the possible production of 
potentially toxic or irritant degradation products [5,72].
A potential type of delivery device related to biodegradable 
devices are pendent chain systems [25,81]. In these types of system, 
a drug is chemically bound to a polymer backbone (which may or may 
not be biodegradable) and is released by hydrolytic or enzymatic 
cleavage. In order to attain zero-order release the cleavage of drug 
from the polymer should be the rate-limiting step.
1-3.4 Stimuli Sensitive Polymer Systems
The use of stimuli sensitive polymers has aroused great 
interest in recent years due to their potential application as 
materials in controlled drug delivery systems. These polymers may 
respond to stimuli such as temperature changes, pH changes or to the
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presence of an enzyme or other specific chemical. The effect elicited 
by a stimulant may include a change in the permeability of the 
polymer or the release of an immobilized drug from the polymeric 
material. These materials would have obvious applications in many of 
the other types of device discussed in this chapter such as reservoir 
devices (section 1.3.1), matrix devices (section 1.3.2) and
biodegradable devices (section 1.3.3).
A recent review on chemically self-regulated drug delivery 
devices summarises some of the systems under investigation, including 
those being examined for potential use in insulin therapy [82]. The 
use of thermally responsive polymers [83,84] and pH responsive 
delivery devices have been reported [85,86,87]. The advantage of 
these stimuli sensitive systems are that potentially self-contained 
responsive controlled delivery devices are feasible. Devices where 
the release rate may be modulated by external stimuli such as a 
magnetic field, ultrasound or an electrophoretic current are 
discussed elsewhere (section 1.3.7, section 1.3.8, section 1.3.9).
An example of a stimulus sensitive device has been reported for 
the release of insulin from a matrix device [88]. The device 
described consists of an ethylene-vinyl acetate copolymer containing 
immobilized glucose oxidase and trilysyl insulin. The presence of 
glucose results in the production of gluconic acid which reduces the 
pH of the polymer microenvironment. The decrease in pH results in an 
increase in the solubility of the insulin and an observed reversible 
increase in the release rate of insulin was found.
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1.3.5 Osmotically Controlled Systems
Osmotically controlled systems, in their simplest forms, are a 
constant release type of device. The elementary osmotic pump consists 
of a water soluble core or reservoir containing drug surrounded by a 
semipermeable membrane, with a small delivery orifice of well defined 
size [89]. When placed in an aqueous medium, water diffuses into the 
device through the semipermeable membrane and forms a saturated 
solution of drug inside the device. The core imbibes water due to 
inequalities in osmotic pressure on either side of the semipermeable 
membrane. For a system of constant internal volume the device will 
deliver a volume of saturated drug solution over a period of time 
equal to the solvent volume uptake. The rate of solute release is 
zero-order as long as excess solid remains in the core, but the rate 
declines parabolically towards zero once the drug concentration 
within the device falls below saturation. Experimentally obtained 
results for this type of device closely agree with the theoretically 
predicted release. The actual magnitude of the release rate will be 
determined by the permeability of the membrane to water and the 
osmotic properties of the core. The size of the orifice is critical 
and must satisfy certain requirements if zero-order release is to 
occur [89]. This type of device offers a number of advantages, 
firstly zero-order release is possible at higher delivery rates than 
possible with matrix or reservoir type devices. The release rate in 
osmotic devices is less likely to be affected by environmental 
conditions such as stationary layers or by the pH of the environment 
then previously discussed devices.
Osmosin, an indomethacin osmotic device, was the first 
clinically used osmotic device, but was withdrawn due to cases of
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peptic ulceration, bleeding and perforation caused by adherence of 
the device to the gut wall resulting in local drug release [1]. 
Reviews of the various developments in the use and design of osmotic 
pumps can be found [1,4,23,90,91]. The use of stimuli sensitive 
polymers (section 1.3.4) has resulted in the development of 
potentially self-regulating osmotic pumps [86].
1.3.6 Infusion Pumps
Mechanical infusion pumps may be considered as either constant 
or controlled type delivery systems depending on their complexity. 
Three types of infusion pump for drug delivery can be distinguished, 
external devices, implantable devices and implantable devices with a 
specific sensor [92]. The latter system offers the opportunity for 
feedback control. Infusion pumps offer a number of advantages 
[25,93,94]. Delivery of drugs that are difficult to absorb or 
inactivated when ingested can be attained using infusion pumps, also 
drugs with very short biological half lives or complex dosage regimes 
may be delivered by infusion. The release from infusion pumps will in 
general be independent of the drugs physical, chemical and diffusive 
properties. These devices may also be designed to deliver drugs to 
specific sites or directly into the bloodstream. An advantage of 
internal over external pumps is the reduced risk of infection which 
is associated with chronic percutaneous access sites. The advantages 
of infusion pumps over other types of delivery device are that 
replenishment of the device may be a simple refill, also these 
systems allow the administration of large volumes of fluid and 
multiple drug therapies. The main disadvantages [25,93] of this type 
of device are cost, lack of portability for external pumps, and
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problems with biocompatibility. Drugs to be administered by infusion 
pumps must also be water soluble and hydrolytically stable. A major 
risk is the consequence of mechanical failure, which includes dumping 
of the drug reservoir and the clogging of pumps. The application of 
these systems to a number of medical conditions have been described 
in several reviews relating to their use in heart failure, diabetes 
and cancer therapy [1,93-99].
1.3.7 Magnetically Modulated Systems
There have been two main divisions in the application of
magnetism in drug delivery. One approach to using magnetism has 
involved drug targeting : drug either attached to or formulated with
a magnetic material is localized at an area of the body by
application of an external magnetic field [100,101]. Reported results 
from animal experiments are very promising, and a study using 
vindesine sulphate formulated into albumin microspheres containing 
magnbtite demonstrates the potential of this method of targeting 
[100]. In experiments using rats with tumour nodules, the magnetic 
microspheres were infused into the rats and a magnetic field
positioned through the nodules for a period of 30 minutes after 
infusion. It was found that high doses, normally fatal, could be 
safely administered. The treatment effected using the magnetic 
microspheres was significantly more successful than control 
experiments. The results from this work showed that the therapeutic 
index of the drug could be increased, together with reduced side 
effects and greater efficacy.
The second approach to the use of magnetism has been based on 
modulating drug release rates from matrix devices, with the aim of
- 19 -
developing controlled release devices. One of the- first reported 
studies adopting this approach to drug delivery was based on slabs of 
ethylene-vinyl acetate copolymer incorporating bovine serum albumin 
(BSA) and magnetic steel beads [102-105]. In aqueous medium the slabs 
were found to release a slow steady basal amount of BSA, however on 
exposure to an oscillating magnetic field, a significant increase in 
the rate of drug release was found over the basal release rate. The 
factors found to affect the delivery rate during application of a 
magnetic field included polymer formulation, magnetic field 
orientation, field strength and frequency. Tests using rabbit corneas 
indicated favourable biocompatibility of the magnetic matrix device.
In vivo experiments using diabetic rats implanted subcutaneously with 
magnetic matrices containing insulin demonstrated significant 
decreases in glucose levels within twenty minutes of applying an 
oscillating magnetic field external to the rats. The mechanism by 
which these devices act is not fully understood, two mechanisms have 
been postulated. The first suggestion is that the oscillating beads 
alternately constrict and dilate the pores within the polymer thereby 
squeezing drug out. A second hypothesis is that new pores are 
temporarily created during exposure to the magnetic field. Recent 
studies with hydrophilic polymers incorporating ferrite 
microparticles have also demonstrated the potential usefulness of 
this type of device [106]. The advantage of a magnetically 
controlled implant device would be that modulated control would be 
possible externally, indeed it is envisaged that perhaps a device may 
be developed whereby a magnetic matrix device may be implanted 
subcutaneously in the wrist and the delivery rate modulated by a 
watch like device [68].
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1.3.8 Ultrasonically Modulated Systems
Two different approaches have been adopted in the investigation 
of the potential utilisation of ultrasound as a method of drug 
delivery. One approach has been to try and enhance the transport of 
drugs through the skin using ultrasound, a method termed 
phonophoresis. The second approach has been based on the modulation 
of the drug delivery rates from polymeric devices using ultrasound.
1.3.8.1 Phonophoretic Delivery Systems
Phonophoresis as a method of enhancing the effects of drugs 
applied transdermally has been the subject of recent reviews 
[107,108]. The reviews cover some of the theories regarding the 
mechanisms of phonophoresis and the effect of phonophoresis on the 
skin, drugs and enzymes. Ultrasound was found to cause damage to 
mouse skin under certain conditions and also to inactivate certain 
enzymes, however one of the drugs which has received the most
attention in phonophoretic studies, hydrocortisone, was found to be 
unaffected by ultrasound. Various theories have been proposed as to 
the mechanism of phonophoresis, including cavitation and 
microstreaming. The authors of the reviews conclude that 
phonophoresis may be a safe technique for enhancing drug
administration and effectiveness in humans. Recently reported 
investigations found no statistically significant effect on the 
absorption of lignocaine, and a small but significant effect on the 
absorption of fluocinolone acetonide using phonophoresis, also many 
previous studies were criticised for having inadequate controls
[109,110]. McElnay et al. [109,110] questioned whether ultrasound
- 21 -
alone may be as effective as in combination with a drug and mention 
the fact that ultrasound is used in physiotherapy in the treatment of 
inflammatory conditions, and suggest that ultrasound has intrinsic 
therapeutic properties. The advantages of phonophoretic delivery 
would be those offered by delivery using the transdermal route 
(section 1.5), with the addition that drug delivery may be modulated.
1.3.8.2 Ultrasonic Delivery Systems
The use of ultrasound as an external means of modulating 
delivery from polymeric devices has been reported, effects on the 
release from reservoir systems [44,111], matrix systems [111,112,113] 
and biodegradable systems [80,112,113,114] have been investigated 
with the aim of developing controlled drug delivery devices where the 
delivery rate may be externally modulated. One of the first reports 
on the use of ultrasound on a polymeric delivery device examined the 
effect of ultrasound on the release of 5-fluorouracil from both 
reservoir and matrix devices constructed of ethylene-vinyl alcohol 
copolymer [111]. It was reported that the drug delivery rate could be 
increased significantly by irradiating with ultrasound, the increase 
being reversible on cessation of the ultrasound. The mechanism of 
action was not certain but it was speculated that an increase in 
temperature may facilitate diffusion. It was found that blood glucose 
levels could be significantly decreased by irradiating externally a 
subcutaneous reservoir device containing insulin which had been 
implanted in rats [44]. Studies investigating the mechanisms by which 
ultrasound increased the solute transport through membranes looked 
at a number of effects [114,115]. The effects of ultrasound on 
stagnant diffusion layers, interfacial temperatures, membrane
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integrity and diffusant stability were investigated and it was found 
that none of these factors alone could explain the observed increases 
in permeability due to ultrasound. A study on the effect of 
ultrasound on the release of drugs from biodegradable polyanhydrides 
found that significant and rapid increases were found in the drug 
release rate upon exposure to ultrasound [80,112,114], the effects 
were reversible on cessation of exposure to the ultrasound. The 
increase in release rate was found to be related to the intensity of 
the ultrasound, the actual increase however could not be solely 
explained by an increase in the rate of bioerosion [116]. Proposed 
mechanisms for the effects of ultrasound were cavitation and acoustic 
streaming [114]. Experiments performed on a biodegradable 
polyanhydride matrix containing insulin subcutaneously implanted in 
rats indicated that the exposure of an external ultrasound source 
caused no damage to skin, also no degradation of insulin occurred on 
exposure to ultrasound [113]. The potential advantages of an 
ultrasound modulated system include the fact that no additional 
substances such as magnetic beads or enzymes need to be added to the 
polymer and drug device in order to achieve modulated drug delivery 
[113].
1.3.9 Electrophoretically Modulated Systems
The principle of electrophoresis has been utilised in the 
development of controlled drug delivery devices. Two different 
approaches have been adopted, the first involving the delivery of 
ionic drugs into the body by the use of an electric field, a method 
termed iontophoresis [117]. The second method involves using an 
electric field to modulate the delivery of ionic drugs from reservoir
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type devices. Strictly speaking the term ionophoresis should be used 
for these systems rather than electrophoresis as the latter term is 
used to describe the migration of charged colloidal particles such as 
proteins in an electric field, whereas ionophoresis is more correctly 
applied to the migration of charged ions or molecules, however the 
term electrophoresis is generally used to encompass the migration of 
any charged particle [118]. The theoretical aspects of 
electrophoresis are discussed below in section 1.4.
1.3.9.1 Iontophoretic Delivery Systems
The facilitated permeation of drugs through the stratum corneum 
of the skin by iontophoresis has been the subject of a number of 
recent reviews [108,117,119]. The components required for 
iontophoresis consist of a drug reservoir, one delivery electrode, 
and one current returning electrode, both of which are attached to 
the skin, and an electrical power source in between them. As a 
consequence of the high resistance in the stratum corneum, the 
current flows through the skin beneath one electrode, through the 
body's interstitial fluids, and back through the skin below the other 
electrode. The flow of current between the electrodes may result in 
an appropriately charged molecule migrating into the skin, however 
the current carried under the skin is probably carried predominantly 
by other more mobile physiological ions. Once the drug penetrates the 
skin it is available for systemic distribution [108]. Iontophoretic 
transport through the skin is thought to be via the skin appendages 
[108,117,119,120,121], Iontophoresis has been shown to enhance the 
transport of uncharged molecules as well as charged molecules, this 
is thought to be a result of current induced convective flow
- 24 -
[119,121,122]. A recently derived expression for the iontophoretic 
transport of ions across the skin (section 1.4.3) was applied to the 
transport of etidronate disodium across pig skin [123]. The derived 
expression was found to be in good agreement with experimental 
findings up to voltages of 0.25 V, however beyond this the 
relationship broke down. It was thought that this may have been due 
to larger voltages altering the properties of the skin, an effect 
which has been reported by some workers [120,124].
The factors affecting iontophoretic drug delivery include the 
charge on the drug, the conductivity of the drug, ionic strength, 
drug concentration and pH [108,117,119,123-126]. Reviews of the large 
number of drugs that have been successfully delivered by 
iontophoresis can be found [108,117,119], including the enhanced 
transport of macromolecules such as insulin.
Iontophoresis as a method of drug delivery offers a number of 
potential advantages including those offered by the transdermal route 
of delivery (section 1.5). In addition iontophoresis may potentially 
be used to deliver drugs in a controlled and modulated manner [117].
The disadvantages of iontophoresis include problems with regards to 
safety, such as burns, electric shocks and skin irritation 
[108,117,119].
1.3.9.2 Electrophoretic Delivery Systems
There have been a number of recent reports on the development of 
an electrophoretically modulated drug delivery device [127-130]. This 
type of device is based on a polymeric reservoir device (section 
1.3.1), with the addition of a pair of electrodes on either side of 





DRUG RESERVOIR POLYMER FILM
Figure 1.1. Diagrammatic representation of an electrophoretically 
modulated drug delivery device.
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principle of the device is that the delivery rate of ionised drugs 
may be controlled. In the absence of an electric field a basal level 
of drug release will occur which may be modulated in a controlled 
and predictable manner by altering the magnitude of the electric 
field between the electrodes. Two approaches have been made to 
controlling the drug delivery rate, one involves the use of constant 
voltage electrophoresis, the other using constant current 
electrophoresis.
One of the first reported studies on an electrophoretic delivery 
system described the transport of a number of drugs, including a 
macromolecule (insulin), across discs of polyacrylamide and the 
effect of applying an electric field on the transport of these drugs 
through the polyacrylamide [127]. The system was characterized and 
several factors affecting migration examined. The author concluded 
that controlled voltage polyacrylamide electrophoresis appeared to be 
a promising means of providing drug release, though problems with 
reproducibility were found, which were thought to be due to changes 
in electrical resistance within the system.
A pencil-shaped electrophoretic delivery system has recently 
been reported for the transdermal application of diphenhydramine HC1 
[129]. The device uses a constant voltage supply and an agar gel drug 
carrier. It was reported that the release from the device could be 
varied over short periods (5 minutes) by varying the voltage, however 
very little information was given on factors affecting release. The 
same author also reports on the development of an electrophoretic 
capsule device for oral use [130].
The use of constant current electrophoresis as a means of 
controlled drug delivery has recently been reported [128]. The
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authors examined an in vitro system based on polyacrylamide gel 
discs, and examined some factors affecting the release of bovine 
serum albumin. It was concluded that an electrophoretically 
controlled system shows potential in the delivery of charged 
molecules into a medium at constant, controlled and modulated rates.
There are a number of envisaged applications of an 
electrophoretic delivery device, one application is as a transdermal 
delivery device. Another envisaged application is as an implant 
system, where a device may be programmed to deliver a drug at a 
predetermined rate, or alternatively act as a feedback system where 
the drug output may be varied in response to a patients need. An 
example of a feedback system might consist of an insulin containing 
device which is refillable via a septum. The insulin output of the 
device could be controlled by a glucose sensor. The potential 
advantages of an electrophoretic delivery device included achieving 
full control over drug release which may be obtained by varying 
either the voltage or current across the device. The disadvantages of 
this type of device include the cost of producing a device, and 
biocompatibility problems associated with implant devices.
1.4 Electrophoresis
The theoretical treatment of the movement of small ions and 
colloidal particles under the influence of an electric field will 
differ, since unlike simple ions the charge carried by a colloidal 
particle is not a constant known quantity, and the behaviour of a 
colloidal particle will be greatly modified by the surrounding 
electric double layer [131].
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1.4.1 Ionic Migration [132-136]
Many drugs are ionic in nature and in aqueous solution will
dissociate into small ions which are free to carry electric currents
when placed in an electric field. The ease with which a current is
passed will depend on the conductivity of the electrolyte, which
depends on the number of ions in a given volume of solution and the
interaction between them. If electrolytes in solution were fully
dissociated and no interaction existed between the ions then
conductivity would be proportional to concentration, however the
relationship is not so straightforward. It is often convenient
therefore to express the conductivity of an electrolyte solution in
terms of molar conductivity :
A = k 
C 
A = Molar Conductivity (Q-1 m2 mol-1) 
k = Conductivity (Q-1 m-1) 
C = Concentration of Electrolyte (mol m-3)
The variation in molar conductivity with concentration will 
depend on whether the electrolyte dissociates completely in solution 
(a strong electrolyte) or only partly (a weak electrolyte). For 
strong electrolytes it is found that at low concentrations molar 
conductivity is a linear function of the square root of 
concentration, as described by the Onsager equation :
A = A0~ (A + B Aj • C1 / 2 
A0= Molar Conductivity at Infinite 
Dilution (Or1 m2 mol-1) 
A = Constant 
B = Constant
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The Onsager equation describes the effects of ion-ion
interactions on conductance in terms of the relaxation and
electrophoretic effects, and is based on the Debye-Huckel theory
which describes the ionic atmosphere around an ion. These effects 
account for the fact that as the chemical concentration of an 
electrolyte is increased the effective concentration will not
increase proportionally. The electrophoretic effect arises when an 
ion moves through a viscous medium and drags with it the solution in 
its immediate vicinity. Neighbouring ions have to move with or 
against the stream depending on their charge. The relaxation effect 
is a result of distortion of the symmetrical distribution of the ion 
cloud around any given ion. At equilibrium the ionic atmosphere is, 
on a time average, distributed with spherical symmetry and therefore 
exerts no resultant force on the central ion. If the central ion 
moves to an off centre position it experiences a restoring force, 
which however rapidly dies away as the atmosphere is rearranged.
In the case of weak electrolytes the relationship between molar 
conductivity and concentration is more complex since the degree of 
dissociation is concentration dependent, the degree of dissociation 
(a) decreasing with increasing concentration. A modified form of the 
Onsager equation accounts for this :
A = [A0- (A + B i\o)(aC)^2]«
At infinite dilutions, it is assumed that there are no forces of 
attraction between ions and the dissociation of all electrolytes is 
complete, thus the motion of an ion is solely determined by its 
interaction with surrounding solvent molecules. Kohlrausch’s law of 
the independent migration of ions states that the molar conductivity 
for an electrolyte at infinite dilution is the sum of the ionic
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conductivities for each type of ion, A ± :
A0= A + + A _
An ion placed in an electric field will tend to move with a 
velocity proportional to the field strength. The electric mobility 
of an ion is defined as the velocity of motion of the ion divided by 
the electric field strength :
ui = _v_ = Q 
E 6nyr
Ui = Mobility of Ion (m2 s~1 V~1)
v = Velocity of Ion (m s_ 1)
E = Electric Field Strength (V nr1)
Q = Charge on Ion (C)
V = Viscosity of medium (kg m_1 s_1) 
r = Radius of the Ion (m)
The molar conductivity of an electrolyte may be related to the 
mobilities of individual ions (u±) in the electrolyte as follows :
A = (u+ + u_) .F
F = Faraday's Constant 
The fraction of the total current carried by a particular type 
of ion is termed the transport number (ti) of that ion :
ti = ui
u+ + u_
1.4.2 Colloid Migration [131,133-137]
Electrophoresis, the movement of a charged surface relative to a 
stationary liquid by an electric field, is one of four electrokinetic 
effects that occur across a solid-liquid interface due to differences 
in electric potential. The other three electrokinetic effects are 
electro-osmosis, streaming potential and sedimentation potential. 
Electro-osmosis is the movement of liquid relative to a stationary
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charged surface by an applied electric field. The streaming potential 
is the potential difference created when a liquid is made to flow 
along a stationary charged surface. The sedimentation potential is 
the electric field created when charged particles move relative to a 
stationary liquid.
A colloidal particle such as a protein placed in water, may 
obtain a charge from either ionisation of surface groups or 
adsorption of ions which confer their charge onto the surface of the 
particle. This surface charge influences the distribution of ions in 
the medium, resulting in the formation of an electric double layer. 
The charged particle will attract a layer of counter-ions. If for 
example the particle has a negative charge, then this will result in 
the particle having a fixed layer of positive ions attracted 
electrically to the surface of the particle, this layer of ions being 
known as the Stern Layer. The electric potential across the Stern 
Layer decreases rapidly and linearly, the surface of this layer is 
the Stern Plane. Beyond the Stern Plane a second diffuse layer exists 
which contains an excess of loosely held positive ions, the surplus 
decreasing with distance from the particle. The electric potential 
decays exponentially across this diffuse layer. When a colloidal 
particle moves, the Stern Layer moves with it together with some 
solvent molecules in the diffuse layer, the outer boundary of this 
unit, the effective surface of the particle, is known as the Shear 
Plane. The zeta potential (C) is the potential at the Shear Plane, 
and it is this potential that determines the behaviour of a colloid 
particle in an electric field. The zeta potential is experimentally 
indistinguishable from the Stern Layer potential and is usually 
assumed to be the same. This will not be correct at high electrolyte
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concentrations when the diffuse layer is compressed. The zeta 
potential can be related to electrophoretic mobilities, a number of 
simplified relationships may be used, the type of relationship 
applied will be determined by the dimensionless quantity ka, which is 
the ratio of radius of curvature to double layer thickness. If ka is 
small the particle may be treated as a point charge, when ka is large 
then the double layer may be treated as a flat surface. A number of
equations have been used to describe the mobility of colloids
including the Huckel equation (small ka) and the Smoluchowski 
equation (large ka). A more general relationship is the Henry 
equation, which for a non-conducting particle can be written as :
u = € { f (ka)
6tt 77
€ = Permittivity of the Medium (C V-1 m-1)
The value of f(ka) varies between 1.0 for a small ka (Huckel
equation) and 1.5 for a large ka (Smoluchowski equation). The Henry
equation takes into account the electrophoretic retardation effect, 
however it makes a number of assumptions, such as the viscosity and 
permittivity being constant throughout the mobile part of the double 
layer. The Henry equation also does not take into account the 
relaxation effect and surface conductance effects in the vicinity of 
the charged surface. The electrical conductance in the diffuse part 
of the double layer is greater than that in the electrolyte medium 
due to the distribution of ions in this region, surface conductance 
may affect the electric field distribution near the surface of the 
charged particle, particularly if ka is not small, and so influence 
the electrokinetic behaviour of the particle.
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1.4.3 Transport of Ions through Homogeneous Membranes
The study of diffusing ions under the influence of an electric 
field has been of importance in the fields of electrochemistry [133] 
and physiology [138]. Keister and Kasting have recently developed a 
model to describe the iontophoretic phenomenon of an ionised drug 
diffusing from a reservoir through an uncharged homogeneous 
macroscopic membrane under the influence of an electric field [139]. 
The derived equation is based on the Nernst-Planck equation which 
separates the flux of an ion diffusing under the influence of an 
electric field into its diffusion and migration components as shown 
below [133] :
J = -D dC + DzeEC 
dx kT
where J is the drug flux, D is the diffusion coefficient, C the 
concentration of ions with valency z and charge e, E the electric 
field strength, k Boltzmann's constant, and T the absolute 
temperature. The boundary conditions of the model were as follows: at 
time t=0 there is no drug in either the membrane or in the receptor 
solution, the solutions on both sides of the membrane are well 
stirred and sink conditions prevail in the receptor. The derived 
equation is based on a number of assumptions, such as the electrical 
field being constant, which the authors justified on the basis that 
the primary current carrying ions are smaller ions such as Na+ and 
Cl-, and that these will be distributed uniformly throughout the 
membrane, and that there will be at most very low net charge 
densities throughout the membrane. The model is however simplistic 
and limited, since the influence on flux as a result of interactions 
between ions is not considered, and would thus only be applicable at 
low ionic strengths [117,140]. The relationships that were derived
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from this model describe the flux enhancement ratio produced by an
applied voltage, J(v)/J(0), once steady state has been attained :
J(v) = v 
JTO) 1 - e-v
where v is defined as :
v = zeV 
W
and the ratio of voltage enhanced lag time to the passive lag time,
T l(v )/Tl(0), is given by :
Tl(v) = 6.[v.coth(v/2)-2]
T[1oT V2
The model predicts that the application of a uniform electric
field across a uniform membrane leads to ion flux enhancements
proportional to v and to a reduction in lag times. The model also
predicts that it should be possible to not only enhance flow but to
also actually shut down transport by reversal of polarity.
1.5 Transdermal Drug Delivery
Drug delivery systems may be classified by the route of 
delivery, such as implantable delivery systems, oral delivery 
systems, transdermal delivery systems, and other non-invasive 
delivery systems. The transdermal route has been extensively 
researched as a potential route for drug delivery due to a number of 
potential advantages which this route offers compared with the oral 
route of delivery, which is currently the most popular method of 
delivery. There are many recent reviews dealing with transdermal drug 
delivery [26,141-151]. Some of the problems with drug absorption from 
the oral route include variability of gastro-intestinal motility and 
transit times, the exposure of drugs to the first-pass effect, 
stability of the drug in the gastro-intestinal tract, and the varying
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and variable absorption capabilities in different parts of the 
gastro-intestinal tract. All of these factors will influence the 
bioavailability of a drug and results in the oral route offering 
limited potential for constant and controlled drug delivery devices 
[24,135,152,153,154]. The transdermal route of delivery can overcome 
some of the variables which affect gastro-intestinal absorption, 
other advantages include an improvement in patient compliance, and 
the fact that treatment may be easily terminated [1,135,141]. The 
transdermal route may also be a suitable route for constant and 
controlled drug delivery devices, however the latter type of device 
would have to overcome the difficulty of the long lag times generally 
involved with transdermal transport [141]. The transdermal route does 
however have a number of significant limitations. One of the main 
functions of the skin is to act as a barrier which is generally very 
effective and has caused transdermal delivery to be limited to 
extremely potent drugs. However, research into enhancing drug 
delivery by either chemical methods (section 1.5.2) or physical 
methods (section 1.3.8.1, section 1.3.9.1) hajs shown that the 
effectiveness of this barrier function may be reduced locally 
[26,141,142]. Another problem with transdermal delivery is possible 
irritation or allergic reaction to either the drug or delivery device 
[142]. Drug degradation either on or in the skin may also be a 
potential problem, this may occur as a result of either the presence 
of enzymes in the skin or micro-organisms on the skin surface 
[142,155,156].
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1.5.1 Transport of Drugs through Skin
The human skin may be considered as consisting of two distinct 
layers (figure 1.2), the stratified avascular cellular epidermis and 
the underlying dermis of connective tissue. A fatty subcutaneous 
layer resides beneath the dermis. Human skin is interspersed with 
appendages, such as hair follicles, sebaceous glands and sweat 
glands, which pass through pores in the epidermis to reach the 
surface. The appendages however only represent a small fractional 
surface area of the skin [157]. The epidermis may be differentiated 
into two layers, the stratum corneum, the uppermost layer which is 
approximately 10 pm in thickness, and the viable epidermis, which may 
vary in thickness between 60 and 800 pm. The stratum corneum is 
composed of flattened keratinized dead epidermal cells, stacked in 
units consisting of highly organized vertical columns. In general 
body areas the stratum corneum is 10 to 15 cell layers in thickness, 
whereas the thickness of the dermis may vary between 3 and 5 mm. A 
more detailed consideration of the skin structure may be found 
elsewhere [26,158].
It has been suggested that the stratum corneum may be 
represented as a wall-like structure built up of protein bricks (the 
corneocytes which are mainly composed of keratin) and joined by lipid 
mortar [159,160]. The lipids within the stratum corneum are thought 
to be structured as bilayers [161,162]. It is the stratum corneum 
that is thought to be the rate-limiting barrier to the transport of 
most drugs through the skin [158,163], except for very lipophilic 
drugs where the aqueous dermal layer may provide significant 
hindrance to transport [142,163]. The transport of drugs across the 























Figure 1.2. Diagrammatic structure of human skin with three possible 
routes for drug transport - (1) via the sweat glands, (2) across the 
intact stratum corneum, (3) via the hair follicles [26].
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transepidermal pathway [26,141,164,157]. The mechanism of transport 
is still not precisely known, though it is believed that the 
transepidermal route is the main transport route for most drugs, 
however the appendageal pathway may be important for short 
diffusional times and for large polar molecules [142,163]. 
Transepidermal transport may be either transcellular or 
intercellular, the relative importance of these routes for a 
particular drug will depend amongst other things on the drugs 
solubility, partitioning behaviour with the various phases, and 
diffusivity within these phases. In general it is thought that the 
transcellular route predominates for polar drugs, and that as 
polarity decreases the intercellular route becomes increasingly 
predominant. Whatever the predominant transepidermal route, it is 
generally acknowledged that the stratum corneum lipids provide a 
significant part of the barrier function of the skin [163,165,166],
It is usually found that lipid-soluble drugs penetrate the skin 
better than water-soluble drugs, and for drugs which can exist as 
both ionised and unionised species, it is generally the unionised 
species that are more permeable [160,167]. It has also been 
demonstrated that the permeation of charged species may be increased 
by increasing the lipophilicity of the ionised permeant through 
ion-pair formation [168,169].
The transport process for a drug permeating the skin is quite 
complex [26,141,170], once delivered to the skin surface the drug 
must partition into the stratum corneum and diffuse through this 
impermeable barrier. The drug may interact with binding sites, free 
drug eventually reaching the viable epidermis and the drug must 
partition into this water rich layer. The drug must then diffuse in
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the viable epidermis and partition into the dermis where a 
combination of events may occur such as the drug forming a depot, the 
drug being degraded or the drug partitioning into a blood capillary 
for systemic transport. Reviews on the many factors that can affect 
the transport of drugs through skin are available [26,147-150,171]. 
Some factors that will affect drug transport include skin age, skin 
condition, absorption variations with body site, individual 
variations, skin hydration, temperature, pH, the solubility 
characteristics of a drug and the partition coefficient of a drug.
1.5.2 Penetration Enhancers
Ideally, transdermal drug delivery devices should deliver drugs 
at a controlling rate well below the maximum rate that the skin can 
accept in order for the delivery device to be genuinely rate 
controlling and safe [108,141,170]. Unfortunately the low 
permeability of the skin makes this difficult to achieve in practice. 
However, using penetration enhancers it may be possible to increase 
the permeability of the skin, and thus increase the range of drugs 
which may be delivered transdermally. An ideal penetration enhancer 
should possess a number of properties [26], such as being 
pharmacologically inert, non-toxic, non-irritating, odourless, 
colourless and tasteless. In addition the enhancer should be specific 
in action, act immediately and its action should be reversible.
A number of compounds have been examined as potential 
penetration enhancers including dimethyl sulphoxide (DMSO), 
pyrrolidones, and a number of surfactants. These and other compounds 
have been the subject of recent reviews [26,108,172,173,174]. 
l-Dodecylhexahydro-2H-azepin-2-one (Azone) is a relatively new
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penetration enhancer which has received a great deal of attention, 
studies having demonstrated the enhanced penetration of both 
hydrophobic and hydrophilic drugs in the presence of Azone [175-183]. 
Reported studies indicate that Azone shows no indications of toxicity 
or irritation, additionally Azone appears to be poorly absorbed, and 
what little is absorbed is rapidly cleared by the kidneys. The 
effects of Azone on the permeability of the skin also appear to be 
reversible.
The mechanism by which penetration enhancers increase the 
transport of drugs through the skin is still uncertain though they 
are believed to act at the stratum corneum. One theory, based on 
results from permeation and differential scanning calorimetry 
studies, is that enhancers affect the nature of lipid bilayers in the 
stratum corneum by disrupting the intercellular lipid structure from 
a state of relative order to disorder, and thus increase the fluidity 
in this region, permitting drugs to permeate more readily
[163,178,184,185,186]. Enhancer molecules may interact at three main 
sites of the lipid bilayer structure, namely the polar heads of the 
lipids, within the aqueous regions between lipid head groups, and 
between the hydrophobic tails of the bilayers. An effect on the 
keratin fibrils and their associated water in the corneocytes may be 
the mechanism by which enhancers affect the intracellular route of 
drug transport. In addition to these effects some penetration 
enhancers may act by altering the partitioning properties of the 
stratum corneum. Support for this theory comes from studies using a 
fluorescent probe technique and electron spin resonance studies on 
model phospholipid membranes which also indicate that enhancers 
increase lipid fluidity [187,188].
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1.5.3 In Vitro Methods for Studying Drug Transport through Skin
The majority of studies that have examined the transport of 
drugs through the skin have been based on in vitro experiments using 
excised skin, the assumption being that the stratum corneum is the 
rate-limiting step in drug transport, and that this dead horny layer 
maintains its barrier function in vitro. In vitro experiments have 
demonstrated the validity of this assumption [189]. Human skin is the 
most satisfactory type of skin for in vitro experiments, however 
availability may be a problem which has lead to the investigation of 
artificial membranes [26,190] and excised skin from a variety of 
animals such as the hairless mouse, pig and rat, however the results 
from using different types of skin should be viewed with care as skin 
morphology and drug transport will vary with species [26,191-194]. 
Even if human skin is used in experiments, data obtained usually 
suffers from considerable variability, even if a specific anatomic 
site is selected the permeability of skin can vary within a site for 
a given individual as well as varying between different individuals 
[26,195].
Hairless mouse skin has been reported to be a useful model for 
human skin, studies on the permeability of a series of alcohols 
indicated that the barrier properties of human skin and hairless 
mouse skin may be similar [196]. The results from a recent report 
however suggest that hydration damage does not make mouse skin 
suitable for long term studies [197]. It has also been recently 
reported that hairless mouse skin displays exaggerated responses to 
penetration enhancers compared to human skin [198,199]. These 
findings suggest that results from in vitro experiments using
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hairless mouse skin should be treated with caution.
The transport of drugs through skin is usually measured by 
clamping the skin in a diffusion cell of some description and 
monitoring the delivery rate of drug from a donor compartment into a 
receptor solution. The choice of receptor solution may significantly 
affect the transport rate, particularly with lipophilic drugs [200]. 
Various types of diffusion cell have been used, however most are 
based on a similar basic design [201]. Two techniques have been 
adopted in studying drug transport, the infinite dose technique and 
the finite dose technique [202]. In the infinite dose technique the 
donor compartment contains a solution of the drug under study, and 
the build up of drug in the receptor is monitored during the course 
of an experiment. Generally the concentration in the donor remains 
constant during an experiment and the receptor acts as an effective 
sink, thus after a lag period steady state diffusion would be
expected (appendix 1). If a plot of amount of drug in the receptor
compartment against time is plotted, the slope of the linear part of 
the plot (steady state region) will give a measure of steady state 
flux. The transport behaviour of drugs in the skin is usually




dM = Flux (mol cm-2 s~1)
at
P = Permeability Coefficient (cm s_1) 
C 1 = Initial Concentration of Drug in Donor 
Compartment (mol cm-3)
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where P is defined as:
P = KD 
h
K = Partition Coefficient of the Solute between 
Membrane and Bathing Solution 
D = Diffusion Coefficient (cm2 s-1) 
h = Membrane Thickness (cm)
The permeability coefficient is used since it may be difficult to 
measure the partition coefficient, also the measurement of membrane 
thickness may be difficult. The infinite dose technique has been 
criticised as not being a realistic model, one of the main objections 
being that both sides of the membrane are exposed to an aqueous 
medium thus excessively hydrating the skin [202]. Some workers prefer 
the use of the finite dose technique where the donor side of the skin 
(the epidermis) is exposed to ambient conditions and a fixed dose of 
drug is applied either by rubbing in, or applying in a volatile 
solvent. Using this technique steady state diffusion is not achieved, 
after a lag time the flux rises to a peak than falls as the drug 
concentration on the exposed epidermal surface decreases, thus 
permeability coefficients can not be calculated. The manner of 
application in the finite dose technique is thought to mimic more 
closely the way that a drug is applied clinically.
1.6 Poly (2-hydroxy ethyl methacrylate) (PHEMA)
The use of polymers as materials for drug delivery systems has 
been the subject of a number of reviews [7-11,25,203-206]. PHEMA is a 
hydrogel that has been extensively researched as a material for 
biomedical applications since it was first introduced by Wichterle 
and Lim [207]. A hydrogel may be defined as a hydrophilic polymeric
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material that swells in water, retaining a significant amount of 
water, but remaining insoluble [208]. The amount of water that 
equilibrated hydrogels may hold can range from 3% to greater than 90% 
depending on the hydrogel [209]. Interest in PHEMA stems from a 
number of favourable properties which this polymer possesses (see 
section 1.6.2), which has made it a candidate for use in drug 
delivery systems.
1.6.1 Preparation and Structure of PHEMA
PHEMA is an addition polymer produced by the free-radical
polymerization of 2-hydroxyethyl methacrylate (HEMA). PHEMA hydrogels 
are usually polymerized in the presence of a crosslinking agent, the 
structure of PHEMA and PHEMA crosslinked with ethylene glycol
dimethacrylate are shown in figure 1.3. Radicals may be generated by 
either chemical catalysts, UV radiation in the presence of a 
photosensitive chemical, or by ionizing radiation [60,209-212]. The 
actual polymerization process may be one of several methods such as 
bulk polymerization of the monomer with crosslinking agent,
crosslinking of the polymer in solution, or simultaneous
polymerization and crosslinking of a monomer with a crosslinking
agent in solution [213]. The latter method is often preferred since 
polymerization may be achieved quickly at a low temperature, also the 
shape of the polymer may be easily determined since the starting 
materials are in liquid form. When HEMA is polymerized in solution 
with a crosslinker, water may be used as a solvent. If the water
content is maintained below a certain value then optically
transparent homogeneous hydrogels are formed, however if the water
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hydrogels are formed due to a phase separation [213,214]. The 
critical value at which this change occurs has been reported to be 
in the region of 40% to 43% [213,215,216].
In the absence of crosslinking agent PHEMA has been reported to 
still possess a significant crosslinking density due to physical 
chain entanglements and noncovalent interactions between the chains 
[217]. In addition to the 3-dimensional covalent network in PHEMA 
there is believed to be a secondary structure superimposed upon the 
covalent network, which is thought to explain some of the properties 
of PHEMA (section 1.6.2) such as the narrow range of swelling that 
PHEMA exhibits at low levels of crosslinking [213]. One of the first 
models proposed for this structure was that hydrophobic bonding 
between the a-methyl groups in PHEMA, and also possibly between the 
chain backbones, was responsible for holding together the secondary 
structure in an aqueous environment [218]. A more favoured model 
however is that the secondary structure consists of hydrogen bonds 
between pendent hydroxyl groups (and less likely pendent hydroxyl and 
carbonyl groups) which are stabilized by the steric exclusion of 
water molecules from the regions containing the bonds [219]. It was 
shown however that some hydrophobic bonding probably does occur 
within the polymer matrix, but is not the main cause of the secondary 
structure. It should be noted that these models are partly based on 
the interpretation of swelling effects that urea has on PHEMA, and 
that doubts have recently been cast on the relevance of these 
experiments. It has been reported that urea does not swell PHEMA 
directly, but that the decomposition of urea in solution occurs which 
results in an increase of pH in the polymer. This increase in pH is 
thought to ionise . methacrylic acid, which is usually present as an
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impurity in PHEMA, and that the swelling caused is a consequence of 
this ionisation and the resultant electrostatic interactions [220].
The equilibrium water content of PHEMA is found to be remarkably 
insensitive to the addition of low levels of crosslinker, the water 
content being approximately 40% [213]. It has been proposed that the 
water within PHEMA is structured at a molecular level within the 
network, there have been a number of theories as to the nature of 
this structuring. One model, the three state model, proposes that the 
water within PHEMA consists of bound, free and intermediate water 
[221]. Evidence for this model stems from a number of studies 
including proton pulse nuclear magnetic resonance (NMR), differential 
scanning calorimetry (DSC) and dilatometry [215,222,223]. The bulk 
water is the water fraction within the polymer with properties most 
like water in free aqueous solution. The bound water fraction is 
strongly associated with the polymer backbone and is thought to be 
orientated around hydrophilic groups. The intermediate water is also 
thought to be associated with the polymer backbone, but is not as 
strongly associated as the bound water. The bound and intermediate 
fractions have been termed Domain A, a region of water thought to be 
associated with the mechanical properties of the polymer backbone and 
relatively hydrophobic in nature. Domain B consists of free bulk 
water, the region of the polymer associated with hydrophilic 
properties [224]. The relative amounts of each type of water will 
vary depending on the total percentage of water within the hydrogel 
and the crosslinker content. Evidence from NMR and DSC studies 
indicate that as PHEMA imbibes water from the dry state the first 
step is the binding of water to hydrophilic sites (bound water), 
additional water is preferentially orientated around the bound water
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and the polymer network structure as a secondary or tertiary 
hydration shell and any excess water is present as free water (bulk 
water) [223]. Thus if the water content of PHEMA is reduced below 
equilibrium the relative proportion of bound water increases at the 
expense of intermediate and bulk water, and at a concentration of 
about 30% water there is thought to be no bulk water present. An 
increase in crosslinker content was also reported to increase the 
proportion of bound water. A more recent model suggests that PHEMA 
containing equilibrium water contains virtually no bulk water. The 
model proposes that the water and polymer form a coherent, integral 
structure in which there is no place for solutes [225], and that the 
internal structure of PHEMA is best described as an elastic solution 
of polymer in water [226,227]. The authors suggest that since swollen 
PHEMA (of 40% water content) contains at most about five molecules 
of water per monomeric unit of PHEMA, that it is unlikely that 
separate regions of water can exist large enough to be free of any 
influence of the polymer. The model is based mainly on DSC, adiabatic 
calorimetry and swelling experiments. The model proposes that solute 
absorption is only possible if the solute can disrupt the integral 
structure which leads to increased water uptake and swelling. 
Alternatively, if a solute cannot enter the polymer structure 
significantly, a deswelling of the polymer will occur due to an 
osmotic effect. The authors of this model have not yet attempted to 
relate the proposed structure to the transport of solutes through 
PHEMA, however the three state model has been extensively used to 
explain the transport behaviour of both hydrophilic and hydrophobic 
solutes through PHEMA (section 1.6.3).
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1.6.2 Properties of PHEMA
PHEMA has attracted much attention as a material for biomedical 
applications due to its physical and chemical properties. The 
literature on the properties and uses of PHEMA and its copolymers in 
drug delivery systems and other biomedical applications is extensive, 
however several reviews have been published [10,60,204,205,206,208,
228]. Some of the biomedical and pharmaceutical applications of PHEMA 
include the use of PHEMA in contact lenses, artificial tendons and 
intrauterine devices. Some of the polymers properties will be briefly 
reviewed in this section, however a more detailed consideration of 
the properties of PHEMA relevant to this work will be considered in 
other sections.
PHEMA has been reported to be a biocompatible material, a 
property which is thought to result partly from its high water 
content [60,207,229,230]. Biocompatibility is a general term used to 
describe a wide variety of biological responses, thus the 
compatibility of a material should be investigated with a view to the 
specific intended application of that material. PHEMA has been 
suggested as a biocompatible material due to a number of favourable 
properties. The high water content and soft rubbery consistency of 
these materials gives them a strong superficial resemblance to living 
tissue which may partly explain why PHEMA does not cause mechanical 
irritation when in contact with cells and tissue. The low interfacial 
tension found between the surface of PHEMA and aqueous solution 
minimises protein adsorption and possibly cell adhesion. In addition 
polymerization initiators, residual monomer and other impurities can 
easily be removed from PHEMA prior to use by washing, which reduces 
the likelihood of toxic reaction to the polymer. The ability of ions
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and metabolites to diffuse through PHEMA has also been cited as an 
advantageous property. There have been studies indicating favourable 
biocompatibility of PHEMA implants in vivo [231], however it has also 
been reported that thick fibrous capsule formation around PHEMA 
implants occurs together with tumour production in rats [232].
PHEMA has been found to be resistant to acid hydrolysis and 
reaction with amines [233]. A polymer related to PHEMA, 
poly(diethyleneglycol methacrylate), was found to incur alkaline 
hydrolysis only at elevated temperatures and at a high pH [234]. The 
water content of PHEMA has been reported to be relatively insensitive 
to the addition of low levels of crosslinking agent [213], 
additionally the equilibrium swelling of PHEMA in water prepared by 
solution polymerization was found to be fairly constant regardless of 
the initial dilution of the monomer solution (providing the solvent 
concentration is not high enough to form heterogeneous PHEMA) [213]. 
PHEMA prepared by bulk polymerization will swell in water to a 
similar equilibrium water content as that prepared in aqueous 
solution [218]. Temperature has been reported to have a small effect 
on the equilibrium water content of PHEMA over the range 10 to 100°C 
[213].
The mechanical properties of PHEMA have also received some 
attention, and the relevant literature has been reviewed by Janacek 
[235].
1.6.3 Diffusion of Solutes in PHEMA
The three state model of water has been used as a basis for 
developing models to describe the transport behaviour of solutes in 
PHEMA. The diffusion of solutes through PHEMA depends on the amount
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and type of crosslinking agent, the water organisation within the 
polymer and the size and nature of the solute (hydrophobic or 
hydrophilic). A number of investigators have examined solute
transport through hydrogel membranes and several reviews of this work 
have been published [10,60,204,205,236]. In this section a selection 
of these studies will be briefly reviewed.
Yasuda et al. examined the permeation of hydrophilic solutes 
through a series of hydrogels of varying hydration utilizing the free 
volume theory [237,238,239]. It was assumed that the effective volume 
for solute diffusion corresponds to the free volume of the aqueous 
phase and that the solute diffuses through "fluctuating pores" by 
successive jumps through holes which are larger than the solute. The 
solute was also assumed to permeate through aqueous regions only and 
that any interactions with the polymer are minimal. The theory was 
found to be applicable at high values of hydration where a predicted 
linear dependence of the logarithm of the permeability on the 
reciprocal of the volume fraction of water in the swollen hydrogel 
was found to occur with the model solutes examined. The slope of 
these plots was found to be dependent on solute size. Wisniewski and 
Kim also applied the free volume theory to examine the effect of 
apparent solute molecular size on the diffusion through PHEMA 
membranes [240]. A range of water soluble molecules were examined in 
the molecular weight range 20-500 Dalton. It was found that for 1 
mole% crosslinked PHEMA that the diffusion coefficient of these 
solutes decreased exponentially with increasing molecular size. The 
authors also implied that the permeation of these solutes probably 
occurs primarily via bulk water, however exceptionally high values 
for the partition coefficients of thiourea and sodium methotrexate
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were found compared to the other solutes examined, and it was 
thought that these solutes may interact with the polymer chains.
Kim et al. examined the permeation of hydrophilic and 
hydrophobic solutes through PHEMA membranes [224,241]. It was 
reported that hydrophilic solute permeation, through PHEMA with a low 
crosslinker content, was consistent with a pore mechanism through 
domain B (section 1.6.1) composed of fluctuating pores created by the 
interpenetration of chains in the polymer network. The pore size is 
determined by the percentage of crosslinking agent which will in turn 
determine the equilibrium water content. The effect of solute 
molecular size on solute diffusion was described in terms of a free 
volume model at low crosslinker contents, at higher crosslinker 
contents however deviations from this model were found. The diffusion 
of hydrophobic solutes through low crosslinked PHEMA was also 
postulated as being predominantly by a pore mechanism, however at 
higher crosslinker contents, as the effective pore size decreases, a 
partitioning mechanism was thought to predominate where diffusion 
occurs between polymer segments via domain A water. The diffusion 
coefficients of hydrophobic solutes were found to be lower than those 
for hydrophilic solutes.
Lee et al. examined the transport of a series of amides across 
PHEMA crosslinked with tetraethylene glycol dimethacrylate (TEGDMA) 
and the effect of varying the amount of TEGDMA in the polymer [242]. 
They found that the permeability and diffusion coefficients decreased 
with an increase in crosslinker concentration for all the amides 
examined. It was proposed that as crosslinker content was increased 
the pore size in the polymer decreased and that the mechanism of 
diffusion changes from a pore mechanism to a partition mechanism.
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Zentner et al. performed a similar experiment with the hydrophobic 
compound progesterone and found similar changes in diffusion 
coefficient as crosslinker content was increased [243]. The results 
were interpreted once again as a change in diffusion mechanism from 
predominantly a pore mechanism to a partition mechanism.
Collett et al. examined the effect of polymer hydration on the 
diffusion of salicylic acid through crosslinked PHEMA. [244,245]. It 
was found that a plot of log diffusion coefficient of salicylic acid 
against polymer concentration showed a sharp change of slope at a 
polymer concentration of 69%. The authors correlated this value to 
the hydration value at which no bulk water exists in PHEMA (about 30% 
[215]) and concluded that at a hydration value of 31% and greater, 
transport of salicylic acid occurred by a pore mechanism via the bulk 
water, however below 31% hydration, the small pore size and absence 
of bulk water resulted in a change in transport mechanism. The effect 
of hydration on effective crosslinking density (calculated from 
stress-strain data) was examined and showed a sharp upward 
displacement when the hydration corresponded to 31%. The authors 
concluded that intermolecular bonding increases in the absence of 
bulk water.
1.6.4 Interaction of PHEMA with Ions in Solution
The accumulation of a component in solution at an interface 
between phases is termed adsorption. It is a surface effect and two 
general types of adsorption may be distinguished, physical 
adsorption, in which the solute is bound through relatively weak 
forces such as van der Waals or hydrogen bonds, and secondly chemical 
adsorption which involves stronger valence forces [135]. Adsorption
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from solution is usually expressed in the form of adsorption 
isotherms in which the uptake of solute per unit weight of adsorbent 
is plotted as a function of the concentration of solute remaining in 
solution at equilibrium. The shape of the isotherm has been used as a 
basis for the classification of solution isotherms [246], the various 
types of isotherm being associated with different adsorption
mechanisms. Adsorption of solutes by polymers and factors affecting 
adsorption such as the solvent type, temperature, pH and ionic 
strength have been reviewed elsewhere [246,247,248].
PHEMA has been shown to non reversibly adsorb the cationic 
preservative chlorhexidine digluconate in solution, the sorption 
isotherm produced being a typical high affinity type isotherm (HI), 
which normally occurs when a solute has such a high affinity for the 
adsorbent that it is completely removed at low concentrations 
[246,249]. The interaction was found to occur to a much greater 
extent when chlorhexidine was in its ionised form. The nature of the 
interaction was suggested to be due to an interaction between the 
cationic chlorhexidine ion and negatively charged sites within the 
polymer. Studies with monofunctional biguanides (chlorhexidine being 
a bis biguanide) indicated that the extent of interaction with PHEMA 
increased with biguanide alkyl chain length, and together with other 
findings it was suggested that the ion-ion interaction between 
chlorhexidine and PHEMA is stabilized by van der Waals forces between 
the alkyl chain and the polymer backbone and perhaps also by 
hydrophobic bonding [250]. The stabilizing effect of van der Waals 
forces would appear to be significant, since smaller cations such as 
aniline and benzocaine were found not to show such a strong 
interaction with PHEMA as chlorhexidine, though similar interactions
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to that between PHEMA and chlorhexidine were envisaged with other 
organic cations [250]. Further studies indicated that the mechanism 
of interaction between chlorhexidine digluconate and PHEMA was 
consistent with an ion-ion interaction, and that the ionic nature of 
PHEMA was due to carboxylic acid sites which were thought to be 
generated in situ during polymerization [251].
The effect of introducing methacrylic acid residues (carboxylic 
acid sites) into PHEMA on the diffusion of sodium chloride through 
crosslinked PHEMA films has been investigated [252]. The presence of 
methacrylic acid was reported to slow down the transport of sodium 
chloride through crosslinked PHEMA films primarily due to an 
exclusion effect on the chloride coion, the decrease in permeability 
being related to the methacrylic acid content in the copolymer. 
However it was not clear from the data presented at what pH the 
effect was examined or to what extent the carboxylic acid residues 
were ionised. The effect of pH on the transport of sodium chloride 
through the methacrylic acid/PHEMA copolymer was investigated, 
however the data presented did not clearly indicate whether an 
increase in pH resulted in an increase or a decrease in the diffusion 
of sodium chloride. The effect of methacrylic acid content on the 
transport of magnesium sulphate was also examined, however in this 
case no effect was reported. In this case, the effect was considered 
due to the larger size of the hydrated magnesium and sulphate ions 
whose transport is considered to be primarily controlled by the 
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2.1 Materials
P ro p ra n o lo l h y d ro c h lo r id e  B.P. was re c e iv e d  as a g i f t  fro m  Forum  
C hem ica ls  L td ., R e d h il l,  U.K. B a tch  No. 3327. The c h e m ica l s t r u c tu re  
o f  p ro p ra n o lo l HC1 (m o le c u la r w e ig h t 295.8) is  show n  b e low  :
2 -H y d ro x y e th y l m e th a c ry la te  (HEMA), s ta te d  p u r i t y  > 97%. The
m onom er was s u p p lie d  by  F lu k a  C hem ica ls , th ro u g h  F lu o ro ch e m  L td , 
G lossop, U.K. B a tch  Nos. 261062 286, 265451 686, 274343 1187.
E th y le n e  g ly c o l d im e th a c ry la te  (EGDMA), s ta te d  p u r i t y  96%. The 
monom er was s u p p lie d  by F lu k a  C hem ica ls , th ro u g h  F lu o ro che m  L td , 
G lossop , U.K. B a tch  No. 200229 286.
Ammonium p e rs u lp h a te , e le c tro p h o re s is  g ra d e , s u p p lie d  by  FSA 
L a b o ra to r ie s  S u p p lie s , L o u g h b o ro u g h , U.K.
D iaza ld , s ta te d  p u r i t y  99%, s u p p lie d  by  A ld r ic h  C hem ica l Co. 
L td ., D o rse t, U.K.
A l l  o th e r  ch em ica ls  and s o lv e n ts  used w ere  o f  'a n a ly t ic a l 
re a g e n t' p u r i t y  u n le ss  o th e rw is e  s ta te d . S o lv e n ts  used in  HPLC 
a n a ly s is  w ere a l l  o f  HPLC g rade . The p re p a ra t io n  o f  a l l  b u f fe rs  used 
in  th is  w o rk  is  d e s c r ib e d  in  a p p e n d ix  2.
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2.2 Methods
2.2.1 Assay of Propranolol HC1 by U.V. Spectrophotometry
A series of different concentrations of propranolol 
hydrochloride solutions were prepared, and a scan performed on a 
double beam spectrophotometer (550S, Perkin Elmer Ltd., Slough, 
U.K.), using 1 cm path length quartz cuvettes. The solutions were 
scanned to determine a wavelength suitable for u.v. assay and to 
examine the effect of pH on the u.v. absorption of propranolol HC1.
The solutions were scanned between the wavelengths 190 and 400 nm. 
The solutions examined were as follows :
i) 9.67 x 10-5 M  Propranolol HC1 in distilled water
ii) 9.67 x 10-5 M  Propranolol HC1 in pH 3.03 buffer
iii) 9.67 x 10-5 M  Propranolol HC1 in pH 4.48 buffer
iv) 9.67 x 10-5 M  Propranolol HC1 in pH 10.05 buffer 
Details of the buffers used are given in appendix 2.
2.2.2 Assay of Propranolol HC1 by High Performance Liquid
Chromatography (HPLC)
The u.v. absorption at 288 nm of a solution of propranolol HC1 
was found to be unaffected when drug degradation was known to have 
occurred (section 2.3.1), thus another assay method capable of 
discerning the degradation products of propranolol HC1 was required.
A modified HPLC assay [127] was used in order to quantify the 
degradation of propranolol HC1. The HPLC column used was a 15 cm 
length, 0.5 cm internal diameter stainless steel column, packed with 
octadecylsilane (ODS) 5 pm reverse phase packing material (Hypersil, 
Shandon Southern Products, Runcorn, U.K.). The column was maintained 
at a constant temperature of 37°C. The mobile phase used was as
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follows :
Tetrabutylammonium hydroxide (40%) 25 ml
Phosphoric acid 8 ml
Methanol 450 ml
Distilled water to 1000 ml
The mobile phase was degassed with helium at room temperature 
for approximately fifteen minutes, and the pH adjusted to 2.5 using 
phosphoric acid. A flow rate of 1.2 ml min-1 was maintained through 
the column. Two systems were used depending on the volume of the 
sample for assay. Samples produced as described in section 4.2.1.3 
required the use of an automated system capable of assaying 0.2 ml 
samples. The system for general assay was composed of a sample 
injection valve (Rheodyne Inc., Cotati, U.S.A.) connected to a 25 pi 
injection loop. A constant flow pump (Constametric III G, LDC/Milton 
Roy, Staffordshire, U.K.) was used to drive the mobile phase through 
the column and through a u.v. detector (Spectromonitor III, 
LDC/Milton Roy, Staffordshire, U.K.). The u.v. detector was set to a 
wavelength of 288 nm, corresponding to one of the principal 
absorption wavelengths of propranolol hydrochloride (section 2.3.1).
The data was obtained as a continuous absorbance plot on a chart 
recorder.
The automated system used for small sample volumes was composed 
of an autosampler (SP8110 autosampler, Spectra-Physics Ltd., St. 
Albans, U.K.) feeding samples to a high performance liquid 
chromatograph (SP8100 liquid chromatograph, Spectra-Physics Ltd.,
St. Albans, U.K.). The presence of propranolol HC1 or its degradation 
products was quantified using a u.v. detector (SP8400 u.v. detector, 
Spectra-Physics Ltd., St. Albans, U.K.) connected to an integrator
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(SP4200 computing integrator, Spectra-Physics Ltd., St. Albans, U.K.)
The actual quantification of propranolol HC1 samples was by 
means of the external standard technique, where unknown samples are 
quantified by direct reference to known concentrations of • propranolol 
HC1.
2.2.3 Stability of Propranolol HC1
Some factors affecting the stability of propranolol HC1 have 
been reported [253]. For example it is known that propranolol HC1 is 
affected by light: in aqueous solution it decomposes through
oxidation of the isopropylamine side chain. This chemical change is 
accompanied by a reduction in the pH and discolouration of the 
solution. Solutions are most stable at pH 3 and decompose rapidly 
when alkaline.
The effect of pH on the aqueous stability of propranolol HCl was 
examined in the present study. A series of solutions containing 
propranolol HCl buffered at different pH's were prepared and stored 
in the dark under conditions of controlled temperature. One 
formulation was stored in the light and at room temperature (table 
2.1).
The solutions were assayed periodically by HPLC (section 2.2.2) 
to detect the amount of propranolol HCl remaining. The solution of 
propranolol HCl in pH 10.03 buffer was designed to accelerate 
degradation in order to validate the HPLC assay (section 2.3.2).
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Table 2.1 Formulation of solutions used in stability studies.
Solution Storage Conditions
0.179 irM propranolol HCl in distilled water
0.179 iriM propranolol HCl in pH 3.03 buffer*
0.179 irM propranolol HCl in pH 4.48 buffer*







2.2.4 Preparation of Poly(2-hydroxyethyl Methacrylate) (PHEMA)
Analytical grade monomers were used as received from suppliers 
without further purification. One reason for this was that simple 
purification techniques such as distillation are reported to be not 
entirely satisfactory since the rate of polymerization and 
trans-esterification reaction increase strongly with temperature 
[254,255]. The monomers may be purified by a complex procedure such 
as that involving extraction with hexane, distillation under vacuum 
and treatment with alumina, however even after this purification, low 
levels of impurity still remain [220,229]. The monomers were stored 
prior to use at 4°C in the dark in order to minimise any such 
degradation. In order to reduce variation within experiments, the 
same batch of polymer was used for any one set of experiments. It is 
known that the concentration of monomers used, together with the 
degree of crosslinking will influence polymerization and thereby 
alter the properties of the resulting gels [211,212,213]. The 
composition of polymers will be described by the terms %T and %C, 
where T denotes the total percentage of all monomers (v/v) in the 
final polymer formula and C denotes the percentage of crosslinker 
(v/v) in the monomer fraction. All polymers used in this work had a 
crosslinker content in the range 0 to 7%C (which corresponds to 
approximately 0 to 4.6 mole % crosslinking), all with a total monomer 
concentration of 62.5%T unless otherwise stated. A concentration of 
total monomer greater than 60% was chosen to ensure that homogeneous 
PHEMA was formed (section 1.6.1).
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2.2.4.1 Preparation of Crosslinked PHEMA by Gamma Irradiation
The use of radiation polymerized, rather than chemically 
polymerized gels has been favoured by some workers [210,211] due to 
reported differences in the swelling properties of PHEMA between the 
two methods and also due to the fact that initiators such as ammonium 
persulphate are not required for irradiation polymerization since 
free radicals are produced by gamma rays.
The gamma source used in the experiments reported here was 
Caesium-137. The gamma dose rate measured was 5.5 J kg-1 min-1 [127].
A 1%C, 62.5%T polymer solution was prepared as described below in
section 2.2.4.2 and 2 ml aliquots were filled into separate moulds.
The moulds used for irradiation polymerization consisted of glass 
tubes having a diameter of 2 cm and a length of 4 cm. The bottom end 
was sealed using a plastic sealing film (Nesco film, FSA, 
Loughborough), and the top end sealed with a glass microscope cover 
slip smeared with vacuum grease (Apiezon N, Apiezon Products Ltd., 
London, U.K.). The moulds were sealed under nitrogen, and were 
subsequently exposed to the gamma source at ambient temperatures for 
18 hours. This corresponded to a total irradiation dose of 594 krad.
2.2.4.2 Preparation of Crosslinked PHEMA by Chemical Initiation
The use of chemically polymerized gels has been reported by many 
workers [210,222,242,256], this method has been adopted for all the 
PHEMA films used in this work. Films were produced by polymerizing 
in an appropriate mould, as described below.
Each mould consisted of two thin glass plates having dimensions: 
0.2 cm thickness, 22 cm length and 11 cm width, as shown in figure 
2.1. Three aluminium strips were fixed onto the surface of one plate
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G la s s  P l a te s
Aluminium St r ip
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F ig u re  2.1. M o u ld  used  f o r  th e  c h e m ic a lly  in i t ia t e d  p o ly m e r iz a t io n  o f  
PHEMA. The tw o  h a lv e s  o f  a m o u ld  p r io r  to  assem b ly  a re  show n above , 
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around the perimeter of three of the plates edges using a silicone 
rubber adhesive (Silicone Rubber Compound, RS Components Ltd., 
Wetherby, U.K.) so that a gap was left between one of the short sides 
of the glass plate. The thickness of the aluminium strips determined 
the polymer film thickness. The mould was prepared for polymer film 
casting by sealing both plates together, spaced by the aluminium 
strips, using hydrogenated vegetable oil (Emvelop, Edward Mendell Co. 
Inc., New York, U.S.A.). This was achieved by heating both the moulds 
and the hydrogenated vegetable oil in an oven at 80°C prior to 
assembly, then carefully applying a layer of molten hydrogenated 
vegetable oil using a heated Pasteur pipette around the three edges 
of the mould having aluminium strips attached to them. The plates 
were then clamped together and allowed to cool, providing a water 
tight seal with one of the shorter edges of the plates being open to 
allow insertion of the polymerizing solution.
An example of a typical polymer formulation for 1%C, 62.5%T 
PHEMA was as follows :
EGDMA. 0.2 ml
HEMA 19.8 ml
Distilled water 8.0 ml
4% ammonium persulphate 4.0 ml
The HEMA monomer is added to the distilled water, the solution 
being stirred rapidly using a magnetic stirrer, the EGDMA was then 
added slowly using a calibrated automated pipette (P200, Gilson, 
Anachem, Luton, U.K.). The mixture was then degassed for 12 minutes, 
using helium. The polymerization initiator, ammonium persulphate, was 
then added as a freshly prepared aqueous solution, to give a final 
concentration of 0.5%, and the solution degassed for a further 3
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minutes. The mixture was then pipetted into the moulds using a 
Pasteur pipette. The moulds were partially immersed (up to the 
polymerizing solution level) in a water bath, which was then switched 
on and gradually allowed to heat up to 55°C so that the seal between 
the plates remained intact. Nitrogen was passed into a glass cover 
surrounding the plates at a slow, near-constant rate, so as to 
prevent contact of air with the polymerizing solution. The 
polymerization was allowed to proceed for 18 hours, after which the 
glass plates were separated and the polymerized PHEMA film peeled 
away. The plates were cleaned in a three stage process : firstly
using a surfactant solution, then acetone and finally distilled 
water.
2.2.5 Swelling Rate of PHEMA in Solution
The swelling characteristics of PHEMA gels polymerized 
chemically were examined gravimetrically. The swelling of 0.83%C, 
60%T PHEMA immersed in both water and pH 4.48 buffer (appendix 2) was 
investigated.
After polymerization was complete and the polymer removed from 
its mould (section 2.2.4.2), 4 cm diameter discs were immediately 
cut, blotted using absorbent paper to remove excess surface liquid, 
weighed and placed in separate beakers containing 40 cm3 of either 
buffer or water. The beakers were immersed in a water bath maintained 
at 25°C. The gel discs were removed at specified time intervals, 
blotted to remove superficial liquid, weighed and then returned to 
fresh water or buffer as appropriate. The degree of swelling was 
estimated from the observed percentage change in weight which was
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calculated as :
% swelling = 100 x Wt-Wo 
Wo
where :
Wt = weight of gel disc at a given immersion time 
Wo = weight of gel disc prior to initial immersion
2.2.6 Equilibrium Water Content of PHEMA
The equilibrium water content of a range of crosslinked PHEMA 
films was examined (0-7%C), the water content of gels stored in both 
water and pH 4.48 buffer (appendix 2) was examined.
Polymer discs of 4 cm diameter were immersed in beakers 
containing either water or buffer maintained at 25°C in a water bath, 
the discs were weighed daily (section 2.2.5) until they had reached 
equilibrium swelling. The gel discs were weighed, then dried in a 
vacuum oven at 55°C over phosphorous pentoxide, and weighed 
periodically until they reached constant weight. The equilibrium 
water content was calculated as a percentage :
% water content in PHEMA = 100 x Wh-Wd 
Wh
where :
Wh  = equilibrium weight of hydrated gel 
Wd = weight of dried gel
2.2.7 Scanning Electron Microscopy of PHEMA
PHEMA gel structure was examined using a scanning electron 
microscope (JEOL JSM 35C, Japanese Electron Optics Ltd., Tokyo, 
Japan).
Discs of 1%C PHEMA were cut and rapidly frozen by immersion in 
liquid nitrogen. The gel discs were then removed using forceps and
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fractured by striking with a hammer. The freeze fractured gels were 
then freeze dried overnight at -60°C (Edwards-Pearse Tissue Dryer 
EPD3, Edwards High Vacuum, Crawley, U.K.). Samples of the gel were 
mounted using a colloidal graphite adhesive on 2.6 cm diameter 
aluminium planchettes. A layer of gold was deposited onto the sample 
surface using a sputter coating technique (Edwards S150B, Edwards 
High Vacuum, Crawley, U.K.). During coating a vacuum of 100 pm of 
mercury was drawn and a current of 20 mA  at 1.4 kV was applied across 
the sample planchettes for six minutes. The gold coated samples were 
then imaged immediately in the scanning electron microscope using an 
electron beam energy of both firstly 5 kV and then 20 kV. The gold 
and graphite layers ensured that the specimens were fully earthed to 
prevent charge build up and overheating.
2.2.8 Diffusion of Propranolol HCl through PHEMA Films
The effect of PHEMA crosslinker content on the diffusion 
coefficient of propranolol HCl through crosslinked PHEMA films was 
investigated. The method used to determine diffusion coefficients was 
based on zero-order flux through a polymer membrane with defined 
boundary conditions (see also appendix 1). The diffusional transport 
of propranolol HCl across crosslinked PHEMA films was monitored from 
a reservoir (or donor) into a receptor compartment. The glass 
diffusion cell used is shown in figure 2.2. Each compartment of the 
cell had a capacity of approximately 220 ml. The cell was designed to 
satisfy the following criteria according to theoretical and 
experimental requirements :
i) Stirring must be adequate and constant in order to (minimize 
boundary layers and to give reproducible analysis of diffusion
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S t i r r e r
PHEMA Film
R e c e p t o rDonor PTFE G a s k e t
F ig u re  2.2. S chem a tic  d ia g ra m  o f  g la ss  c e l l  used  to  s tu d y  th e  
d i f fu s io n  o f  p ro p ra n o lo l H C l th ro u g h  c ro s s lin k e d  PHEMA f ilm s .
-  70 -
results.
ii) The cell interface must be designed to provide an efficient 
seal.
iii) The cell interface should not excessively strain the polymer 
film, which would result in distortion and could thus induce 
flaws in the film and produce erroneous or misleading results.
A range of crosslinked PHEMA films (0-7%C) of approximately 
0.1 cm thickness were prepared as described above in section 2.2.4.2, 
and discs of 4 cm diameter were cut. The discs were stored in pH 4.48 
buffer prior to use. The interfacial ground glass joints of the 
diffusion cell were smeared with a thin layer of vacuum grease 
(Apiezon N). An annular sheet of polytetrafluoroethylene (PTFE), 
with a thickness of 0.08 cm and internal diameter of 4 cm was used as 
a liquid-tight gasket. The PTFE gasket was placed at the interface of 
the donor cell, and a disc of polymer film placed in its centre. The 
diffusion cell was then clamped tightly and provided an exposed area 
of polymer film of 6.16 cm2. Into the receptor compartment was placed 
210 ml of pH 4.48 buffer, prepared as described in appendix 2, and 
into the donor was placed 200 ml of pH 4.48 buffer. The whole 
diffusion cell was mounted in a specially constructed perspex stand 
and immersed in a water bath maintained at 25°C. The compartments 
were stirred continuously using perspex stirrers driven by 12 volt 
motors at 330 rev min-1 (RS Components Ltd., Corby, U.K.), which were 
powered by a constant voltage power supply (E30/1 Farnell Instruments 
Ltd, Wetherby, U.K.).
The cell was allowed to equilibrate for 30 minutes, after which 
20 ml of a stock propranolol HCl solution was added to the donor 
compartment to give a concentration of approximately 7 mM, timing was
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started. After 15 seconds a 10 ml sample was withdrawn from the donor 
compartment using a pipette to give a measurement of the initial 
donor propranolol HCl concentration. This sample was analysed by u.v. 
spectrophotometry (section 2.2.1).
The diffusion coefficient was determined by monitoring the 
concentration of propranolol HCl in the receptor compartment. The 
receptor cell analysis, data collection and data manipulation were 
all automated. The receptor cell solution was pumped at a rate of 
0.5 ml min-1 (Gilson Minipuls 2, Anachem, Luton, U.K.) into a 
flow-through u.v. detector (Gilson 116, Anachem, Luton, U.K.), and 
the outflow returned to the receptor cell. The u.v. detector, set to 
a wavelength of 288 nm corresponding to the wavelength of principal 
absorption for propranolol HCl (section 2.3.1), was connected to a 
microcomputer (BBC Master, Acorn Computers Ltd., Cambridge, U.K.), 
which collected the data at preprogrammed time intervals of one hour, 
converted them into concentration values, and stored all the data 
onto floppy disc at the end of each experiment. The data was then 
analysed using a statistics package (INSTAT, University of Reading, 
U.K.), which enabled diffusion parameters to be calculated from 
Barrer Plots, as described in appendix 1. A schematic diagram of the 
apparatus used is shown in figure 2.3.
The computer was calibrated by passing a number of solutions of 
known concentration through the u.v. detector. The programs used to 
calibrate the detector and collect data are given in appendix 3. A 
control experiment was performed in which no drug was added to the 
donor compartment to check for baseline drift. A second control 
experiment was also performed where a solution of approximately 
4 x 10-5M propranolol HCl was pumped through the u.v. detector. No
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Figure 2.3. Schematic diagram of the apparatus used to measure the 
diffusion coefficient of propranolol HCl through crosslinked PHEMA 
films.
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significant drift in either control was found over a period of five 
days under these conditions.
A series of crosslinked PHEMA films were investigated, three 
replicates being performed for any particular crosslinked hydrogel.
At the end of each experiment the hydrogel film thickness was 
measured (section 2.3.4.2).
2.2.9 Uptake of Propranolol HCl by PHEMA
An interaction between the cationic preservative chlorhexidine 
and PHEMA has previously been shown in aqueous solution (as described 
in section 1.6.4) and it has been postulated that similar 
interactions may occur between PHEMA and other cationic drugs [250]. 
Thus in the experiments reported here the sorption isotherm of 
propranolol HCl in solution with PHEMA was investigated to see 
whether any similar interaction exists between PHEMA and propranolol 
HCl in solution.
Films of 1% crosslinked PHEMA, with a thickness of approximately 
0.1 cm, were prepared as described in section 2.2.4.2, and discs of 
1 cm diameter cut. The discs were then stored in pH 4.48 buffer 
(appendix 2) for approximately three weeks, the buffer being 
exchanged several times. The discs were then blotted with tissue to 
remove any excess surface liquid, and accurately weighed. The samples 
were then placed in a series of dry, 20 ml screw-top vials. A series 
of different concentrations of propranolol HCl in pH 4.48 buffer |was 
prepared in the concentration range 0 to 3.4 mM. 10 ml of the 
appropriate propranolol HCl solution was then added to each vial. 
Five replicates were performed for each concentration. Samples of 
polymer in buffer without propranolol HCl, and samples of propranolol
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HCl . in buffer without polymer were also prepared in a similar way as 
controls. The vials were then inserted into racks which were placed 
in a thermostatted shaking water bath maintained at a temperature of 
25°C, and shaken at a rate of 70 cycles min-1. The racks ensured that 
the vials remained upright during the experiment. The samples were 
allowed to equilibrate for 21 days after which samples were taken 
from the vials, and following appropriate dilution were assayed by 
means of u.v. spectrophotometry (as described in section 2.2.1). The 
sorption isotherm was determined by calculating the equilibrium 
concentration of propranolol HCl, and the uptake of propranolol HCl 
by the PHEMA films.
2.2.10 Effect of Methylation of the Free Carboxyl Groups in PHEMA
The effect of methylating the free carboxyl groups in PHEMA by 
esterification using diazomethane was examined. The effect on the 
interaction of propranolol HCl with PHEMA was determined, together 
with the effect on the diffusion of propranolol HCl through 
crosslinked PHEMA films.
2.2.10.1 Methylation of PHEMA
Esterification of carboxyl groups in PHEMA was effected with 
diazomethane which is a selective methylating agent for acidic 
protons under the reaction conditions used [251,257,258], alcoholic 
protons being inert towards the methylating agent. The reaction may 
be expressed in the following manner :
CH2N2 + RCOOH --►  RCOOCH3 + N 2
A range of crosslinked PHEMA films (0-7%C) of approximately 
0.1 cm thickness and 4 cm diameter were prepared as described above
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in section 2.2.4.2. Additionally 1 cm discs of 1%C were prepared for 
use in the uptake studies in section 2.2.10.3. The water in the 
polymer was exchanged with absolute ethanol by suspending the discs 
in 100 ml portions of absolute ethanol. The absolute ethanol was 
replaced daily over a period of two weeks.
Freshly distilled ethereal solutions of diazomethane were 
prepared [259]. Diazomethane production is a potentially explosive 
reaction, and therefore full safety precautions were necessary, 
including the use of scratch free glassware (Diazald Kit, supplied by 
Aldrich Chemical Co. Ltd., Dorset, U.K.). 50 ml of 96% ethanol was 
added to a solution of 10 g of potassium hydroxide in 15 ml of water, 
in a 200 ml distillation flask, mounted in a water bath maintained at 
63°C. To the flask was connected a dropping funnel and an efficient 
condenser. The condenser was connected with a 500 ml round bottom 
receiving flask, which was cooled with an ice-salt mixture. A 
solution of 43 g of N-methyl-N-nitrosotoluene-4-sulphonamide 
(Diazald, supplied by Aldrich Chemical Co. Ltd., Dorset, U.K.) in 
250 ml of ether was placed into the dropping funnel, which was 
adjusted so that the drop rate from it was approximately equal to 
the distillate drop rate. When the dropping funnel emptied, another 
fresh portion of approximately 25 ml of ether was added to the 
dropping funnel until the condensing distillate became colourless.
The receiving flask containing ethereal diazomethane was then stored 
in an ice-salt mixture until ready for use.
Methylation of the polymer was achieved at room temperature, by 
adding 10 ml of the ethereal diazomethane to a series of conical 
flasks containing the polymer discs suspended in 100 ml of absolute 
ethanol. The polymer was allowed to stand for two hours, and the
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suspending liquid poured into dilute acetic acid to destroy residual 
diazomethane. The process was repeated again with a fresh portion of 
absolute ethanol and another portion of ethereal diazomethane added 
to the flasks, and allowed to stand for a further two hours. The 
suspending liquid was then once again replenished with fresh absolute 
ethanol and ethereal diazomethane, and allowed to stand overnight. 
The absolute ethanol was then exchanged with water. This was achieved 
by suspending the discs in distilled water for a period of two weeks, 
replacing the water daily. The discs were then separated into three 
portions; one portion was retained for the diffusion studies in 
section 2.2.10.4, the discs being immersed in pH 4.48 buffer 
(appendix 2), which was replaced several times. The 1 cm, 1%C discs, 
also immersed in pH 4.48 buffer, were retained for use in the uptake 
studies in section 2.2.10.3. The final portion of 1%C discs were 
retained for assay to check for the presence of carboxyl groups 
(section 2.2.10.2).
2.2.10.2 Assay of PHEMA for Free Carboxyl Groups
An assay of the free carboxyl content in PHEMA by directly 
titrating the carboxyl groups with potassium hydroxide has been 
reported [251] and was adopted in these experiments.
Samples of 1%C PHEMA (prepared as described in section 2.2.4.2) 
and 1%C methylated PHEMA (prepared as described in section 2.2.10.1) 
stored in distilled water were used to assess the carboxyl content of 
PHEMA and also to assess the success of the methylation reaction 
described in section 2.2.10.1. The samples were firstly dried over 
phosphorous pentoxide in a vacuum oven at 60°C for 48 hours, with a 
fresh portion of phosphorous pentoxide used after 24 hours. The
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polymer samples were then ground in an analytical mill (A10, Janke 
and Kunkel, supplied by Sartorius Instruments, Surrey, U.K.), and the 
powdered polymer stored in screw cap vials which were placed in a low 
humidity jar until ready for use. HEMA monomer was also analysed for 
carboxyl content.
The titration of carboxyl end groups in PHEMA required a 
standardised ethanolic solution of potassium hydroxide. A fresh 
solution of approximately 0.008 M  potassium hydroxide in absolute 
ethanol was prepared daily and standardised against benzoic acid; a 
stream of nitrogen was bubbled through 20 ml of 0.008 M  benzoic acid 
in absolute ethanol for five minutes to displace carbon dioxide. The 
solution was then titrated with the ethanolic potassium hydroxide, 
using two drops of phenolphthalein as indicator. 20 ml aliquots of 
absolute ethanol were also titrated to allow for solvent blank 
corrections.
The assay of the carboxyl groups was performed using
approximately 1 g of either powdered PHEMA or 1 g of HEMA monomer 
suspended in 20 ml of absolute ethanol, in a glass stoppered two neck 
flask. Nitrogen was bubbled through the suspension for five minutes.
The polymer suspension was then titrated with the ethanolic potassium 
hydroxide, using phenolphthalein as an indicator. The end point was 
considered to have been reached once a stable pink colour was 
obtained and which persisted for one hour, to allow diffusion of 
hydroxide ions into the polymer. The flask was frequently flushed 
with nitrogen during the titration.
The carboxyl content was determined in the form of millimoles of 
carboxyl groups per kilogram of polymer. Solvent blank corrections 
were taken into account in the calculations. Each assay was performed
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in triplicate.
2.2.10.3 Uptake of Propranolol HCl by Methylated PHEMA
The uptake of propranolol HCl by PHEMA, expressed as a sorption 
isotherm, indicates an interaction between propranolol HCl and PHEMA 
in aqueous solution (section 2.3.9). A similar type of interaction 
has been shown between the cationic preservative chlorhexidine and 
PHEMA in aqueous solution, where the interaction was due to an 
ion-ion interaction between the free carboxyl groups in PHEMA and 
chlorhexidine [250,251]. In the present study the uptake of 
propranolol HCl by methylated PHEMA will be examined to see whether 
the interaction can be explained by a similar ion-ion mechanism.
Samples of 1%C methylated PHEMA, in the form of 1 cm discs were 
prepared (section 2.2.10.1). The uptake of propranolol HCl by the 
methylated polymer was determined according to the method described 
in section 2.2.9.
2.2.10.4 Diffusion of Propranolol HCl through Methylated PHEMA Films
The diffusion of propranolol HCl through films of crosslinked
PHEMA films was found to be anomalous with respect to the effect 
which an alteration of the crosslinker content in PHEMA had on the 
diffusion coefficient of propranolol HCl through PHEMA (section
2.3.8). In the present study the effect of the carboxyl content in 
PHEMA on the diffusion coefficient of propranolol HCl through 
crosslinked PHEMA films was investigated, to examine whether this 
anomalous diffusion behaviour is a result of an ion-ion interaction 
between propranolol HCl and PHEMA.
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4 cm Discs of methylated PHEMA films of approximately 0.1 cm 
thickness were prepared (section 2.2.10.1) in the crosslinker range 0 
to 7%C. The diffusion coefficient of propranolol HCl through the 
films were determined according to the method described in section 
2.2.8. Three replicates were performed for any particular crosslinked 
polymer.
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2.3 Results and Discussion
2.3.1 Assay of Propranolol HCl by U.V. Spectrophotometry
Scans on solutions containing propranolol HCl in buffers ranging 
from pH 3 to 10 showed that the spectra were unaffected by pH in the 
region 190 to 400 nm. The spectra obtained (figure 2.4) showed 
absorption peaks characteristic of the naphthalene group found in 
propranolol HCl [260]. The peak at 288 nm was chosen for assay use 
since it was the principal absorption peak. A series of solutions of 
propranolol HCl in pH 4.48 buffer were prepared in the range 0 to 
3.0 x 10-4M  from which a Beer-Lambert plot was constructed (figure 
2.5). Linear regression analysis of the data produced the following 
statistics :
Number of data points : 5
r2 : 0.9999
Slope (S.D) : 5700.2 (25.39)
Intercept (S.D) : 6.986 x 10"3 (4.289 x 10"3)
The results showed a linear relationship and it was therefore 
considered that use of a u.v. assay was appropriate for analyses in 
the concentration range examined. The molar absorption coefficient, 
c, was found to be 5700, corresponding to an E(1 per cent, 1cm) value 
of 192.7. These values are consistent with those that would be 
expected for a naphthalene group absorbing at a wavelength of 288 nm. 
The assay though satisfactory for quantifying concentrations of drug 
in solution was found not to be stability indicating. The absorbance 
value of a decomposing solution of propranolol HCl in pH 10.03 buffer 
(section 2.2.3) was found not to change with time, thus a u.v. assay 
alone would not be capable of distinguishing the presence of 
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Figure 2.4. U.V. spectrum of propranolol HCl at a concentration of 
9.67 x 10-5M in pH 4.48 buffer.
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Figure 2.5. Beer-Lambert plot for propranolol HCl in pH 4.48 buffer 
at 288nm.
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2.3.2 Assay of Propranolol HCl by High Performance Liquid 
Chromatography (HPLC)
An example of a HPLC chromatogram of propranolol HCl is shown in 
figure 2.6. The HPLC assay was shown to be stability indicating by 
analysis of data obtained by injecting decomposing samples of 
propranolol HCl in pH 10.03 buffer (section 2.2.3). The main 
propranolol peak, with a retention time of approximately 3.6 minutes, 
was found to decrease, accompanied by a decomposition product peak 
which increased as progressively older solutions were injected. 
Propranolol HCl in pH 4.48 buffer produced only one peak, with a 
retention time of approximately 3.6 minutes.
The relationship between peak area (and peak height) against 
concentration for propranolol HCl were found to be linear over the
concentration range of 0 to 1.4 x 10_4M. Sample solutions were
prepared in pH 4.48 buffer (appendix 2) and were injected in 
duplicate to give a mean value for peak area (and height). A 
calibration curve is shown in figure 2.7 of mean peak area against 
concentration. The accompanying linear regression analysis data is 
shown below :
Number of data points : 5
r2 : 0.9997
The results show a linear relationship thus the HPLC assay using 
the external standard method was deemed satisfactory. The assay was 
also shown to be stability indicating.
Slope (S.D) 
Intercept (S.D)





Figure 2.6. HPLC chromatogram of propranolol HCl (9.67 xlO-5M) in 
pH 10.05 buffer showing a degradation product peak (A) and 
propranolol HCl peak (B).
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Figure 2.7. HPLC calibration plot for propranolol HCI.
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2.3.3 Stability of Propranolol HCI
The samples prepared for stability studies were analysed 
periodically over a period of three months using HPLC (section 
2.2.2). As expected the solution of propranolol HCI in pH 10.03 
buffer degraded visibly, with the solution turning a light brown with 
time. The amount of propranolol HCI remaining in solution with 
respect to time was monitored for all four solutions. The pH of the 
aqueous solution was found to be 5.33 (appendix 2). The percentage of 
propranolol HCI remaining in solution with time and the effect of pH 
is shown in table 2.2. The results show that propranolol HCI 
decomposes rapidly at a pH of 10.05, but is stable for at least one 
month if stored at a pH below 5.33 and at a temperature of 25°C 
protected from light.
Table 2.2 The percentage of propranolol HCI remaining in 
solution with time when stored at various pH's. (See section 2.2.3 
for storage conditions)
PH
Time 3 .03 4.48 5.33 10.03
10 Days 100 100 100 88
23 Days 100 100 100 66
37 Days 100 100 100 50
3 Months 98 98 94 0
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2.3.4 Preparation of Poly(2-Hydroxyethyl Methacrylate) PHEMA
2.3.4.1 Preparation of Crosslinked PHEMA by Gamma Irradiation
Successful polymerization could not be achieved using gamma
irradiation. Polymerization was found to be incomplete after 12 
hours, however after 18 hours the polymerization was found to be 
complete. The resultant polymer however was unsatisfactory. 
Macroscopic examination of the polymer showed that its shape was 
deformed and had an uneven surface, there were also air bubbles 
within the structure. The same problem has been previously 
encountered using the same radiation source [127]. The cause of the 
problem is probably related to a number of factors. Due to the nature 
of the source, samples are in very close proximity to the source 
which may result in uneven irradiation. In addition, due to the 
physical location of the source, it is not possible to exclude air 
from the polymerizing system. Another problem was that no temperature 
control could be effected during polymerization. In view of these 
problems and the nature of the radiation source it was decided to use 
chemically polymerized PHEMA in all subsequent work.
2.3.4.2 Preparation of Crosslinked PHEMA by Chemical Initiation
The method of solution polymerization produced homogeneous, 
transparent, ductile films. The films were free of any air bubbles 
and were easily removed from the glass moulds. The effect on the 
physical properties of increasing the crosslinker content was to 
decrease the polymers ductility. The films produced were homogeneous, 
however it was found that if higher water contents than about 42% 
were used, heterogeneous films were produced due to phase separation. 
These heterogeneous films were visibly different being white, opaque
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and spongy in nature. The critical value of water that causes this 
turbidity is determined by amongst other things, the crosslinker 
content in the film [214].
The films were stored in distilled water in a fridge at 4°C, the 
distilled water being changed daily for 21 days. The purpose of this 
being to leach out any ammonium persulphate or unreacted monomers, 
and to allow the polymer to swell to its equilibrium volume [255].
The polymer was then cut into disc form and immersed in either buffer 
or water, depending on the intended experiment, and stored in the 
dark at 4°C until ready for use.
The hydrogel film thickness was measured by placing it between 
two glass plates of known thickness and measuring the total thickness 
with a precision digital micrometer (Mitutoyo, supplied by RS 
Components Ltd., Corby, U.K.), using the torque control so as not to 
compress the hydrogel. The films were found to be approximately 
0.09 cm in thickness.
2.3.5 Swelling Rate of PHEMA in Solution
The results obtained for the swelling of PHEMA in water (figure
2.8) show that the polymer attained equilibrium after approximately 
48 hours, the same type of profile has been obtained independently by 
other workers [209]. Some work has demonstrated anomalous swelling of 
chemically polymerized PHEMA [210] where the swelling exhibited a 
maximum followed by a minimum, the polymer not reaching equilibrium 
for about 14 days. This behaviour was ascribed to adsorption of 
initiator persulphate ions onto the polymer chains, however this 
effect was not seen in this work. The swelling in acetate buffer 
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found to be followed by a minimum which was in turn followed by a 
second gradual reswelling. This anomalous swelling behaviour was 
reproducible but is not easily explained. The swelling of PHEMA in 
solutions with other solutes including sodium acetate and acetic 
acid alone has been examined [210], each producing a different 
swelling behaviour attributed to the fact that with acetic acid, 
mainly unionised solute exists which can penetrate the polymer 
easily, unlike in the fully ionised sodium acetate. Factors 
determining solute effects on swelling include osmotic activity, 
solute size, and effects on polymer network bonding. Thus the 
anomalous behaviour seen in acetate buffer may be a complex 
combination of different effects on polymer swelling.
2.3.6 Equilibrium Water Content of PHEMA
The effect of crosslinker content on the equilibrium water 
content of PHEMA is shown in figure 2.9. The equilibrium water 
content of PHEMA stored in acetate buffer is slightly greater than 
that of polymer stored in water for all crosslinker contents. In the 
case of PHEMA stored in both water and buffer we see a relatively 
small decrease in equilibrium water content as crosslinker content is 
increased. This effect has been attributed to the network structure 
of PHEMA, in particular to the non-covalent secondary structure 
(section 1.6.1). The secondary structure, superimposed onto the 
covalent network is thought to control the swelling behaviour of the 
hydrogel. The equilibrium water content of PHEMA stored in water has 
been looked at by other workers, similar results being found 
[213,261]. Though increasing crosslinker content only decreases water 
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within the hydrogel is thought to change significantly, the 
percentage of bulk water decreasing, accompanied by an increase in 
the percentage of bound and interfacial water (section 1.6.1). These 
subtle changes can have a significant effect on the diffusion 
behaviour of solutes through PHEMA (section 1.6.3, section 2.3.8).
2.3.7 Scanning Electron Microscopy of PHEMA
Electron micrographs of PHEMA are shown in figure 2.10. The low 
magnification micrograph shows an exposed fracture surface of the 
hydrogel (figure 2.10a), at this magnification the polymer surface 
appears quite smooth. The maximum magnification that could be 
achieved was limited by the electron beam energy. The use of high 
energy beams on a localised area resulted in destruction of the PHEMA 
surface, seen visibly as blistering. The highest magnification that 
could be achieved was X5000 (figure 2.10b), with a beam energy of 
5 kV. At this magnification no details of the polymers ultrastructure 
could be seen. Similar results have been found by other workers 
[262], however some ultrastructure was visible when the sample was 
frozen and observed at liquid nitrogen temperatures, allowing the 
sample to warm up slowly. This results in sublimation of the ice to 
reveal a fine structure, however the authors suspect the structure 
could be an artefact. Other SEM work on porous PHEMA has revealed an 
ultrastructure on the surface of PHEMA [212], but there were no 
details provided of preparation of the samples for microscopy.
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F ig u re  2.10a. E le c tro n  m ic ro g ra p h  o f  1% c ro s s lin k e d  PHEMA (X 75).
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Figure 2.10b. Electron micrograph of 1% crosslinked PHEMA (X 5000).
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2.3.8 Diffusion of Propranolol HCI through PHEMA Films
A typical Barrer Plot showing the concentration of propranolol 
HCI in the receptor compartment against time is shown in figure 
2.11. The advantages of using an automated data collecting method can 
be seen in the large number of data points that can be collected, 
facilitating the analyses of data. The diffusion coefficients of 
propranolol HCI through the films of PHEMA were calculated from the 
lag times of the Barrer Plots (appendix 1), steady state not being 
assumed to have been reached until at least 2.7 times the initial lag 
period was achieved. Figure 2.12 shows the relationship found between 
the diffusion coefficient of propranolol HCI through PHEMA films and 
crosslinker content, each datum point representing the mean of three 
replicates. The results show that as crosslinker content is 
decreased, the diffusion coefficient increases rapidly, then tails 
off.
There are two main factors affecting the diffusion
characteristics of solutes through PHEMA, namely the crosslinking 
density and the organisation of water within the gel [244]. There 
have been relatively few studies investigating the effect of
crosslinking density on the diffusion coefficient of a particular 
solute [263], however those that have been carried out have shown a
relationship which differs from that found with propranolol HCI
[242,243,245,264]. Similar results are found at higher crosslinker 
contents, however the tailing at lower crosslinker contents was not 
found in any previous work, other workers having found that the 






























Figure 2.11. Barrer Plot for the diffusion of propranolol HCI through 
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Figure 2.12. Effect of crosslinker content in PHEMA on the diffusion 
coefficient of propranolol HCI through crosslinked PHEMA films (with 
standard error bars shown).
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The effect of crosslinker content on the diffusion coefficient 
in crosslinked PHEMA can be related to changes in the diffusion 
mechanism that occur (section 1.6.3). At low crosslinker contents a 
predominantly pore mechanism of diffusion exists as a result of the 
bulk water within the hydrogel. As the crosslinker content is 
increased a decrease in pore size is considered to occur along with 
changes in the water composition within the hydrogel, and solute 
diffusion is now predominantly the result of the so-called partition 
mechanism, where a solute is thought to be transported along the 
polymer backbone, via the bound and interfacial water fractions. 
These changes in mechanism can be seen in figure 2.12 with 
propranolol HCI, where at low crosslinker contents (about 3%C and 
less) a predominantly pore mechanism of diffusion probably exists, 
but as the crosslinker content is increased, diffusional transport 
becomes predominantly partition mechanism dominated. For the 
generalized condition it is considered that both mechanisms probably 
occur synchronously, with one of the two predominating in specific 
conditions.
It would be expected from previous work, and from theory, that 
the diffusion coefficient should increase more rapidly as the 
crosslinker content is decreased. It was thought that the cause of 
the anomaly found in the present study may result from an interaction 
between propranolol HCI and PHEMA in aqueous solution; this is 
considered further in section 2.3.9.
In support of the proposed change in mechanism of diffusion are 
the changes in partition coefficients obtained as the crosslinker 
content is increased. Partition coefficients were determined from 
the gradient of the steady state portion of the Barrer plots (see
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appendix 1), using the diffusion coefficients obtained from lag times 
to give an estimate of the partition coefficient. The general trend 
found was a decrease in the value of the partition coefficients as 
crosslinker content was increased as shown in table 2.3. It should 
also be noted that for all crosslinker contents the partition 
coefficients are greater than one, which suggests that propranolol 
HCI may be interacting with the polymer.
The changes in equilibrium water content of PHEMA as crosslinker 
content is increased also supports the proposed changes in diffusion 
mechanism (section 2.3.6). The changes in the diffusion coefficient 
are consistent with an expected decrease in the proportion of 
Domain B water accompanied by an increase in the proportion of 
Domain A water as crosslinker content is increased and equilibrium 
water content decreased (section 1.6.1).
Table 2.3 Variation in the partition coefficient of propranolol HCI 
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2.3.9 Uptake of Propranolol HCI by PHEMA
The sorption isotherm at 25°C of propranolol HCI in buffered 
solution with PHEMA is shown in figure 2.13. The control samples 
showed that there was no measurable loss of propranolol HCI to the 
glass vials, and that the PHEMA samples did not leach any substances 
detectable by u.v. assay.
The isotherm obtained was found to be similar to that obtained 
for chlorhexidine digluconate in aqueous solution with PHEMA [249], 
where an initial steep portion is found, which then decreased in 
steepness. This type of isotherm has been classified as a high 
affinity (HI) isotherm [246], and is associated with a surface 
adsorption process where a solute has a high affinity for adsorbent, 
however one would expect the isotherm to plateau as the polymer 
becomes saturated, though this was not found with either 
chlorhexidine digluconate, or propranolol HCI studied in this work, 
perhaps because the concentrations examined were too low.
It has been suggested that the interaction between chlorhexidine 
digluconate and PHEMA is due to an ion-ion interaction between 
carboxyl groups in PHEMA and the positively charged chlorhexidine ion 
(see section 1.6.4), the sorption isotherm perhaps being a 
composition of an initial portion representing a high affinity 
uptake, superimposed on which is an interaction with the polymer 
matrix [251]. This would perhaps explain why no plateau is found in 
the sorption isotherm.
It has been speculated that the type of interaction between 
chlorhexidine and PHEMA may be a feature of other positively charged 
ions besides chlorhexidine [250], thus the cause of the interaction 
between propranolol HCI and PHEMA in buffered solution may also be
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Figure 2.13. Sorption isotherm of propranolol HCI in buffer at 25°C 
with 1%C PHEMA.
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due to such an interaction between the cationic propranolol ion and 
carboxyl groups in PHEMA, this is investigated in section 2.2.10.3.
There are also the possibilities of hydrogen bonding or even 
hydrophobic bonding between the propranolol molecule and PHEMA which 
may act as stabilizing bonds, as seems to occur with chlorhexidine 
[250].
If such an interaction can be shown between propranolol HCI and 
PHEMA, it may explain the anomalous diffusion behaviour of 
propranolol HCI through PHEMA films found in section 2.2.8.
2.3.10 Effect of Methylation of the Free Carboxyl Groups in PHEMA
2.3.10.1 Methylation of PHEMA
The PHEMA discs initially became slightly opaque when the water 
was exchanged with ethanol prior to methylation, however the discs 
became transparent again after approximately 24 hours. The size of 
the discs changed after storage in ethanol, their diameters 
increasing together with an increase in their thickness. This process 
was reversed after methylation when the ethanol was exchanged with 
water, the polymers returning to their original size.
The production of diazomethane appeared successful, the activity 
of the pale yellow ethereal diazomethane was demonstrated by 
vigorous bubbling due to the evolution of nitrogen when a few drops 
of diazomethane were carefully transferred to a beaker of dilute 
acetic acid. After each methylation reaction the diazomethane 
solution was found to retain some activity as vigorous bubbling 
occurred when the residual solution was poured into dilute acetic 
acid, indicating the presence of excess diazomethane.
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2.3.10.2 Assay of PHEMA for Free Carboxyl Groups
The carboxyl content of the samples analysed were as follows :
HEMA monomer : 110.2 mmolkg-1 (S.D.=5.7)
Untreated PHEMA : 92.7 mmolkg-1 (S.D.=9.3)
Methylated PHEMA : 3.6 mmolkg-1 (S.D.=0.5)
The actual value for the HEMA monomer is probably less than that 
value produced in the assay as HEMA contains hydroquinone as a 
stabilizer. If both hydroxyl groups on the hydroquinone molecule 
react with potassium hydroxide in the titration, then the 
hydroquinone, at a concentration of 0.03%, will account for 
approximately 5 mmolkg-1. There is probably a negligible amount of 
the stabilizer in the PHEMA as it would have been leached out in the 
preparation process (section 2.3.4.2).
The results appear to show the methylation of PHEMA to have been 
successful. The value for the carboxyl content of the methylated 
PHEMA are comparable to published values [251], however the values 
for both the untreated PHEMA and the HEMA monomer are greater than 
those found in previous studies. The values published in the 
literature for HEMA monomer is 2.2 mmolkg-1, and for untreated PHEMA 
as 30 to 34 mmolkg-1 depending on the batch of polymer. It was 
suggested that the difference between the monomer content and 
untreated PHEMA carboxyl content was due to acidic residues being 
generated in situ during polymerization [251]. In this present study 
however the values for monomer and untreated PHEMA are comparable, 
suggesting that PHEMA carboxyl content is related to monomer 
methacrylic acid content.
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2.3.10.3 Uptake of Propranolol HCI by Methylated PHEMA
The sorption isotherms at 25°C for propranolol HCI in buffered 
solution with both methylated and untreated PHEMA are shown in 
figure 2.14. The isotherm for the methylated PHEMA shows that the 
propranolol HCI is taken up to a lesser extent than the untreated 
PHEMA, however the dramatic reduction in uptake that is seen with 
chlorhexidine digluconate and methylated PHEMA is not found in this 
study [251]. In the case of chlorhexidine uptake, a dramatic 
reduction is found, with only a small uptake compared to the 
untreated PHEMA, the residual interaction being related to the 
unreacted carboxyl residues.
The isotherm for propranolol HCI and methylated PHEMA 
(figure 2.14) shows that the carboxyl groups are only partly 
responsible for the interaction between propranolol HCI and PHEMA, 
one or more other interactions such as van der Waals forces, hydrogen 
bonding, or hydrophobic bonding may also be occurring, which in view 
of the functional groups present in propranolol HCI are all feasible. 
Support for this hypothesis comes from the values of partition 
coefficients calculated in section 2.3.8. The results indicate that 
the carboxyl content in PHEMA may be the predominant cause of 
interaction with some cationic drugs such as chlorhexidine, but as 
shown with propranolol HCI other interactions may be equally 
significant.
The pKa of the carboxyl groups in PHEMA should be carefully 
considered as it will determine the extent of ionisation of the 
groups at any given pH. The literature value for the pKa of 
methacrylic acid is 4.7 [265], however this may not be the value at
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Figure 2.14. Sorption isotherms of propranolol HCI in buffer at 25°C 
with 1%C methylated and untreated PHEMA.
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methacrylic acid may alter this pKa value. The pKa will also be 
affected by the nature of bound water, which would be expected to 
possess a lower dielectric constant than free aqueous water. Recent 
studies have indicated that the pKa of methacrylic acid incorporated 
into PHEMA may be as high as 6 to 7 [220], thus some caution is
necessary in interpreting the results found in this study and 
previous studies with chlorhexidine digluconate as the pKa of the 
polymeric carboxyl groups was anticipated as being in the region of 3 
to 4.
2.3.10.4 Diffusion of Propranolol HCL through Methylated PHEMA Films
The effect of methylating the carboxyl groups in PHEMA on the 
diffusion coefficient of propranolol HCI through crosslinked PHEMA 
films is shown in figure 2.15. Each pair of data points at any given 
crosslinker concentration were examined using a Students t-test to 
see if there was any statistically significant difference between the 
diffusion coefficient through methylated and untreated PHEMA, 
table 2.4 shows the significance levels calculated for each pair of 
points. These results suggest that the carboxyl groups in PHEMA 
appear to have an effect on the diffusion of propranolol HCI through 
PHEMA films when the predominant route of diffusion is via the pore 
mechanism (at low crosslinker content), however the carboxyl content 
does not seem to have any effect on the diffusion coefficient when a 
partition mechanism is in operation at higher crosslinker contents 
(section 2.3.8).
The results found are not what were initially anticipated, a 
possible cause of the anomalous diffusion behaviour of propranolol 
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Figure 2.15. Effect of crosslinker content in PHEMA (methylated and 
untreated) on the diffusion coefficient of propranolol HCI through 
crosslinked PHEMA films (with standard error bars shown).
interaction between propranolol HCI and the carboxyl groups in PHEMA 
(section 2.3.8, section 2.3.9). If this was the cause then by 
methylating the carboxyl groups the diffusion coefficient of 
propranolol HCI through methylated PHEMA would be expected to 
increase at crosslinker contents less than about 3%C, rather than 
decrease as is found in this study. It was however found that the 
carboxyl groups in PHEMA are only partially responsible for the 
interaction between propranolol HCI and PHEMA (section 2.3.10.3), yet 
this still does not explain why methylation causes a decrease in 
diffusion coefficient. A small increase in the diffusion coefficient 
of some sort might still be expected rather than a decrease as was 
found, this would suggest that perhaps the decrease of diffusion 
coefficients caused by methylating the free carboxyl groups in PHEMA 
may be related to some other factor rather than just an effect on 
the interaction between propranolol HCI and PHEMA.
A possible explanation would be in terms of steric hindrance by 
the introduced methyl groups onto the polymer structure. At low 
crosslinker content the pore size is large enough to allow drug 
diffusion through the polymer by a pore mechanism, thus the 
introduction of methyl groups into the polymer structure might be 
expected to decrease the diffusion rate by steric hindrance. At high 
crosslinker contents where a partition mechanism is thought to occur, 
the introduction of methyl groups would not be expected to have such 
a drastic effect.
An alternative explanation for this effect would be if the 
presence of carboxyl groups caused PHEMA to swell, however it has 
been reported that significant swelling of PHEMA with small amounts 
of methacrylic acid does not occur unless the pH is greater than
- 109 -
about 6 [220]. Additionally the water content of PHEMA in pH 4.48
buffer determined in section 2.3.6 did not indicate any swelling 
greater than that which would be expected for crosslinked PHEMA.
If the carboxyl content in PHEMA is regarded as an impurity due 
to methacrylic acid, then the effect of this impurity on diffusion is 
to increase the diffusion coefficient of propranolol HCI through low 
crosslinked PHEMA films.
Table 2.4 Significance values calculated from a two-tailed Students 
t-test to examine whether there is any significant difference between 














Controlled Transport of Propranolol HCl through 
Crosslinked EHEMA Using Constant Current Electrophoresis
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3.1 Materials
Platinum foil, 10 m m  x 10 m m  x 0.025 mm, supplied by FSA 
Laboratories Supplies, Loughborough, U.K.
Platinum wire, 0.5 m m  diameter, supplied by FSA Laboratories 
Supplies, Loughborough, U.K.
For all other materials used see section 2.1.
3.2 Methods
3.2.1 Apparatus and Techniques for Electrophoresis Studies
In this chapter the feasibility of an electrophoretically driven 
drug delivery device will be examined (section 1.3.9.2). The ability 
of this type of device to deliver a model ionised drug, propranolol 
HC1, to a delivery site in a fully controlled and predictable manner 
is investigated. The system examined in the present study is based on 
constant current electrophoresis, the polymer examined being 
crosslinked films of PHEMA. In designing the experiments, the main 
criterion was to demonstrate the full potential of this type of 
delivery device, in particular the possible application as a feedback 
controlled delivery system.
A schematic diagram of the electrophoretic model system used in 
this study is shown in figure 3.1, with a photograph of the actual 
apparatus in figure 3.2. The electrophoresis cell consisted of two 
equal compartments, and was based on the diffusion cell used in 
section 2.2.8 (figure 2.2). The same criteria used in the design of 
the diffusion cell were applied in the electrophoresis cell design. 
Each compartment of the cell has a capacity of approximately 220 ml, 
the dimensions of the cell being similar to that of the diffusion 
cell. The differences between the diffusion cell and electrophoresis
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ELECTRO PHO RESIS CELL
Receptor
F ig u re  3.1. S chem atic  d ia g ra m  o f  th e  a p p a ra tu s  used  in  
e le c tro p h o re s is  s tu d ie s .
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Figure 3.2. Photograph of the apparatus used in electrophoresis 
studies.
Key : 1 - stirrers, 2 - electrophoresis cell, 3 - thermostatted water 
bath, 4 - stirrer power supply, 5 - peristaltic pump, 6 - u.v. 
detector, 7 - temperature control cabinet, 8 - computer, 9 - constant 
current power supply, 10 - monitor.
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cell being that the electrophoresis cell was designed with extra 
arms, one set to enable the insertion of electrodes, and the second 
set to allow stirring of the two compartments. The electrodes were 
fabricated from 1 cm2 uncoated platinum foil, suspended on platinum 
wire (the use of uncoated platinum foil as opposed to platinized foil 
is discussed below in section 3.2.2). The separation of the two 
electrodes was maintained constant throughout all the experiments, at 
a distance of 8.5 cm. In all the experiments, unless otherwise 
stated, the receptor compartment electrode was the cathode.
The assembly of the electrophoresis cell and preparatory 
experimental details are very similar to those described for the 
diffusion cell in section 2.2.8. PHEMA films of the desired
crosslinker content, having a thickness of approximately 0.1 cm were 
prepared as described in section 2.2.4.2, and discs of 4 cm diameter 
were cut. The discs were stored in pH 4.48 buffer at 4°C (appendix 2) 
prior to use. The interfacial ground glass joints of the
electrophoresis cell were smeared with a thin layer of vacuum grease 
(Apiezon N). An annular sheet of polytetrafluoroethylene (PTFE), 
with a thickness of 0.08 cm and internal diameter of 4 cm was used as 
a liquid-tight gasket. The PTFE gasket was placed at the interface of 
the donor electrophoresis cell, and a disc of polymer film placed in 
its centre. The cell halves were then clamped tightly and provided
an exposed area of polymer film of 6.16 cm2. Into the receptor
compartment was placed 210 ml of pH 4.48 buffer having an ionic 
strength of 0.039, prepared as described in appendix 2, and into the 
drug reservoir was placed 200 ml of pH 4.48 buffer. The two 
electrodes were then inserted into the appropriate arms of the 
electrophoresis cell (each electrode was always placed in the same
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compartment for any given experiment to eliminate errors due to any 
differences in the electrode surface area). The whole cell was 
mounted in a specially constructed perspex stand and immersed in a 
water bath maintained at 25°C, unless otherwise stated. The 
compartments were stirred continuously using perspex stirrers driven 
by 12 volt motors at 330 rev min-1 (RS Components Ltd., Corby, U.K.), 
which were powered by a constant voltage power supply (E30/1 Farnell 
Instruments Ltd, Wetherby, U.K.).
The cell was allowed to equilibrate for 30 minutes, after which 
20 ml of a stock propranolol HC1 solution in acetate buffer was 
added to the reservoir compartment to give a final concentration of 
approximately 14 mM, unless otherwise stated. Timing was then 
started, and after 15 seconds a 10 ml sample was withdrawn from the 
reservoir compartment to give a measurement of the initial reservoir 
propranolol HC1 concentration. This sample was analysed by u.v. 
spectrophotometry (section 2.2.1).
The receptor cell solution was pumped at a rate of 0.5 ml min-1 
(Gilson Minipuls 2, Anachem, Luton, U.K.) into a flow-through u.v. 
detector (Gilson 116, Anachem, Luton, U.K.), and the outflow returned 
to the receptor cell. The u.v. detector, set to a wavelength of 
288 nm, was connected to a microcomputer (BBC Master, Acorn Computers 
Ltd., Cambridge, U.K.), which collected the data at preprogrammed 
time intervals, usually of one hour. The computer was calibrated by 
passing a number of solutions of known concentration through the u.v. 
detector. The program used to calibrate the detector is shown in 
appendix 3. The computer, as well as recording the variation of 
receptor concentration with time was used to control the power 
supply. The constant current power supply, which was specially
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designed and constructed in the School of Electrical Engineering at 
the University of Bath, was interfaced with the computer via the 
1 MHz bus. The power supply could be controlled either manually or as 
in this study via the computer. Appendix 6 shows a block diagram of 
the power supply. The power supply could be set to two different 
current ranges, namely 0 to 25 m A  and 0 to 2.5 mA, with the latter 
being selected for most experiments to ensure chemical stability as 
discussed in section 3.2.2 below. In addition to using software for 
controlling the magnitude of the current, the polarity of the 
electrodes could also be reversed, and the values of current (to two 
decimal places) and voltage (to one decimal place) read at any time 
by the computer. The computer could thus be programmed to control the 
power supply in a flexible manner. The effect of using electric 
currents on the transport of propranolol HC1 was not examined until 
transport due to diffusion had become constant, which could be
estimated from a plot of receptor propranolol HC1 concentration 
against time. The computer was programmed to store values of
absorbance, concentration, current, voltage and estimated drug 
delivery rate against time. The method used to calculate drug
delivery rate is explained in section 3.2.11. The software written 
for this part of the study is shown in appendix 3, details of which 
will be further discussed below. At the end of any given experiment 
the data was stored onto floppy disc and analysed using a statistics 
package (INSTAT, University of Reading, U.K.), which enabled the
effects of electrophoresis on the transport of propranolol HC1 
through crosslinked PHEMA films to be examined, as well as allowing 
the calculation of various parameters such as drug delivery rate.
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At the end of each experiment the hydrogel thickness was 
measured (section 2.3.4.2). The electrodes were thoroughly rinsed in 
distilled water, followed by double distilled water. The electrodes 
were then stored in fresh double distilled water until required.
A control experiment was performed where no propranolol HC1 was 
added to the drug reservoir, and the power supply turned on for 
several periods of four hours at a value of 15 mA. No significant 
baseline drift was found over a period of five days.
Control over the transport of propranolol HC1 was achieved 
through PHEMA films using constant current electrophoresis in a model 
system, and this together with details of methodology used to study 
the effect of various parameters on the electrophoretically 
modulated release of propranolol HC1 is described below. The 
experiments used were all based on the system described earlier in 
this section unless otherwise stated. In order to achieve the desired 
objectives, computer software was written to allow flexible control 
of both the power supply and data collection. The software written 
enabled a number of different experiments to be performed (appendix 
3). Four types of experiment were possible with the software written, 
as shown by the first menu on lines 510-600. The first option, 
"keyboard control of power supply at any given time", was used mainly 
for diffusion studies in section 2.2.8, where the power supply was 
not required; it was also used in electrophoresis studies where it 
was required to turn the power supply power supply on or off at any 
given time. The second option, "power supply turned on and off at 
fixed times", allowed the power supply to be programmed to supply a 
given constant current between preprogrammed intervals. The third 
experimental option, "feedback control", was used to examine the
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possible use of an electrophoresis device as part of a feedback 
controlled drug delivery device. This part of the program will be 
discussed in detail in section 3.2.11. The fourth option, "fixed 
release profile", enabled the power supply to be preprogrammed to 
turn on and off to any desired value or polarity several times in an 
experiment. A range of experiments are therefore possible with these 
options, however an experiment could be modified whilst in progress, 
and extra data collected if required. These available choices are 
shown in the second menu of the data collecting program (appendix 3) 
on lines 1090-1190. The options allow the power supply to be turned 
on or off to any desired value during an experiment, the polarity of 
the electrodes could also be reversed. The current, voltage, 
absorbance and associated concentration of propranolol HC1 in the 
receptor could also be read at any time. The drug delivery rate into 
the receptor compartment at any given time could also be estimated 
(section 3.2.11). The program also allowed extra data to be collected 
at any time, therefore if any extra data points were required, or 
more frequent sampling then this option could be used.
3.2.2 Factors Affecting Degradation of Propranolol HC1 During 
Electrophoresis
Despite the recent interest in the use of electrophoretically 
controlled drug delivery systems, no attention has been given to any 
potential degradation of active drug in the electrophoretic system 
[127,128,129], either due to electrode processes [266] or local 
heating effects in the polymer [118,267]. A previous study has 
commented on suspected drug degradation, but no detailed study was 
made [127]. This is a very important aspect of an electrophoretic
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drug delivery device, as degradation of a drug could lead to 
inactivation of the drug or the production of irritant or toxic 
products. This would clearly be undesirable. In this present study 
the stability of propranolol HC1 during electrophoresis will be 
investigated.
3.2.2.1 Use of Platinized Electrodes
In order to reduce polarization at platinum electrodes, a thin 
layer of platinum black is usually coated onto the electrode surfaces 
(section 3.3.8) [268]. The platinizing of electrodes was achieved by 
electro-deposition from a solution consisting of 2 g chloroplatinic 
acid and 0.02 g lead acetate in 100 ml of distilled water. The 
electrodes to be coated were placed in the solution and a 12 V power 
supply (E30/1 Farnell Instruments Ltd, Wetherby, U.K.) connected 
across the electrodes, the polarity of the electrodes being reversed 
every 30 seconds, this was repeated for 10 minutes. The electrodes 
were then placed in dilute sulphuric acid and the 12 V power supply 
was again connected for 10 minutes, the polarity being reversed every 
minute. The purpose of this was to remove traces of platinizing 
solution which are liable to adsorb onto the electrodes. The 
electrodes were then rinsed in warm distilled water several times, 
followed by double distilled water. The electrodes were subsequently 
stored in double distilled water prior to use.
3.2.2.1.1 Effect of High Electrophoretic Currents (0 - 25 mA)
Initial electrophoresis experiments were based on using currents 
in the range of 0 to 25 mA. The electrophoresis cell was assembled as 
detailed in section 3.2.1, with 1%C PHEMA and an initial drug
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reservoir concentration of approximately 6 m M  propranolol HC1 was 
used. Once the delivery rate due to diffusion had become constant, 
the power supply was turned on to a current of 15 m A  for a period of 
seven minutes. After approximately 17 hours the power supply was 
again turned on for a further seven minutes. The effect on the 
delivery rate of propranolol HC1 into the receptor was examined.
3.2.2.1.2 Effect of Low Electrophoretic Currents (0 - 2.5 mA)
It was found that significant degradation of propranolol HC1 
occurred when a current of 15 m A  was used in the model 
electrophoretic system (section 3.3.2.1.1). The power supply was 
modified as a result and the range scaled down by a factor of ten, to 
give a range of 0 to 2.5 mA. The electrophoresis cell was assembled 
as detailed in section 3.2.1, with 1%C PHEMA and an initial reservoir 
concentration of approximately 6 m M  propranolol HC1. Once the 
delivery rate due to diffusion had become constant, the power supply 
was turned on to a current of 1 mA  for one hour, then after 
approximately 19 hours the power supply was turned on to a current of 
2 m A  for a further hour, and the effect on propranolol HCl delivery 
rate into the receptor compartment examined.
3.2.2.1.3 Heating Effects in PHEMA
A significant but low level of degradation of propranolol HCl 
was still found in the current range of 0 to 2.5 m A  (section 
3.3.2.1.2). This degradation was probably due to one of two factors, 
either an electrode reaction was causing degradation, or
alternatively a heating effect may be occurring in the PHEMA film 
during electrophoresis leading to thermal decomposition of
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propranolol HCl. In the present study the temperature changes within 
PHEMA were examined during electrophoresis, to determine whether any 
significant heating was occurring, which might account for the small 
amount of degradation found during electrophoresis.
1%C PHEMA films were prepared as described in section 2.2.4.2, 
with one difference : a Type K nickel-chromium/nickel-aluminium
thermocouple wire (RS Components Ltd., Corby, U.K.) was also placed 
into the polymerizing solution between the glass moulds. This 
required several experimental attempts to ensure that the 
thermocouple tip did not protrude from the hydrogel and was firmly 
embedded in the polymer film. A disc of 4 cm was then cut around the 
thermocouple tip using a scalpel. The electrophoresis cell was then 
assembled as in section 3.2.1, with the thermocouple wire being fed 
through the electrode arm in the reservoir compartment and connected 
to a digital temperature indicator (RS Components Ltd., Corby, U.K.).
The initial reservoir concentration of propranolol HCl was 6 mM. Once 
the delivery rate due to diffusion had become constant, the power 
supply was turned on to a current of 15 m A  for two hours, and any 
changes in temperature were noted.
3.2.2.2 Use of Uncoated Electrodes
Traditionally, electrophoresis studies using platinum electrodes 
have involved the use of platinized electrodes in order to reduce 
electrode polarization. The effect of platinizing the electrodes with 
a layer of platinum black is to increase the effective electrode 
surface area, and the platinum salt also acts as a catalyst for 
electrode processes [268,269]. In the present study uncoated platinum 
electrodes were used in the electrophoresis cell, in order to examine
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whether the platinum black was responsible for, or catalysed the 
degradation of propranolol HCl found during electrophoresis using 
currents in the range of 0 to 2.5 m A  (section 3.3.2.1.2). The 
electrophoresis cell was assembled as described in section 3.2.1, 
with 1%C PHEMA, and an initial reservoir concentration of 
approximately 6 m M  propranolol HCl. Uncoated platinum electrodes were 
used in this experiment. Once the delivery rate due to diffusion had 
become constant, a current of 1 m A  was passed for a period of 4 
hours. The effect on propranolol HCl degradation was examined, 
together with the effect on the voltage required to maintain a 
constant current of 1 mA. The experiment was performed in duplicate.
3.2.3 Effect of Constant Current Electrophoresis on the Transport 
of Propranolol HCl through Crosslinked PHEMA Films 
The effect of constant current electrophoresis on the transport 
of propranolol HCl through 1%C PHEMA films was examined. The 
electrophoresis cell was assembled as detailed in section 3.2.1, with 
an initial reservoir concentration of 14 mM, and once the delivery 
rate due to diffusion had become constant, a constant current was 
produced by the power supply for a period of 4 hours, then turned off 
again. The experiment was repeated for a range of currents from 0 to
2.5 mA, and changes in the delivery rate of propranolol HCl and in 
voltage were examined. Each experiment at a given current was 
performed in triplicate.
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3.2.4 Effect of PHEMA Crosslinker Content on Electrophoresis
The majority of other experiments in this work were based on the 
use of 1%C PHEMA, where the transport of propranolol HCl through 
PHEMA is believed to be via a "pore mechanism" (section 2.3.8). In 
this part of the study the effect of using lower crosslinked PHEMA, 
0.1%C on electrophoresis was examined, as was the effect of using a 
more highly crosslinked polymer, 7%C, where transport of propranolol 
HCl through the polymer is believed to be via a "partition mechanism" 
(section 2.3.8). The electrophoresis cell was assembled as described 
in section 3.2.1, with PHEMA of the appropriate crosslinker content. 
After the delivery rate due to diffusion had become constant, a 
constant current was produced by the power supply for a period of 
four hours, then turned off again. For any given crosslinker content 
the effect of different currents on electrophoresis was examined over 
the range 0 to 2.5 mA. Each experiment at a given current was 
performed in triplicate for 1%C and 7%C, and in duplicate for 0.1%C.
3.2.5 Effect of Buffer Ionic Strength on Electrophoresis and
pH Changes During Electrophoresis
The effect of ionic strength on the electrophoretic delivery of 
propranolol HCl through crosslinked PHEMA film was examined in the 
present study. A range of ionic strengths was examined, from that of 
the acetate buffer (appendix 2), 0.039, to an ionic strength of 0.2.
This range of ionic strengths was examined as it encompassed the 
ionic strength of plasma. The interest in this range stems from one 
of the envisaged applications of the electrophoretic delivery device 
as an implant system (section 1.3.9.2), where the ionic strength of 
the environment may have an effect on the device. The ionic strength
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of plasma was approximated from the concentration of the principal 
ions in plasma [270], the value estimated as 0.149.
The electrophoretic cell was assembled as described in section 
3.2.1, using 1%C PHEMA. Once the delivery rate due to diffusion had 
become constant, a constant current of 2.4 m A  was produced for a 
period of 4 hours. The experiment was repeated for a range of ionic 
strengths, the reservoir concentration of propranolol HCl being kept 
constant at 14 m M  for all the experiments.
A range of ionic strengths of the acetate buffer were prepared 
by adding a known quantity of sodium chloride to the acetate buffer. 
Prior to use, the sodium chloride was dried over phosphorous 
pentoxide in a vacuum oven at 80°C for 48 hours to remove traces of 
water. The effect of ionic strength on the pH of the buffer was 
estimated by taking account of activity effects (using the 
Debye-Huckel equation) on the pH of the buffer, calculated using the 
Henderson-Hasselbalch equation [271]. The calculated change in pH 
caused by increasing the ionic strength of the buffer to 0.2 is 
approximately 0.06 pH units. This change in pH was thought to be 
insignificant as far as electrophoresis is concerned since the pKa of 
propranolol HCl is 9.5 [253]. The actual pH of the various ionic
strength buffers was measured and compared to the theoretically 
calculated values. A u.v. scan of the 0.039 and 0.20 ionic strength 
buffer was performed between the wavelengths of 200 and 400 nm 
(section 2.2.1) in order to examine whether the addition of sodium 
chloride affected the u.v. absorbance of the acetate buffer. A series 
of stock solutions were prepared, containing propranolol HCl in 
acetate buffer of the same concentration as those being investigated 
in this study but having a range of ionic strengths. This was done so
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that the effect on ionic strength of adding stock propranolol HCl at 
the start of an experiment was constant.
As well as examining the effects of ionic strength on
electrophoresis, the changes in pH that occurred during
electrophoresis were also examined for each experiment. A combination 
electrode, 0.7 cm in diameter and 10 cm long (Russell CTWL/B14, 
Russell pH Ltd., Fife, U.K.) was used in this study. The electrode 
could be inserted into either compartment of the electrophoresis cell 
periodically during an experiment to measure the pH (appendix 2).
3.2.6 Effect of Temperature on Electrophoresis
The effect of temperature on the electrophoretic transport of 
propranolol HCl through 1%C PHEMA was examined. The electrophoretic 
cell was assembled as described in section 3.2.1, using a film
consisting of 1%C PHEMA and an initial reservoir concentration of 
14 m M  Propranolol HCl. Once the delivery rate due to diffusion had 
become constant, a constant current was produced by the power supply 
for a period of 4 hours. The experiment was repeated in triplicate 
for a range of currents from 0 to 2.5 mA, and changes in the delivery 
rate of propranolol HCl determined. This series of experiments was
repeated at both 31°C and 37°C, data for 25°C conditions having
already been obtained in section 3.2.3.
3.2.7 Effect of Reservoir Propranolol HCl Concentration on
Electrophoresis
The effect of varying the concentration of propranolol HCl in 
the reservoir compartment on the drug delivery rate produced by an 
electrophoretic current of 1 m A  was examined in the present study.
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Varying the reservoir concentration would be expected to alter the 
delivery rate across the PHEMA film as a result of diffusion effects 
as well as effects on electrophoretic control. The electrophoretic 
cell was assembled as described in section 3.2.1 using a film of 1%C 
PHEMA. Usually the volume of buffer placed in the reservoir 
compartment was 200 ml, with 20 ml of stock propranolol HCl added at 
the start of an experiment. However, in the present study, the volume 
of buffer placed in the reservoir was varied so that on addition of 
an appropriate volume of stock propranolol HCl solution necessary to 
make the volume up to 220 ml, a range of reservoir propranolol HCl 
concentrations could be obtained from 1 to 55 mM. The final 
concentration of the reservoir was determined as described in section
3.2.1 by removing a 10 ml sample from the reservoir for assay. Once 
the delivery rate due to diffusion had become constant, a constant 
current of 1 m A  was produced by the power supply for a period of 4 
hours. The experiment was repeated for a range of reservoir 
concentrations.
3.2.8 Factors Affecting the Resistance Across PHEMA Films During 
Electrophoresis
The effect of a number of factors on the resistance of the model 
electrophoretic system were examined. The voltage across the platinum 
electrodes was measured using a voltmeter (Weston 6100, supplied by 
RS Components Ltd., Corby, U.K.). The computer supply only measured 
voltages in the range 0 to 25 V to one decimal place which was not 
considered of a high enough precision for the present study. The 
resistance across the electrodes was measured at the end of each 
experiment. A  range of currents from 0 to 2.5 m A  was applied to the
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system, and for any given current, the voltage measured after 10 
minutes. From these results the resistance could be calculated by 
determining the gradient of a plot of voltage against current, using 
O h m ’s law :
V = I.R
V = Voltage (V)
I = Current (A)
R = Resistance (£2)
The results were used to give an indication of the influence of 
various factors on the electrophoretic system, such as temperature, 
ionic strength and crosslinker content, as well as to provide an 
indication of the power requirements of an electrophoretic device.
3.2.9 Effect of Reversing Electrode Polarity
The effect of electrophoresis on the transport of propranolol 
HCl through 1%C PHEMA films caused by reversing the polarity of the 
platinum electrodes was examined. Earlier experiments showed that 
constant current electrophoresis could be used to modulate the 
delivery of propranolol HCl across films of crosslinked PHEMA 
(section 3.3.3), however a basal delivery rate due to diffusion was 
always apparent. The aim of this part of the study was to investigate 
whether such basal drug delivery due to diffusion could be reduced or 
even halted by electrical intervention. A previous study has examined 
the modification of polymer formulation to reduce basal drug delivery 
due to diffusion (see section 3.3.3) [127]. The electrophoretic cell
was assembled as described in section 3.2.1, with 1%C PHEMA and an 
initial reservoir concentration of 14 m M  propranolol HCl. Once the 
delivery rate due to diffusion had become constant the computer was
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programmed to turn the power supply alternately on and off 
continually at fixed intervals. The power supply was turned on for 
six hour periods, and off for seven hour periods. The electrode 
polarity was reversed from that which was used in the rest of this 
work, so that the receptor electrode was now the anode. On each 
subsequent period of electrophoresis, the computer was programmed to 
increase the current in small steps, and the effect on delivery rate 
examined.
3.2.10 Effect of Electrophoresis on Diffusion Lag Time
In all experiments designed to investigate controlled drug 
transport through crosslinked PHEMA films using constant current 
electrophoresis, electrophoresis studies were only commenced after 
the delivery rate due to diffusion had become constant (section 
3.2.1), for reasons discussed in section 3.3.3. One disadvantage of 
using such an approach was that a lag time greater than 24 hours was 
necessary before any studies could be performed. This long lag time 
could in many cases be unacceptable from a therapeutic point of view. 
However other types of drug reservoir devices such as the transdermal 
patch, TTS-scopolamine, contain a priming dose in the contact 
adhesive which partly compensates for the time required for steady 
state conditions to be established [26]. Previous studies on the use 
of electrophoretic drug delivery devices [127,128] have not 
considered whether any significant differences exist between the 
effects of electrophoresis during the time period before steady state 
diffusion has been attained and the effects of electrophoresis once 
steady state diffusion has been attained. In these previous studies 
the effects of electrophoresis appear to have been examined prior to
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steady state diffusion being attained (section 3.3.3). The aim of 
this part of the study was to examine the significance of attainment 
of steady state diffusion on electrophoretically controlled drug 
delivery. The electrophoresis cell was assembled as described in 
section 3.2.1, with 1% PHEMA and an initial reservoir concentration 
of 14 m M  propranolol HCl. An electrophoretic current of 2 m A  was 
applied for a period of 8 hours starting approximately 20 seconds 
after initiation of the experiment. The effect of the electrophoretic 
current on drug delivery was examined.
3.2.11 Delivery of Propranolol HCl through Crosslinked PHEMA by a 
Programmable Feedback Electrophoresis System 
The most innovative and therapeutically significant aspect of an 
electrophoretic drug delivery device is its potential for use as a 
feedback driven device (section 1.3.9.2). In this part of the study, 
the feasibility of delivering propranolol HCl through crosslinked 
PHEMA by a programmable feedback electrophoresis system will be 
examined. A feedback system is envisaged as comprising of the 
electrophoretic device, and a transducer capable of detecting 
therapeutically significant changes effected by the drug. Depending 
on the relationship between the transducer output and a pre-set 
level, the output of the electrophoretic device should be capable of 
being altered appropriately until the transducer detects the desired 
effect and outputs a signal corresponding to the pre-set level. In 
the present study the u.v. detector was used as a model transducer, 
and the computer was used to estimate the drug delivery rate at any 
given time. The computer was programmed to adjust the output of the 
constant current power supply in response to the output level from
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the u.v. detector so that a desired preprogrammed drug delivery rate 
could be achieved for a fixed period of time.
The electrophoretic cell was assembled as described in section
3.2.1 using a film of 1%C PHEMA and an initial reservoir
concentration of 14 m M  propranolol HCl. The computer was programmed 
to allow for feedback control of propranolol HCl over a period of 8 
hours commencing at 35 hours and the effects on drug delivery rate 
were examined. There were two major problems in designing the 
feedback experiments: firstly, obtaining an appropriate assessment of 
the delivery rate at any given time; secondly, having determined the 
delivery rate, selecting an appropriate method of adjusting the power 
supply output in order to obtain the desired delivery rate.
The method used initially to estimate the delivery rate of 
propranolol HCl into the receptor was based on setting the computer 
to collect data from the detector at intervals of three minutes. The 
program then selected the ten most recent data points covering the 
previous 30 minutes, from which the computer estimated the delivery 
rate using linear regression analysis. The procedure used to perform 
this calculation, PROCz, can be found at line 2410 in the data 
collecting program shown in appendix 3. The initial feedback 
experiments were based simply on programming the computer with a 
desired delivery rate, then during the period of feedback control the 
computer compared the pre-set value corresponding to the desired 
delivery rate to the value obtained from linear regression analysis.
If the estimated delivery rate was less than the pre-set value, the 
power supply was turned on to provide a current of 2.4 mA. If the 
estimated value exceeded the desired value the power supply was 
switched off. A series of experiments were performed using this
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method of feedback, with the computer programmed to deliver 
propranolol HCl at one of three delivery rates ; 0.6 mg/h, 0.8 mg/h,
1.0 mg/h.
The method by which the delivery rate was estimated using data 
from the detector was also examined. The effect of using different 
sample sizes and frequencies on the feedback control was examined 
when a desired delivery rate of 0.8 mg/h was programmed into the 
computer. The sampling routine used initially was based on 10 samples 
at three minute intervals, other routines examined were 10 samples at
5 minute intervals, 5 samples at 10 minute intervals and 5 samples at
6 minute intervals.
A second method of adjusting the power supply during feedback 
control was also examined. In section 3.3.3 a linear relationship was 
determined between current and drug delivery rate for 1%C PHEMA, thus 
an equation relating current and delivery rate could be obtained. For 
example, if a particular delivery rate was measured and a higher or 
lower delivery rate was required, then the change in current needed 
to obtain the new delivery rate could be calculated using the known 
relationship between current and delivery rate. The procedure PROCbi, 
found at line 2660 of the data collecting program (appendix 3), is 
the routine used to adjust the power supply according to this method. 
The computer was programmed to compare the estimated delivery rate 
(based on 10 samples at 5 minute intervals) to the required delivery 
rate, then to change the current appropriately to that which would be 
expected to give the desired delivery rate. The procedure was written 
so that the highest current output was 2.4 m A  and the lowest 0 mA. 
The experiment was performed using a single programmed rate of 
0.8 mg/h.
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3.3 Results and Discussion
3.3.1 Apparatus and techniques for electrophoresis studies
A typical plot obtained during an electrophoresis experiment 
showing the effect of an applied current on the transport of 
propranolol HCl through crosslinked PHEMA is shown in figure 3.3. The 
example shown is for 1%C PHEMA with a propranolol HCl reservoir 
concentration of 14 mM, obtained using a current of 2.3 m A  applied 
for a period of four hours. Samples were taken at hourly intervals, 
except during electrophoresis when samples were taken every twenty 
minutes. Application of a current had an almost immediate effect, 
increasing the drug delivery rate into the receptor significantly. On 
removal of the current, the drug delivery rate dropped significantly.
The data for each experiment was analysed to check for linearity of 
the drug delivery rate during electrophoresis. For each experiment 
the diffusion coefficient of propranolol HCl through PHEMA (without 
electrophoresis) was calculated from the lag time and film thickness 
(appendix 1), in order to check the integrity of the system. The 
initial reservoir concentration was also calculated.
3.3.2 Factors Affecting Degradation of Propranolol HCl During
Electrophoresis
3.3.2.1 Use of Platinized Electrodes
3.3.2.1.1 Effect of High Electrophoretic Currents (0 - 25 mA)
The effect of application of a constant current of 15 m A  on the 
delivery rate of propranolol HCl into the receptor compartment was 
dramatic, each time a current was supplied a rapid and large rise in 
the delivery rate occurred compared with that of due to diffusion 










F ig u re  3.3. E f fe c t  o f  a p p lie d  c u r r e n t  on th e  t r a n s p o r t  o f  p ro p r a n o lo l 
















F ig u re  3.4. E f fe c t  o f  a p p ly in g  an e le c tro p h o re t ic  c u r r e n t  o f  15 mA on 
tw o  s e p a ra te  o cc a s io n s  (each tim e  f o r  a p e r io d  o f  seven  m in u te s ) on 
th e  t r a n s p o r t  o f  p ro p ra n o lo l H C l th ro u g h  1%C PHEMA f i lm .
- 135 -
electrophoresis there appeared to be visible electrolysis of water, 
with bubbles being evolved at the electrodes: assumed to be hydrogen 
at the cathode and oxygen at the anode. At the end of the experiment, 
the solutions in both reservoir and donor compartments were coloured 
brown. A control experiment (section 3.2.1) showed no discolouration 
in the absence of propranolol HC1 from the reservoir compartment. 
This would suggest that the discolouration was not caused by 
material coming off the electrodes or being leached from the polymer, 
but more likely to be due to degradation of propranolol HC1 as a 
result of application of a current. Samples of the reservoir and 
receptor compartments were taken at the end of the experiment and 
analysed for degradation of propranolol HC1 using HPLC assay (section 
2.2.2). The assay showed that although only 5.0% degradation of 
propranolol HC1 had occurred in the reservoir, 45.6% of the delivered 
propranolol HC1 had degraded in the receptor. Thus even though a 
constant current of 15 mA  had a significant effect on the drug 
delivery rate, a significant level of drug degradation had also 
occurred, thus making the use of such a high current unsuitable for 
modulating the delivery of propranolol HC1.
3.3.2.1.2 Effect of Low Electrophoretic Currents (0 - 2.5 mA)
The effect on the delivery rate of propranolol HC1 into the 
receptor compartment using lower currents was significant, but not as 
great as that produced by a current of 15 m A  (section 3.3.2.1.1). The 
delivery rate produced by the 2 m A  current was greater than that 
produced by the 1 m A  current, which was in turn greater than the 
delivery rate produced by diffusion alone (figure 3.5). A 












F ig u re  3.5. E f fe c t  o f  a p p ly in g  a c u r re n t  o f  1 mA f o r  a p e r io d  o f  one 
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fo r  one h o u r ,  on  th e  t r a n s p o r t  o f  p ro p ra n o lo l HC1 th ro u g h  1%C PHEMA 
f i lm .
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delivery rate is found in section 3.2.3. No visible electrolysis of 
water was found with the lower currents, however there was still the 
presence of a slight brown discolouration after the electrophoresis. 
Samples of the reservoir and receptor compartments were removed at 
the end of the experiment and analysed for degradation of propranolol 
HC1 using HPLC assay (section 2.2.2). The assay showed a 1.2% 
degradation of propranolol HC1 in the reservoir, and that 7.8% of the 
delivered propranolol HC1 had degraded in the receptor. Thus using 
the lower currents a significant effect on the drug delivery rate can 
still be produced, with drug degradation much less of a problem, 
though still present.
3.3.2.1.3 Heating Effects in PHEMA
Use of a thermocouple embedded in PHEMA films did not reveal any 
significant heating effects during electrophoresis, the digital 
temperature indicator was found to remain constant at 25°C throughout 
electrophoresis. Visible gas evolution occurred from the electrodes 
and visible darkening of the solutions occurred in this period. 
Heating effects during polyacrylamide electrophoresis, when used as 
an analytical technique, are well known [118,267], however, in this 
use of electrophoresis very high voltages and currents are applied 
across polyacrylamide discs. It was therefore considered that the 
reason that no localized heating effects were found in the present 
study was due to the very low currents used, perhaps combined with 
efficient heat transfer. It was therefore concluded that heating 
effects were probably not involved in producing the degradation of 
propranolol HC1 found during electrophoresis in the system under 
investigation.
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3.3.2.2 Use of Uncoated Electrodes
A significant effect on the delivery rate of propranolol HC1 
into the receptor compartment was still found when using uncoated 
platinum electrodes (figure 3.6). However, the voltage required to 
provide the current increased by approximately 1 volt in comparison 
with that required in the system using platinized electrodes 
(details on the magnitude of current and voltages are found in 
section 3.3.3). No brown discolouration was found after 
electrophoresis. Samples of the reservoir and receptor compartments 
were taken at the end of both experiments and analysed for 
degradation of propranolol HC1 using HPLC assay (section 2.2.2). The 
assay showed that no detectable degradation had occurred after a 
constant current of 1 m A  had been flowing for 4 hours. Thus it would 
appear that the layer of platinum black on the electrodes may be 
responsible for the previously detected degradation of propranolol 
HC1 (section 3.3.2.1.2). Degradation may still be occurring, but at a 
much less significant level. Thus significant degradation of 
propranolol HC1 can be avoided during constant current 
electrophoresis provided that uncoated platinum electrode are used. 
In the rest of this work uncoated platinum electrodes were used. 
Several checks on degradation were performed on later experiments 
using a range of currents where the initial propranolol HC1 reservoir 
concentration was 14 m M  as opposed to 6 m M  in this degradation study. 






Figure 3.6. Effect of an applied current of 1 m A  for four hours on
the transport of propranolol HC1 through 1%C PHEMA film.
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3.3.3 Effect of Constant Current Electrophoresis on the Transport
of Propranolol HC1 through Crosslinked PHEMA Films
Figure 3.3 shows the relationship between propranolol HC1 
receptor compartment concentration and time using a 1%C PHEMA film, 
showing the effect that an electric current of 2.3 m A  has on the 
delivery rate of propranolol HC1 into the receptor when applied for a 
period of four hours. This type of profile is representative of those 
obtained with all the currents examined in the range 0 to 2.5 mA, the 
magnitude of the change in drug delivery rate was found to vary with 
current. Examples of the types of profiles obtained in 
electrophoresis experiments may be found in appendix 4. A significant 
effect on the delivery rate of propranolol HC1 was produced by the 
application of a current, the effect of a current being to increase 
the delivery rate over that produced by diffusion alone.
Previous studies on electrophoretic devices using polyacrylamide 
[127,128] have indicated that when no electrophoretic current is 
applied, no measurable drug delivery occurs, thus drug delivery will 
only occur during electrophoresis. This type of control over drug 
delivery rate would be highly desirable, however these results should 
be viewed with caution as these models may not be realistic. In the 
case of Lescure et al. [128], no details of the concentrations of 
drugs used or polymer thickness are given, so no comments can be 
passed. However, in work reported by Kumar [127], the absence of drug 
delivery due to diffusion may be explained. There are two factors to 
be considered. The first and most important concerns the lag period 
of diffusion. In permeability studies it was found that with a 
polyacrylamide disc of 1.5 m m  thickness, taking hyoscine methyl 
chloride as an example, a lag time of approximately two hours was
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found [127]. In the electrophoresis studies which were over a period 
of approximately 90 hours, the polyacrylamide discs used were of a 
thickness of 10 mm. On the basis of these figures, with a 10 m m  disc, 
if diffusion was the only process occurring then it could be expected 
that a lag period of approximately 88 hours would exist, since lag 
time is proportional to the square of polymer thickness (appendix 1). 
Drug delivery produced by electrophoresis before the calculated 
diffusion lag time is not surprising, since as was shown in this work 
lag times can be interrupted using electrophoresis, the lag time 
apparently resuming after cessation of electrophoresis (section 
3.3.10). Examining electrophoretic effects during this lag time may 
lead to misleading interpretation of results, since as well as 
examining the effect of electrophoresis, there will be the 
concomitant changes in concentration that occur during the diffusion 
lag time. The second and probably less important factor is that 
significant depletion of the reservoir compartment occurred in the 
reported study during electrophoresis (leading to a significant 
build-up in the receptor). This factor may also contribute to the 
fact that no drug delivery due to diffusion was detected in that 
study. Diffusion controlled drug delivery is dependent on the 
maintenance of a concentration gradient (appendix 1), however if this 
concentration gradient decreases, as would appear to be happening in 
the previous study, then there will be a gradual decrease in the 
driving force of diffusion, resulting in a continual decrease in the 
amount of drug being delivered by diffusion, and possibly resulting 
in a diffusion delivery rate too small to be detected. In the 
present study, high concentrations of propranolol HC1 were used in 
the reservoir and sink conditions prevailed throughout the
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experimental time (the receptor concentration never exceeded 2% of 
the reservoir concentration during experiments), also electrophoresis 
studies were commenced only after the delivery rate due to diffusion 
had become constant. This model was thought to be more realistic of 
an electrophoretically controlled drug delivery device where a drug 
loaded reservoir would probably be used. The maintenance of sink 
conditions explains why diffusion controlled drug delivery was found 
in this study.
The lag time before which an applied current had a significant 
effect on the drug delivery rate was found to be less than five 
minutes (see figure 3.3 and appendix 4). Only one previous study was 
found on the use of electrophoretic drug delivery devices that 
commented on the magnitude of this lag time [128], where it was 
reported that using crosslinked polyacrylamide discs a lag time of 
about one hour occurred before any noticeable effect on drug delivery 
rate was produced. The work was carried out using a constant current 
power supply to control the delivery of bovine serum albumin. No 
details of the polyacrylamide gel thickness were given, however this 
long lag time would suggest that the polymer thickness was 
considerably greater than that examined in the present study.
The drug delivery rate during electrophoresis was found to be 
linear (zero-order) for all values of current examined; the value of 
the delivery rate of propranolol HC1 into the receptor compartment 
was determined from the change in concentration that occurred with 
time during electrophoresis. The relationship between propranolol HC1 
delivery rate and current was found to be linear, figure 3.7 shows 
this relationship (standard error bars were too small to be shown). 
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Figure 3.7. Effect of applied constant current on the transport of
propranolol HC1 through 1%C PHEMA films.
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statistics :
Number of points : 5
0.9999
Slope (S.D) 0.4448 (0.0024)
Intercept (S.D) 0.1297 (0.0037)
The intercept of the line in figure 3.7 with the y-axis 
represents the approximate delivery rate of propranolol HCl under 
diffusion control, without any electrophoretic contribution. Previous 
studies on electrophoretic drug delivery devices have shown a similar 
linear relationship when insulin was investigated using constant 
voltages [127] and bovine serum albumin using constant currents 
[128], both these studies used polyacrylamide as the membrane 
material.
An interesting observation was that the delivery rate of 
propranolol HCl due to diffusion prior to electrophoresis varied 
slightly in each experiment due to slight differences in film 
thickness and initial reservoir concentration. These differences 
however were not reflected in changes in delivery rate produced 
during electrophoresis, the delivery rate for any given current 
showing very little variability between the replicates.
On cessation of electrophoresis, the drug delivery rate 
decreased significantly in less than 20 minutes and quickly 
approached the pre-electrophoresis level (see figure 3.3 and appendix 
4). However, the instantaneous value of the post-electrophoresis 
delivery rate was found to be up to 30% greater than the delivery 
rate pre-electrophoresis, although this delivery rate usually 
decreased down to a value within 5% after about 6 to 10 hours from 
the cessation of electrophoresis. A possible explanation for this
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effect is that during electrophoresis the PHEMA disc is loaded with a 
higher level of propranolol HCl than would normally be present during 
diffusion, so that on removal of the current, this "extra” 
propranolol HCl is released before the concentration returns to its 
"normal" level.
The recorded changes in voltage that occurred during 
electrophoresis were similar in shape for all currents examined. A 
detailed study of the relationship between current and voltage is 
found in section 3.2.8. A typical relationship between measured
voltage across the electrodes and time (figure 3.8) shows that the
voltage rises rapidly and plateaus to give a near constant value
during electrophoresis. It can therefore be assumed that
electrophoresis was carried out under near constant power conditions. 
Different results were found when the changes in voltage during 
constant current polyacrylamide electrophoresis were examined [128]; 
an initial voltage was measured, which after a lag time of about one 
hour (corresponding to the lag time of bovine serum albumin release) 
reached a maximum value, then decayed slowly to a value obtained 
during the lag time so that electrophoresis was carried out under 
conditions of decreasing power. This effect may be due to the fact 
that diffusion of the bovine serum albumin had not attained steady 
state before electrophoresis was commenced (section 3.3.10).
The results obtained showed that constant current 
electrophoresis in the range 0 to 2.5 m A  had a significant effect on 
the delivery rate of propranolol HCl through 1%C PHEMA films (figure 
3.3, appendix 4). The effect is rapid and reversible. The results 
also indicated that the delivery rate of propranolol HCl during 








Figure 3.8. Changes in voltage measured during electrophoresis at a 
constant current of 1.4 mA.
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(figure 3.7). The linear relationship between drug delivery rate and 
current probably extends beyond the range examined, however the 
limiting value of current that would be suitable for an
electrophoretically controlled drug delivery device would be 
determined by degradation of drug and whether significant
electrolysis of water occurred.
3.3.4 Effect of PHEMA Crosslinker Content on Electrophoresis
The effect of PHEMA crosslinker content on the delivery rate of 
propranolol HCl produced by constant current electrophoresis is shown 
in figure 3.9. Linear regression analysis of the three curves 
indicated that for 0.1%C PHEMA and 1.0%C the relationship between 
delivery rate and current is linear, however for 7.0%C the 
relationship appears slightly curvilinear. The results are surprising 
and do not follow the pattern of delivery which might be expected; in 
the current range examined the delivery rate produced for a given
current was greatest for 1%C PHEMA followed by 0.1%C PHEMA and 7%C 
PHEMA. This was not expected because the diffusion coefficients, 
calculated from the steady state diffusion period prior to 
electrophoresis, showed the following expected order: 
0.1%C PHEMA > 1.0%C PHEMA > 7%C PHEMA. The lines of best fit for the 
0.1%C PHEMA and 1.0%C PHEMA, if extrapolated to zero current, cross 
over and give approximate intercepts of drug delivery produced by 
diffusion alone, with the intercept being greatest for the 0.1%C 
PHEMA film, as would be expected. Thus the change produced in drug 
delivery rate caused by changes in current are greater for the 1.0%C 
PHEMA than the 0.1%C PHEMA. The order of drug delivery produced by 








Figure 3.9. Effect of crosslinker content on the electrophoretic
transport of propranolol HCl through PHEMA films.
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electrical resistance across these films is measured (table 3.2); the 
pattern of resistance follows the expected order with 0.1%C PHEMA 
producing the lowest resistance. The curvilinear nature of the 
relationship between delivery rate and current with 7%C PHEMA is not 
easily interpreted, as the relationship between voltage and current 
in section 3.3.8 was linear, indicating that the resistance across 
the film was constant over the current range examined.
Previous electrophoretic studies using polyacrylamide have shown 
that as crosslinker content increases, electrophoretic mobility 
decreases [267,272,273]. Recent studies into electrophoretic drug 
delivery devices using polyacrylamide have however shown a biphasic 
relationship between mobility and crosslinker content; as crosslinker 
content is increased initially, a decrease in mobility is found, 
which reaches a minimum and then increases again as crosslinker 
content is increased further [127,128]. This effect was attributed to 
a re-arrangement of the polyacrylamide network with changes in 
crosslinker content. At low crosslinker contents, as crosslinker 
concentration is increased, a decrease in gel mesh size is thought to 
occur, and thus a decrease in mobility is found. At higher 
crosslinker contents a re-arrangement of the network is thought to 
occur resulting in an increase in mesh size and thus increase in 
mobility. A similar pattern of delivery rate and crosslinker content 
may be followed with PHEMA, however insufficient data is available to 
confirm this hypothesis. There is no evidence to suggest however that 
such a re-arrangement of PHEMA structure occurs as crosslinker 
content is altered.
An alternative explanation for the effect found in the present 
study is that the structure of PHEMA may somehow be affected by the
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application of an electrophoretic field, indeed polyacrylamide has 
been shown to swell slightly during electrophoresis [127]. If there 
is a change in structure occurring as a result of electrophoresis, 
then this change may be related to the electric field strength, which 
is directly related to the applied electrophoretic current. In the 
case of both 0.1%C PHEMA and 1%C PHEMA, transport within PHEMA is 
believed to be via a "pore mechanism" (section 2.3.8), the diffusion 
coefficients of these two crosslinked films being similar (figure 
2.12). One would expect a more rigid structure in the higher 
crosslinked 1.0%C PHEMA than the 0.1%C PHEMA film, thus the 1.0%C 
PHEMA may be more resistant to changes in structure produced by an 
electric field. This effect may explain the results obtained if the 
changes in the structure of PHEMA caused by an electric field results 
in the transport of propranolol HCl through PHEMA being hindered. 
This explanation however may be an oversimplification since changes 
in the crosslinker content in PHEMA has effects on both the effective 
pore size and the nature of water within the polymer (section 1.6.1).
The crosslinker content can also determine the type of effect 
produced by a constant current. Figure 3.10 shows the relationship 
between receptor propranolol HCl concentration and time using a 7%C 
PHEMA film, together with the effect of application of a current of
2.4 m A  during experimentation. The effect is in contrast to that 
produced with 1%C PHEMA in figure 3.3. The ratio between delivery 
rate during electrophoresis and delivery rate due to diffusion prior 
to an electrophoretic current of 1.9 m A  is 32 for 7%C PHEMA. The same 
ratios calculated for 0.1%C PHEMA and 1.0%C PHEMA are 6 and 7.5 
respectively. Thus with the lower crosslinked PHEMA (0.1%C and 


















Figure 3.10. Effect of electrophoresis on the transport of









given current, the change in delivery rate caused by electrophoresis 
over that of diffusion is much greater with the higher crosslinked 
7%C PHEMA. It was reported in section 2.3.8 that a change in 
diffusion mechanism is thought to occur as the crosslinker content in 
PHEMA is increased, and it would therefore be expected that transport 
of propranolol HCl through 0.1%C PHEMA and 1.0%C PHEMA would be by a 
different mechanism to that of 7%C PHEMA. This difference in 
mechanism may be the cause of the different effects produced by the 
highly crosslinked 7%C PHEMA and the lower crosslinked PHEMA films. A 
difference in the properties of the films is also indicated by the 
resistance data (section 3.3.8); the resistance across the 0.1%C and 
1.0%C films were found to be very similar where as the resistance 
across 7%C PHEMA was found to be much greater.
3.3.5 Effect of Buffer Ionic Strength on Electrophoresis and 
pH Changes During Electrophoresis 
The measured pH's for the acetate buffers of various ionic 
strengths were found to be in close agreement with the theoretically 
predicted values as shown below :






The u.v. scans of the 0.039 and 0.20 ionic strength buffers 
showed no significant differences, therefore the u.v. assay of
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propranolol HCl used in electrophoresis experiments was considered to 
be unaffected by the presence of sodium chloride.
The effect of ionic strength on the electrophoretic delivery of 
propranolol HCl is shown in figure 3.11. As can be seen, at a 
constant current of 2.4 mA, as ionic strength is increased, the 
delivery rate decreases, tending towards a value for delivery rate 
which is produced by diffusion alone. Figure 3.12 shows the effect of 
ionic strength on pre-electrophoresis drug delivery due to diffusion, 
the results indicate that an increase in ionic strength causes a 
slight decrease in the delivery rate produced by diffusion alone, 
this decrease is probably due to a reduction in the effective 
reservoir concentration of propranolol HCl due to activity effects 
[132]. A similar effect of ionic strength on electrophoresis has 
recently been reported on the delivery rate of bovine serum albumin 
produced by a constant electrophoretic current [128]. The effect of 
ionic strength on the delivery rate can be explained by two main 
effects that are occurring as ionic strength is changed. The first 
and least significant effect in this particular model, occurs as a 
result of the changes in the conductance of propranolol cations 
arising from electrophoretic and relaxation phenomena, which are the 
result of concentration dependent interactions between ions in 
solution (section 1.4.1). The Onsager equation relates ionic strength 

















Figure 3.11. Effect of ionic strength on the electrophoretic
transport of propranolol HCl through 1%C PHEMA film at a constant















Figure 3.12. Effect of ionic strength on the pre-electrophoretic
transport (due to diffusion) of propranolol HCl through 1%C PHEMA
film.
- 156 -
simplified form of the relationship is :
A = A0- (A + BA0 ) .I1/2
A = Molar Conductivity (fl-1 m 2 mol-1)
A0= Molar Conductivity at
Infinite Dilution (ft-1 m 2 mol-1)
I = Ionic Strength 
A = Constant 
B = Constant
Molar conductivity is the conductivity of an electrolyte divided by 
its molar concentration, thus an inverse relationship between 
increasing ionic strength and molar conductivity exists. This 
relationship is significant in the present work because it shows that 
for a fixed concentration of propranolol HCl an increase in ionic 
strength would be expected to decrease the conductivity of 
propranolol HCl.
The second and more significant reason for the decrease in drug 
delivery rate is related to the concentration of ions in solution and 
that electrophoresis of propranolol HCl was carried out in constant 
current conditions. Electric current is a measure of the rate at 
which electric charge is transported, and thus the rate at which ions 
are transported into the receptor [134]. Since in this study the 
effect of constant current was being investigated, irrespective of 
the ionic strength of the buffer, the same number of ions will be 
transported over a given period. As ionic strength is increased, the 
proportion of propranolol cations to the total number of ions in 
solution decreases, thus one would expect the amount of propranolol 
HCl transported during electrophoresis to decrease as ionic strength 
increases. Gross [274] predicted that electrophoretic mobility should
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be inversely proportional to the square root of ionic strength; a 
plot of the ratio of drug delivery rate to electrical resistance 
against the reciprocal of the square root of ionic strength is shown 
in figure 3.13. Since a constant current was used in this study, the 
electric field strength will be proportional to the measured 
resistance (section 3.3.8), thus the electrophoretic mobility will be 
proportional to the ratio of drug delivery rate to resistance. The 
results from this study indicate that electrophoretic mobility is 
inversely proportional to the square root of ionic strength as 
predicted by Gross [274]. It should be noted that in this study the 
contribution of propranolol HCl to the ionic strength was not 
considered, and that a slightly higher ionic strength prevailed in 
the reservoir than the receptor compartment due to the higher 
concentration of propranolol HCl.
The resistance across the electrodes was found to decrease as 
ionic strength was increased due to an increase in conductivity of 
the buffer system. It was observed that at ionic strengths of 0.12 
and above, at the end of electrophoresis the anode had a fine mauve 
coloured film, which increased in colour intensity as the ionic 
strength was increased. It was found that the film was easily removed 
with concentrated sulphuric acid, the resulting solution having a 
green colouration. It was considered that the film may have been due 
to an accumulation of chloride ions since the same effect occurred 
at high reservoir concentrations of propranolol HCl (section 3.3.7) 
although the nature of the electrode reaction is not understood.
The results indicated that ionic strength had a significant 
effect on the electrophoresis of propranolol HCl, higher ionic 


























Figure 3.13. A plot of the ratio of drug delivery rate to electrical 
resistance versus the reciprocal of the square root of ionic 
strength.
electrophoretic current. This may prove to be a limitation on the use 
of an electrophoretic device for drug delivery in a varying or high 
ionic strength environment. In order to investigate further it would 
be interesting to examine the effect on electrophoresis of having a 
relatively low ionic strength in the reservoir compartment and high 
ionic strength in the receptor compartment (the environment of the 
device) and examining whether changes in the ionic strength of the 
receptor compartment alone have a significant effect on 
electrophoretic drug delivery.
The changes in pH that occurred during the study of ionic 
strength effects on drug delivery rates are shown in table 3.1. The 
values shown are the difference between pH after electrophoresis and 
pH before electrophoresis. The results show that as a result of 
electrophoresis there is a slight decrease in pH in the reservoir 
(anolytic) compartment and a slight increase in pH in the receptor 
(catholytic) compartment. These changes may be the result of low 
level electrolysis of water, although no evolution of gases was seen 
at the electrodes, possibly because the rate of gas production was 
too low to allow visible build up. The electrolysis of water may be 
represented as follows [275] :
Anode 6H20 — ►  0 2 + 4H30+ + 4e_
Cathode 4H20 + 4e~ -- ►  2H2 + 40H~
Ionic strength did not appear to have any significant effect on 
the changes in pH.
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Table 3.1 The relationship between changes in pH and ionic strength
found after electrophoresis of propranolol HC1 in acetate buffer 
carried out for four hours at 2.4 mA.









3.3.6 Effect of Temperature on Electrophoresis
The effect of temperature on the electrophoretic transport of 
propranolol HC1 through films of 1%C PHEMA was investigated. Figure
3.14 shows the effect of current on the electrophoretic delivery of 
propranolol HC1 through 1%C PHEMA at different temperatures, figure
3.15 shows the relationship between delivery rate and temperature at 
different currents. For any given current it can be seen that as 
temperature is increased so does the drug delivery rate. In addition 
the rate of change of delivery rate with current increases as 
temperature is increased. Figure 3.16 shows the relationship between 
the logarithm of the delivery rate per unit current and the 
reciprocal of absolute temperature, the results suggest that the 
effect of temperature on the relationship between drug delivery rate 
and current may be described by the Arrhenius equation [134]. The 
effect of increasing temperature may be explained by an associated 
increase in free diffusion and ionic mobility, together with a 



















F ig u re  3.14. E f fe c t  o f  c u r re n t  on  th e  e le c tro p h o re t ic  d e l iv e ry  o f  













F ig u re  3.15. E f fe c t  o f  te m p e ra tu re  on th e  e le c tr o p h o r e t ic  d e l iv e r y  o f  
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effect of temperature on the electrical resistance across the 1%C 
PHEMA films was also determined (section 3.3.8) and it is interesting 
to note that a linear relationship exists between the logarithm of 
electrical resistance and the reciprocal of absolute temperature 
(figure 3.17). An analogy may be made with the viscosity of liquids 
where an equation analogous to the Arrhenius equation is also found 
to describe the dependence of viscosity on temperature [136].
3.3.7 Effect of Reservoir Propranolol HC1 Concentration on 
Electrophoresis
The effect of varying the reservoir concentration of propranolol 
HC1 on the delivery rate produced by an electrophoretic current of 
1 m A  was studied. Figure 3.18 shows that as reservoir concentration 
was increased initially, a rapid increase in drug delivery rate due 
to electrophoresis occurred. However, the gradient of the delivery 
rate versus concentration curve became less steep as reservoir 
concentration increased. It was also found that as the delivery rate 
due to electrophoresis increased, so did the measured delivery rate 
due to diffusion prior to electrophoresis (figure 3.19). Figure 3.19 
also shows that as the concentration of reservoir propranolol HC1 
increased, the change in drug delivery rate produced by an 
electrophoretic current of 1 m A  decreased, tending towards a limiting 
value corresponding to that produced by diffusion alone. These 
results seem to indicate that the choice of reservoir concentration 
is critical: too high a concentration making electrophoretic control 
ineffective; too low a concentration being unsuitable for practical 
use as a drug reservoir. The influence of concentration on the effect 
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Figure 3.18. Effect of propranolol HCI reservoir concentration on the 
electrophoretic delivery of propranolol HCI through 1%C PHEMA films 
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Figure 3.19. Effect of propranolol HCI reservoir concentration on the 
change in delivery rate produced by an electrophoretic current of 
1 mA.
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[127], however this may have been due to the fact that experiments 
were performed during the lag period of diffusion, as described 
earlier in section 3.3.3. The actual mechanism by which concentration 
affects drug delivery rate appears complex. As well as increasing the 
contribution of diffusion, increasing the reservoir concentration 
also increases the ionic strength of the reservoir compartment, and 
will affect the conductance of the propranolol cation as described in 
section 3.3.5.
It was observed that following electrophoresis using a 
propranolol HCI concentration of 54.9 mM, the anode had a fine mauve 
film, as found with high ionic strength buffer (section 3.3.5). As 
before, the film was easily removed with concentrated sulphuric acid, 
the nature of this film was associated with the accumulation of 
chloride ions (section 3.3.5).
3.3.8 Factors Affecting the Resistance Across PHEMA Films During 
Electrophoresis
Figure 3.20 shows the relationship between voltage and current 
across 1% PHEMA at 25°C with a buffer ionic strength of 0.039. The 
linear relationship between voltage and current in figure 3.20 was 
typical, of that found in all experiments in this study, which allowed 
the resistance across the system to be calculated from the gradients 
of these plots. Linear regression was performed on all of the plots 
to check for linearity. The calculated resistance values are shown in 
tables 3.2 to 3.4. The results will be discussed further in context 
with other relevant sections.
It should be noted that plots of voltage versus current had 










Figure 3.20. Relationship between voltage and current across 1%C 
PHEMA film.
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Table 3.2 The effect of PHEMA crosslinker content on the measured
resistance between the platinum electrodes at 25°C and an ionic
strength of 0.039.
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2.01 to 2.3 volts depending on the experimental conditions. This 
positive intercept may be explained by electrode polarization. The 
change in electrode potential resulting from polarization is termed 
the overpotential (overvoltage), and no current will flow between the 
electrodes unless the applied voltage exceeds the overpotential
[276]. The appearance and magnitude of electrode polarization may be 
dependent on a number of factors including electrolyte 
concentrations, temperature, stirring rate and current density.
The values of resistance give an indication of the power 
requirements of an electrophoretic drug delivery device. If we 
consider the resistance of the model system at 37°C with 1%C PHEMA 
and an ionic strength of 0.039, then the power requirements can be 
calculated from the following relationship :
P = I2.R 
P = Power (W)
I = Current (A)
R = Resistance (fl)
The calculated power requirements at a constant current of
2.0 m A  would be 2.5 mW. These values have significant implications in 
respect of the use of a low-power electrophoresis drug delivery 
device for clinical use. Such a device could be powered by batteries, 
for example a typical button-type lithium cell is capable of 
supplying 200 mAh at a constant 3 V (RS Components Ltd., Corby, 
U.K.), which is approximately equivalent to 200 operating hours at 
the power consumption calculated above. Alternatively power for an 
electrophoretic device could be generated from transducers utilising 
the bodies own energy sources; for example a piezo-electric device 
could generate a current from the pulsing of a major artery, or
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thermocouples could generate a current from the bodies own heat
[277].
3.3.9 Effect of Reversing Electrode Polarity
Figure 3.21 shows the effect of changing the magnitude of the 
constant current on the electrophoretic transport of propranolol HCI 
through 1%C PHEMA, with the receptor electrode as the anode. It was 
found that as the current magnitude was increased from 0.7 m A  to
1.2 mA, the delivery rate of propranolol HCI during electrophoresis 
decreased gradually, the delivery produced by a current of 0.9 m A  was 
found anomalous, being lower than expected from subsequent higher 
electrophoretic currents. From the initial results a current was 
estimated (1.09 mA) which would give a zero delivery rate, and was 
applied for two successive periods. The results in figure 3.21 show 
that on the first application of a current of 1.09 mA, the delivery 
rate is practically zero, however on the second application the 
delivery rate actually becomes slightly negative in magnitude with 
the same current. This may be because the electrophoretic current is 
depleting the PHEMA film of propranolol HCI, thus reducing the 
contribution to delivery rate due to diffusion. Since the net 
delivery rate during electrophoresis is the sum of diffusional and 
electrophoretic effects, then a decrease in the diffusional 
component might be expected to produce a decrease in the delivery 
rate into the receptor compartment. This assumption may be valid 
since the measured delivery rates during the periods when no 
electrophoretic current is applied show a gradual decrease with time, 
the value being 0.148 mg/h at 30 hours, decreasing gradually to a 






























Figure 3.21. Effect of current on the transport of propranolol HCI 
through 1%C PHEMA film with the receptor electrode as the anode.
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The results show that as well as being able to increase the 
delivery rate of propranolol HCI, constant current electrophoresis 
can also be used to reduce the delivery rate below the basal 
delivery rate produced by diffusion. Further, the results show that 
control of both the magnitude and polarity of the electrophoretic 
driving force allows drug delivery rates to be modulated continuously 
from zero up to the maximum limiting value.
3.3.10 Effect of Electrophoresis on Diffusion Lag Time
Figure 3.22 shows the relationship between propranolol HCI 
concentration in the receptor compartment and electrophoresis time. 
The results show a lag time of approximately 1.2 hours before a 
change in drug concentration occurred, which was much greater than 
the time taken for an electrophoretic current to produce a change in 
delivery rate during steady state diffusion (section 3.3.3). After 
the lag time, zero-order delivery of propranolol HCI was found to 
occur at a rate of 0.75 mg/h. This value is much less than that which 
would be expected if electrophoresis at 2 m A  was performed after 
steady state diffusion had been attained, the expected value would be 
in the region of 1.02 mg/h (section 3.3.3). The voltage profile 
obtained against time was also markedly different to that obtained 
when electrophoresis was effected during steady state diffusion. 
Figure 3.8 shows a typical voltage-time profile for electrophoresis 
when the delivery rate due to diffusion is constant, figure 3.23 
shows the profile obtained in the present study, the voltage reaching 
a peak corresponding to the lag time for drug appearance, the voltage 
then decreased gradually. The measured voltages in this study are 






Figure 3.22. Effect of application of a constant electrophoretic
current of 2 m A  on the transport of propranolol HCI through 1%C PHEMA




















Figure 3.23. Changes in voltage measured during electrophoresis at a 
current of 2 mA applied during the diffusion lag time.
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effected during steady state diffusion, peaking at 6.4 V, the 
expected voltage being approximately 4.5 V. These findings suggest a 
greater resistance to passage of an electrophoretic current prior to 
steady state diffusion having been attained. This effect is not fully 
understood, however it may be related to the PHEMA not having 
attained equilibrium conditions with propranolol HCI, thus on 
application of an electrophoretic current there is an additional 
retarding force imposed by the affinity of drug for the polymer. This 
effect may not be important at later times when the polymer is loaded 
with drug.
On removal of the electrophoretic current, the build up of 
propranolol HCI in the receptor appears to carry on as if the lag 
period had merely been interrupted by the electrophoretic current, 
the delivery rate decreasing slightly from that which would be 
expected during the lag time. From previous experiments on the 
diffusion of propranolol HCI through 1%C PHEMA, during the lag phase 
(section 3.3.3), between the times of 8 and 32 hours, the increase in 
mass of propranolol HCI in the receptor was found to be approximately 
2.94 mg, in this present study it was found to be 2.07 mg.
The results in this study clearly indicate that a significant 
difference between drug delivery rates is produced by application of 
an electrophoretic current before and after steady state diffusion 
has been attained. Interestingly the voltage-time profile produced in 
this study follows a similar pattern to that found in the work of 
Lescure [128], where a constant current was applied from the start of 
experiments (without waiting for a lag time), a peak voltage 
corresponding to the lag time of bovine serum albumin appearance was 
found. The results in this study may also explain some of the
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findings of Kumar [127], where the drug delivery rate appeared to be 
virtually zero during periods of no electrophoresis. This was 
probably due to the fact that experiments were all performed during 
the lag phase of diffusion (section 3.3.3), which may also explain 
why different measured rates of drug delivery were obtained when a 
constant voltage was applied at different stages of an experiment. It 
could be speculated that voltage-time profiles during the application 
of a constant current across polymer films may give information on 
whether a charged species has attained steady state diffusion or not.
3.3.11 Delivery of Propranolol HCI through Crosslinked PHEMA by a 
Programmable Feedback Electrophoresis System
The method used to estimate the drug delivery rate based on 10 
samples at 3 minute intervals was checked during the periods of 
diffusion prior to electrophoresis where the delivery rate was 
constant. The mean of the computer-estimated drug delivery rate over 
a period of four hours was found to be within 3% of the delivery rate 
calculated from the concentration and time data stored by the 
computer. This was found to be the case for three successive 
experiments and thus the routine was assumed to be a satisfactory 
estimate of the drug delivery rate.
In all the initial feedback experiments based on the simple 
turning on and off of the power supply, during the period of feedback 
electrophoresis there was a slight undulation in the delivery rate, 
however over the eight hour period a zero-order type delivery rate 
was apparent. Figure 3.24 shows the type of relationship obtained 
between concentration and time, the example shown being for a 
programmed rate of 0.8 mg/h. Figure 3.25 shows the current changes
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Figure 3.24. Changes in propranolol HCI concentration with time 
















Figure 3.25. Variation of current during the feedback electrophoresis 
experiment shown in figure 3.24.
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during the feedback period. For all the experiments performed the 
overall delivery rate during the feedback period was calculated using 
linear regression of the receptor concentration data collected by the 
computer. The results showed that the delivery rates obtained were 
less than the programmed desired delivery rates, the values obtained 
were :




The discrepancies between the programmed and actual delivery 
rates were thought to be related to the method used to estimate the 
delivery rate. The method used was simple but insensitive to sudden 
changes in drug delivery rates, as occurs when an electrophoretic 
current is applied. This may explain why the discrepancy increased as 
the programmed delivery rate was increased. In order to reduce the 
discrepancies, a number of different sampling sizes and frequencies 
were tested, and the effect examined on the actual delivery rate when 
the programmed delivery rate was 0.8 mg/h. The computer was 
programmed to record all changes in the estimated drug delivery rate 
with respect to time. This enabled all changes to be examined in 
detail. The results obtained were as follows :
Sample Size and Frequency Actual Delivery Rate (mg/h) 
10 samples at 3 minute intervals 0.711
10 samples at 5 minute intervals 0.718
5 samples at 10 minute intervals 0.669
5 samples at 6 minute intervals 0.692
The results showed that there was not much difference between
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the various sampling routines, however for future experiments the 
routine was changed to that based on 10 samples at 5 minute 
intervals.
The second feedback system examined was based on altering the 
electrophoretic current in a more controlled manner rather than on a 
simple on/off basis. The effect was to produce an actual delivery 
rate closer to the programmed value. Figure 3.26 shows the changes in 
concentration that occur during the experiment, once again an 
undulating pattern of delivery during feedback control was observed. 
The calculated delivery rate was 0.757 mg/h. The changes in current 
that occurred during feedback control are shown in figure 3.27. 
Figure 3.28 shows the relationship between receptor propranolol HCI 
concentration, electrophoretic current and computer estimated 
delivery rate to one another with respect to time. The insensitivity 
of the method used to estimate the drug delivery rate is demonstrated 
by the lag time required to detect actual changes in the delivery 
rate. The undulating changes in concentration with time during 
feedback are probably due to this lag time.
In this part of the study it has been shown that even using a 
very simple feedback model, an electrophoretic drug delivery device 
has great potential as a feedback controlled system. It can be 
envisaged that such an electrophoretically modulated delivery device 
with feedback control could act as a synthetic gland, containing, for 










Figure 3.26. Changes in propranolol HCI concentration with time 















Figure 3.27. Variation of current during the feedback electrophoresis 













Figure 3.28. The relationship between concentration (---- ), current
(— # — ), and computer estimated delivery rate (— ) with time for 














An In Vitro Model of a Transdermal 
Electrophoretic Drug Delivery Device
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4.1 Materials
Hairless mice, MFl/Hr.Hr, male, 13-23 weeks, from a nucleus 
stock obtained from Harlan Olac Ltd., Bicester, U.K., were supplied 
by the Animal House, University of Bath, Bath, U.K.
Tritiated water, stated specific activity 80 pCi ml-1, supplied 
by Amersham International pic, Little Chalfont, U.K. Batch No. LA 
8451.
OptiPhase Safe (scintillation liquid), supplied by Fisons pic, 
Loughborough, U.K.
Sodium dodecyl sulphate, specially purified for biochemical 
work, supplied by BDH Ltd., Poole, U.K. Batch No. 5126230H.
Azone, pharmaceutical purity, was received as a gift from 
Nelson Research and Development, Irvine, CA, U.S.A. Batch No. 
0923Q0312.
Polyoxyethylene 20 sorbitan monolaurate (Tween 20), supplied by 
Sigma Chemical Company Ltd., Poole, U.K. Batch No. 34C-1690.
For all other materials used see section 2.1 and section 3.1.
4.2 Methods
In this chapter the transport of propranolol HC1 through 
hairless mouse skin will be examined, together with methods for the 
possible enhancement of this transport. The information derived from 
these experiments will be used in the investigation of the 
performance of an in vitro model of a transdermal electrophoretic 
drug delivery device using hairless mouse skin. The ultimate aim is 
to investigate whether controlled drug delivery may be achieved from 
this type of device.
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4.2.1 Measurement of the Permeability Coefficient of Propranolol HC1
through Hairless Mouse Skin
4.2.1.1 Design of Skin Diffusion Cell
The measurement of the permeability coefficients of water and 
propranolol HC1 across hairless mouse skin was based on the infinite 
dose technique (section 1.5.3). A number of designs of skin diffusion 
cells have been used in this type of study, however many of the cells 
used are based on the Franz diffusion cell [26,189,201]. The cells 
manufactured for this study were made of glass and based on the Franz 
cell, a schematic diagram of the cell is shown in figure 4.1. The 
cell is composed of a donor compartment and a receptor compartment. 
The cell was prepared for experiments by firstly smearing a thin 
layer of vacuum grease (Apiezon N) onto the interfacial ground glass 
joints of the donor and receptor compartments. A magnetic stirring 
bar, 0.2 x 0.2 x 0.7 cm, was then placed into the receptor 
compartment. A circular stainless steel wire mesh was placed into a 
groove in the receptor compartment which provided a flat supporting 
surface for skin samples. Fresh hairless mouse skin samples were 
obtained for experiments. The mice were sacrificed by cervical 
dislocation, and an area of approximately 4 x 5  cm of whole-thickness 
abdominal skin removed. The sample of skin was gently stretched and 
placed onto the surface of the receptor compartment, with the dermal 
side facing into the receptor compartment. The donor compartment was 
placed on top of the receptor and the the excess skin was then 
trimmed using scissors before the whole cell was clamped together. 
The effective diffusional area of the skin was 1.77 cm2. Into the 
receptor compartment was placed 4 ml of acetate buffer (appendix 2),
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R e c e p t o r  Compartment S t i r r e r Receptor  Solution Level
Figure 4.1. Schematic diagram of the diffusion cell used to study the 
permeation of propranolol HC1 through hairless mouse skin.
this was slowly pipetted into the inverted diffusion cell, ensuring 
no air bubbles were trapped in the receptor compartment. The 4 ml of 
buffer ensured that the receptor was completely filled, with only a 
short length of the sampling arm containing buffer (this level was 
maintained by surface tension). The reason for not filling the 
sampling arm was due to poor mixing effects in this region (see 
below). The cell was then placed onto an underwater air-driven 
magnetic stirrer (Jencons Scientific Ltd., Leighton Buzzard, U.K.).
The level of the magnetic stirrer was such that when the skin cell 
was placed on its surface, the water bath level was just below the 
interface of the donor and receptor compartments. The stirring rate 
of the magnetic stirrer was maintained constant by connecting a 
pressure gauge into the air-line and ensuring that a constant air 
pressure was maintained during experiments. The water bath was 
maintained at 30°C for all permeation experiments. The skin cell was 
allowed to equilibrate for 15 minutes, after which 3 ml of an 
appropriate donor solution was placed into the donor compartment and 
timing commenced. A square microscope slide, smeared with vacuum 
grease (Apiezon N), was placed onto the donor compartment to prevent 
a change in the concentration of the donor solution due to 
evaporation.
Initial experiments using tritiated water in the skin diffusion 
cell were as described above with the exception that 5 ml of buffer 
was present in the receptor compartment, which resulted in the 
sampling arm containing a significant volume of buffer. Though 
apparently satisfactory results were obtained with tritiated water 
using this volume (section 4.3.1.2), extremely low and erratic 
permeability data were produced with propranolol HC1. It was thought
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that this may have been the result of poor mixing in the sampling 
arm, which was further investigated in subsequent experiments. The 
skin diffusion cell was prepared as described above using a plastic 
sealing film (Nesco Film) to replace the skin sample. A crystal of 
potassium permanganate was placed into the receptor compartment 
together with the magnetic stirring bar. The experiment was repeated 
with both 4 ml and 5 ml of buffer present in the receptor 
compartment, and the change in colouration of the receptor 
compartment observed.
4.2.1.2 Permeation of Tritiated Water through Hairless Mouse Skin
In order to ensure that the method used to determine the 
permeability of propranolol HC1 through hairless mouse skin 
maintained the skins integrity (section 4.2.1.3), the permeability of 
tritiated water through hairless mouse skin was determined and 
compared with literature values. The permeation of tritiated water 
through hairless mouse skin was examined according to the method 
described in section 4.2.1.1. The skin cell was assembled as 
described, with 5 ml of acetate buffer in the receptor compartment, 
and after allowing the cell to equilibrate, 3 ml of tritiated water 
with a stated specific activity of 80 pCi ml-1 was placed into the 
donor compartment and timing started. Samples of 0.2 ml were removed 
from the receptor compartment at approximately 50 minute intervals up 
to a time of approximately five hours and retained for assay using a 
liquid scintillation counting technique. The samples were removed 
using a calibrated automated pipette (P200, Gilson) and after each 
sample was removed, 0.2 ml of acetate buffer was pipetted back into 
the receptor compartment. The removed samples were placed into 5 ml
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polyethylene scintillation counting vials (LKB Wallac Oy, Turku, 
Finland) and 4 ml of scintillation liquid measured using an automatic 
pipette (Oxford Pipettor 400/401) into each of the vials. The 
scintillation cocktail used (Optiphase Safe) was suitable for the 
incorporation of aqueous samples. The vials were capped and vortex 
mixed (Whirlimixer, Fisons Scientific Apparatus, Loughborough, U.K.) 
for approximately 10 seconds before being placed into glass 
scintillation vials (LKB). The samples were counted in a liquid 
scintillation counter (Rackbeta 1215, LKB Wallac Oy), employing a 
predetermined quench curve (see below). Each sample was counted in 
duplicate for one minute and an average value taken. A background 
count was subtracted from all counts. The external standard ratio 
time was 30 seconds. After correcting for dilution, the permeability 
coefficient of tritiated water through hairless mouse skin was 
determined from the gradient of the linear part of a plot of the 
cumulative amount of tritiated water in the receptor compartment 
versus time. Six replicates of the experiment were performed. The 
specific activity of the stock tritiated water (stated activity 
80 pCi ml-1) was also determined.
A quench curve was constructed using the external standards 
ratio method. Into each of ten empty 5 ml polyethylene scintillation 
counting vials was placed 0.2 ml of tritiated water with an activity 
of 0.88 pCi ml-1 and 4 ml of scintillation liquid (Oxford Pipettor 
400/401). Vial 1 was capped. To vials 2 to 10 was added 5, 10, 15,
20, 30, 50, 75, 100, and 150 pi of carbon tetrachloride respectively; 
the carbon tetrachloride acted as a quenching agent. The vials were 
vortex mixed and then loaded into the liquid scintillation counter 
which was programmed to count and construct a quench curve by means
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of an external standard source, the quench curve is shown in figure 
4.2. The quench curve, which is expressed as counting efficiency 
versus external standard ratio, was stored in the instruments memory. 
For all subsequent samples the scintillation counter determined the 
counts per minute and the degree of quenching for an unknown sample. 
Using the external standard ratio and quench curve, the efficiency is 
calculated and the liquid scintillation counter thus produces a value 
for the disintegrations per minute (dpm).
In order to demonstrate that a linear relationship existed 
between the measured dpm and tritiated water specific activity, a 
series of dilutions from a stock solution (0.88 pCi ml-1) were 
prepared and the resulting solutions assayed for tritium activity.
4.2.1.3 Permeation of Propranolol HC1 through Hairless Mouse Skin
The permeation of propranolol HC1 through hairless mouse skin 
was examined according to the method described in section 4.2.1.1.
The skin cell was assembled as described, and after allowing the cell 
to equilibrate, 3 ml of an approximately 8.4 m M  solution of 
propranolol HC1 in acetate buffer (appendix 2) was placed into the 
donor compartment and timing started. Samples of 0.2 ml were removed 
from the receptor compartment at approximately 16, 18, 20, 22 and 24 
hours. The samples were removed using a calibrated automated pipette 
(P200, Gilson) and after each sample was removed, 0.2 ml of acetate 
buffer was pipetted back into the receptor compartment. The removed 
samples were placed into 0.3 ml HPLC vials (Chromacol Ltd., London, 
U.K.) and capped using a crimper. The samples were stored at 4°C 
until ready for assay. Six replicates of the experiment were 






















Figure 4.2. Quench curve for tritiated water in Optiphase Safe.
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correcting for dilution, the concentration of propranolol HC1 in the 
receptor compartment at each sampling time was calculated, and from 
the gradient of the linear part of a plot of the cumulative molar 
concentration of propranolol HC1 in the receptor compartment versus 
time the permeability coefficient of propranolol HC1 through hairless 
mouse skin was calculated (section 1.5.3).
4.2.2 Effect of Penetration Enhancers on the Permeation of 
Propranolol HC1 through Hairless Mouse Skin 
The transport of ionised drugs across the stratum corneum by 
passive diffusion is very slow due to unfavourable partitioning into 
this lipophilic membrane [169]. Ionised drug transport may be 
enhanced by a number of methods as described above in sections
1.3.8.1, 1.3.9.1, 1.5.1, and 1.5.2. In the present study just two of 
these methods were investigated. The first method studied was to 
increase the lipophilicity of the ionised permeant by ion-pair 
formation [168,169,278,279]. In this study the use of sodium dodecyl 
sulphate as an ion pair for propranolol HC1 was investigated. The 
second method studied here by which the transport of charged species 
may be enhanced was to disrupt the skin structure by means of a 
penetration enhancer (section 1.5.2), thereby reducing the stratum 
corneum resistance. The use of Azone as such an agent was 
investigated.
4.2.2.1 Sodium Dodecyl Sulphate (SDDS) as an Ion-Pairing Agent
The interaction between large organic anions and cations in 
aqueous solution leading to the formation of ion-pairs has been 
demonstrated by a number of workers [280,281]. It is believed that
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the forces holding ion-pairs together are a combination of 
electrostatic and hydrophobic interactions [281]. One of the 
intrinsic properties of ion-pair systems is low aqueous solubility 
[278]. This was found in the present study when an equimolar solution 
of approximately 8.4 m M  of SDDS and propranolol HC1 was prepared in 
acetate buffer (appendix 2). A white, cloudy precipitate was formed, 
which also occurred when the same solution was prepared in double 
distilled water rather than buffer. The interaction between SDDS and 
a number of organic cations has previously been described [280,281], 
these systems showing complex interactions in aqueous solution. If a 
low concentration of an ion-pairing organic cation is taken and small 
volumes of a concentrated solution of SDDS added then a number of 
changes may be observed as the concentration of SDDS increases. 
Initially a clear region exists where soluble ion-pairs between SDDS 
and the organic cation exist in equilibrium with the homogeneous 
solution of the various other dissociated and non-dissociated ions 
present. As the concentration of SDDS is increased a heterogeneous 
phase separation occurs, apparent by the appearance of turbidity, 
which is the point at which the solubility product of the ion-pair 
species is exceeded and a coacervate phase is formed. As the 
concentration of SDDS is increased further a stage will be attained 
where the system becomes clear again following the micellar 
solubilisation of the complex coacervate.
The concentration of ions present will therefore greatly affect 
the type of interaction occurring in ion-pairing systems, which will 
in turn be expected to affect the disposition of the ions involved.
The effect of these ion-pair interactions on the transport of a model 
organic ion, cromoglycate, through a polyamide membrane has been
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reported [279]. It was found that before the solubility product of 
the system had been exceeded, an increase in ion-pair formation 
resulted in an increase in cromoglycate flux, however once the 
formation of complex coacervate occurred, a marked reduction in 
cromoglycate flux resulted, thought to be due to a decrease in the 
thermodynamic activities of cromoglycate and its ion pair. In the 
present study the effect of SDDS on the transport of propranolol HC1 
across hairless mouse skin was examined. Two systems were 
investigated, firstly the case where the concentration of the ions 
present were such that the solubility product was not exceeded. The 
second system examined, as a control, was where the complex 
coacervate was solubilised by a sufficient concentration of SDDS.
4.2.2.1.1 Determination of the Apparent Solubility Product of the 
Complex between SDDS and Propranolol HC1 
The determination of the apparent solubility product (K'sp) of 
the complex between SDDS and propranolol HC1 in both distilled water 
and acetate buffer was based on a combination of a static 
conductimetric and turbidimetric titration [280,281]. If a 
concentrated solution of surfactant is added in increasing amounts to 
a dilute solution of an organic ion-pair, a progressive increase in 
conductivity occurs as the concentration of surfactant increases 
until the K'sp is attained, this end-point is associated with a 
marked change in the slope of the conductivity curve, together with 
the appearance of turbidity. The K'sp of the complex between SDDS and 
propranolol HC1 in double distilled water was determined by both 
conductimetric and turbidimetric methods. The K*sp of the complex 
would be expected to change in the presence of acetate buffer
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[280,282], however conductimetric methods can not be used at higher 
ionic strengths since the change in conductivity measured with 
increasing concentrations of surfactant are small relative to the 
high background conductivity. Thus a turbidimetric method was used to 
estimate the K'sp in buffer.
The SDDS used in this study was obtained as a specially purified 
sample, however it is known that hydrolysis may occur upon storage 
[280,281], therefore the sample was further purified immediately 
before use. Soxhlet extraction was performed with petroleum ether for 
48 hours at approximately 50°C. The sample was dried at room 
temperature in a vacuum oven and recrystallized twice from absolute 
ethanol. The resulting crystals were then dried in a vacuum oven at 
40°C to constant weight at a pressure of approximately 900 mBar.
Double distilled water from an all-glass still was used in this 
study. The double distilled water was freshly prepared approximately 
24 hours before use, and was stored in a specially reserved glass 
container. All glassware used in this study was aged by soaking in a 
concentrated solution of SDDS overnight and thoroughly rinsing with 
distilled water several times and then finally with double distilled 
water before drying in an oven.
The apparatus used for measuring conductivity consisted of a 
jacketed beaker (figure 4.3), whose temperature was maintained 
constant by water circulated from a water bath. The conductivity of 
the system was measured using a glass-platinum Mullard dip cell, in 
conjunction with a conductivity bridge (Wayne Kerr B642, Wayne Kerr 
Company Ltd., New Malden, U.K.). The magnetic stirrer was only used 
to agitate the sample solution until the temperature had 
equilibrated, stirring was stopped whilst readings were taken as the
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Figure 4.3. Schematic diagram of the jacketed beaker in which
conductivity was measured.
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stirrer was found to interfere with the conductivity bridge. Whilst 
allowing the solutions to attain equilibrium temperature, the 
jacketed beaker was carefully covered with a layer of aluminium foil 
to reduce evaporation. Prior to any measurements the conductivity 
bridge was trimmed and calibrated as described in the instrument 
manual.
The cell constant of the dip cell was determined by measuring 
the conductivity of a range of potassium chloride solutions at 25°C. 
The potassium chloride used was dried at 60°C in an oven over 
phosphorous pentoxide for 24 hours. A range of solutions (5 x 10-4 to 
2 x 10_2M) were prepared in double distilled water. 50 ml of each 
solution was in turn placed in the jacketed beaker, and after 
allowing the temperature to equilibrate to 25°C the conductivity 
measured. After correcting for the conductivity of water, the derived 
cell constant was determined from literature values of specific 
conductivity [283], the results shown in table 4.1. The mean cell 
constant was found to be 1.41 cm-1.
In order to determine the stoichiometry and the K'sp of the 
complex between SDDS and propranolol HC1, the K'sp was determined for 
three different concentrations of propranolol HC1 in double distilled 
water, for each concentration a series of solutions were prepared
with successive increments in the amount of SDDS. The three systems 
examined were :
1) 7.96 x 10~4M  propranolol HC1 in double distilled water with the
concentration of SDDS ranging from 0.3 to 1.6 x 10_4M.
2) 5.04 x 10_4M  propranolol HC1 in double distilled water with the
concentration of SDDS ranging from 0.6 to 3.2 x 10-4M.
3) 2.02 x 10“4M  propranolol HC1 in double distilled water with the
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Table 4.1 Calculated cell constants frcm conductivity readings and
literature specific conductivity values for a range of potassium 




(S X  106)
Corrected 
Conductivity 








0 0.8 - - -
0.5 54.0 53.2 73.9 1.389
1.0 106.8 106.0 147.0 1.387
5.0 512.2 511.4 716.8 1.402
10.0 997.4 996.6 1412.7 1.418
20.0 1936.0 1935.2 2766.8 1.430
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concentration of SDDS ranging from 2 to 8 x 10~4M.
The solutions were prepared and equilibrated for 24 hours at 30°Ct 
For each system the conductivity of 50 ml of each solution was 
measured in the jacketed beaker at a temperature of 30°C. The 
turbidity of each system was determined by measuring the apparent 
absorbance of the solutions in a 1 cm cuvette at 500 nm (UV-120-02, 
Shimadzu Corporation, Kyoto, Japan). The solutions were transferred 
to the cuvette and measured immediately to minimise temperature 
changes.
Solutions containing SDDS-propranolol HC1 ion-pairs were 
examined by nuclear magnetic resonance (NMR) together with pure 
sample solutions of SDDS and propranolol HC1. A solution of 100 ml 
0.1 M  propranolol HC1 and 0.01 M  SDDS in distilled water gave a white 
precipitate of the ion-pair which was isolated by centrifugation, and 
the supernatant layer discarded. The ion-pair was dissolved in 
150 ml of chloroform and washed with distilled water (3 x 10 ml). The 
organic layer was evaporated in vacuo to leave a white waxy solid. 
This was dried in a vacuum oven at room temperature at a pressure of 
approximately 900 mBar and the solid j dissolved in CDC13 subjected 
| to NMR analysis (appendix 5)^
The K'Sp of the ion-pair complex in acetate buffer at 30°C was 
estimated using the turbidimetric method as described above on a 
series of solutions containing 7.98 x 10-4M  propranolol HC1 in 
acetate buffer, with the concentration of SDDS varying from 0.5 to
3.2 x 10~4M.
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4.2.2.1.2 Determination of the Concentration of SDDS Required to
Solubilise the Complex between SDDS and Propranolol HC1 
The determination of the concentration of SDDS required to 
solubilise the complex between SDDS and propranolol HC1 was by a 
turbidimetric method [281]. A series of solutions of 8.45 x 10-3M 
propranolol HC1 in acetate buffer were prepared with the 
concentration of SDDS varying from 0.5 to 3.2 x 10-4M. The solutions 
were equilibrated at a temperature of 30°C for 24 hours, and the 
apparent absorbance of the solutions measured as described in section
4.2.2.1.1.
4.2.2.1.3 Effect of SDDS on the Permeation of Propranolol HC1
through Hairless Mouse Skin 
The effect of SDDS on the permeability of hairless mouse skin to 
propranolol HC1 was investigated. The method used was similar to that 
in section 4.2.1.3 except for the composition of the donor 
compartment solution. The donor compartment contained 3 ml of
approximately 8.4 m M  propranolol HC1 in acetate buffer in the 
presence of either 9.40 x 10_6M  SDDS or 2.69 x 10-2M  SDDS. The former 
concentration of SDDS was chosen as it is just below that which would 
be expected to exceed the K ’sp of the complex between SDDS and
propranolol HC1 at 30°C (section 4.3.2.1.1). Six replicates of the 
permeation experiment were performed at this concentration of SDDS. 
The higher concentration of SDDS represents the estimated value
necessary to solubilise the complex between SDDS and propranolol HC1
at 30°C (section 4.3.2.1.2). Three replicates of the permeation 
experiment were performed at this concentration of SDDS.
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4.2.2.2 Effect of Azone on the Permeation of Propranolol HC1 
through Hairless Mouse Skin 
The effect of the penetration enhancer Azone on the permeability 
coefficient of propranolol HC1 was investigated. The method used was 
similar to that described above in section 4.2.1.3 except for the 
composition of the donor compartment solution. The donor compartment 
contained 3 ml of approximately 8.4 m M  propranolol HC1 in one of the 
following formulations :
A - 2% w/v Azone in acetate buffer (appendix 2)
B - 0.11% w/v Tween 20 in acetate buffer 
C - 1% w/v Azone and 0.11% w/v Tween 20 in acetate buffer
D - 2% w/v Azone and 0.11% w/v Tween 20 in acetate buffer
E - 3% w/v Azone and 0.11% w/v Tween 20 in acetate buffer
F - 5% w/v Azone and 0.11% w/v Tween 20 in acetate buffer
G - 10% w/v Azone and 0.11% w/v TWeen 20 in acetate buffer 
Formulation A was used as a control since it has been reported that 
Azone alone when mixed in solution may have some enhancement effect 
[176]. The rest of the formulations used Tween 20 to form an emulsion 
of Azone in acetate buffer [284], formulation B acting as a control.
Six replicate skin permeation experiments were performed for each 
formulation. The sampling, assaying and calculation of permeability 
coefficients were as described in section 4.2.1.3.
4.2.3 In Vitro Model of a Transdermal Electrophoretic Device
In this section an in vitro model of a transdermal 
electrophoretic delivery device using hairless mouse skin is 
investigated. It has been demonstrated by work reported in chapter 3 
that constant current electrophoresis can be used to control the
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transport of propranolol HC1 through crosslinked PHEMA films. It will 
also be seen from results reported subsequently in section 4.3.2.2 
that the transport of propranolol HC1 across hairless mouse skin in 
vitro is significantly enhanced using Azone. The information derived 
from these experiments was used to investigate the potential of a 
transdermal electrophoretic system as a controlled drug delivery 
device.
A schematic diagram of the model system used in this study is 
shown in figure 4.4, together with a photograph of the actual three 
compartment cell (figure 4.5). The design of the three compartment 
cell was based on the electrophoresis cell described in section
3.2.1. The receptor and drug reservoir compartments each had a 
capacity of approximately 220 ml, the cathode compartment having a 
capacity of approximately 3.5 ml. The separation of the uncoated 
platinum electrodes (section 3.2.1) in this system was 4.5 cm.
The assembly of the three compartment cell and preparatory 
experimental details are very similar to those described for the 
electrophoresis cell in section 3.2.1. 1%C PHEMA films having a 
thickness of approximately 0.1 cm were prepared as described in 
section 2.2.4.2, and discs of 4 cm diameter were cut. The discs were 
stored in pH 4.48 buffer at 4°C (appendix 2) prior to use. The 
interfacial ground glass joints of the three compartment cell were 
smeared with a thin layer of vacuum grease (Apiezon N). A section of 
hairless mouse skin was obtained (section 4.2.1.1) and placed over 
the interface of the receptor compartment, with the dermal side 
facing into the receptor. The exposed area of skin was 2.54 cm2. The 
cathode compartment, with a platinum electrode in position, was 
carefully positioned onto the interface of the receptor compartment.
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Figure 4.4. Schematic diagram of the three compartment model used to 
investigate a transdermal electrophoretic device.
- 207 -




An annular sheet of polytetrafluoroethylene (PTFE), with a thickness 
of 0.08 cm and internal diameter of 4 cm was placed at the exposed
interface of the cathode compartment, and a disc of polymer film
placed in its centre. The reservoir compartment was then assembled 
into position next to the cathode compartment and the three 
compartments clamped tightly. Into the cathode compartment was then 
placed one of two solutions :
1) 3.5 ml of acetate buffer (appendix 2)
2) 3.5 ml of 1% w/v Azone and 0.11% w/v Tween 20 in acetate buffer
Into the receptor compartment was placed 210 ml of pH 4.48 buffer, 
and into the drug reservoir was placed 200 ml of pH 4.48 buffer. The 
anode electrode was then inserted into the drug reservoir 
compartment. The whole cell was mounted in a specially constructed 
perspex stand and immersed in a water bath maintained at 25°C. The 
drug reservoir and receptor compartments were stirred continuously 
using perspex stirrers driven by 12 volt motors at 330 rev min-1 (RS 
Components Ltd., Corby, U.K.), which were powered by a constant 
voltage power supply (E30/1 Farnell Instruments Ltd, Wetherby, U.K.).
The cell was allowed to equilibrate for 30 minutes, after which 
20 ml of a stock propranolol HC1 solution in acetate buffer was 
added to the reservoir compartment to give a final concentration of 
approximately 14 m M  (0.43%w/v), timing was then started. After 15 
seconds a 10 ml sample was withdrawn from the reservoir compartment 
to give a measurement of the initial reservoir propranolol HC1 
concentration. This sample was analysed by u.v. spectrophotometry 
(section 2.2.1). The concentration of propranolol HC1 in the receptor 
compartment was measured using a flow through u.v. detector system as 
described in section 3.2.1.
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At the end of each experiment the hydrogel thickness was 
measured (section 2.3.4.2). The electrodes were thoroughly rinsed in 
distilled water, followed by double distilled water. The electrodes 
were then stored in fresh double distilled water until required.
Three experiments were performed, in each experiment the power 
supply was turned on to a constant current of 2 m A  for two periods of 
4 hours, the first period commencing at 57 hours and the second at 
75 hours. The first experiment examined the appearance of propranolol 
HC1 in the receptor compartment with just buffer in the cathode 
compartment. A second experiment examined the effect of an Azone 
emulsion (as described above) in the cathode compartment. A third 
experiment was performed as a control where no propranolol HC1 was 
added to the drug reservoir, with an Azone emulsion present in the 
cathode compartment.
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4.3 Results and Discussion
4.3.1 Measurement of the Permeability Coefficient of Propranolol HC1
through Hairless Mouse Skin
4.3.1.1 Design of Skin Diffusion Cell
By investigating the mixing of a solution containing a crystal 
of potassium permanganate in the receptor compartment it was found 
that with 5 ml of buffer present the majority of the receptor 
attained a uniform purple colour within about 20 seconds, however the 
sampling arm was not evenly coloured. The purple colouration in the 
buffer became less intense with distance up the sampling arm 
indicating that mixing was not occurring in this area. In the study 
using 4 ml of buffer, uniform colouration occurred in all parts of 
the buffer within about 20 seconds. It was therefore assumed that 
uniform mixing was occurring in all parts of the cell, and 4 ml of 
receptor buffer was used in all skin transport studies using 
propranolol HC1. This mixing effect may explain why lower than 
expected values were obtained for the permeability coefficient of 
tritiated water where 5 ml of receptor solution was used in the 
studies (section 4.3.1.2).
4.3.1.2 Permeation of Tritiated Water through Hairless Mouse Skin 
The specific activity of the stock tritiated water was
determined as 73.6 pCi ml-1. The reproducibility of liquid 
scintillation counting was determined by preparing four dilutions of 
the stock solution of tritiated water to give values ranging from 
3000 to 366000 disintegrations per minute. The coefficient of 
variation did not exceed + 2.0% (n=5) for any of the samples, thus 
the reproducibility of the technique was considered satisfactory.
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Figure 4.6 indicates that a linear relationship exists between 
relative count and tritiated water specific activity. Linear 
regression analysis of the line yielded the following statistics :







-1.1803 x 10-2 (8.69 x 10~3)
It was therefore considered that liquid scintillation counting was a 
satisfactory assay method for the determination of tritiated water 
activity.
The permeability coefficient of tritiated water through hairless 
mouse skin at 30°C was calculated from the linear part of a plot of 
cumulative tritium activity in the receptor compartment versus time 
(section 1.5.3). An example of a plot is shown in figure 4.7. The 
mean value of the permeability coefficient of tritiated water through 
hairless mouse skin was calculated as 9.65 x 10~4 cm h_1 with a 
standard error of 0.75 x 10-4. A reported value for the permeability 
coefficient of tritiated water through hairless mouse skin is 3.36 x 
10-3 cm h-1 at 31°C [197], which is higher than the value obtained in 
the present study. The lower value obtained in the present study may 
be partly due to the different temperature used in the studies and 
partly due to mixing effects in the receptor compartment described 
above (section 4.3.1.1). Corresponding values for the permeability 
coefficient of tritiated water in human skin have been reported as
1.4 x 10-3 cm h_1 at 31°C [197], and also as varying between 1.2 and
1.5 x 10-3 cm h-1 depending on the skin sample [285], though no 
indication was given in the latter report as to the temperature at 











Tritiated Water Specific Activity (pCi ml1)
Figure 4.6. Calibration plot for the liquid scintillation counting 





















Figure 4.7. Relationship between cumulative tritium activity in the 
receptor compartment versus time.
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the methodolgy used maintains the integrity of hairless mouse skin.
4.3.1.3 Permeation of Propranolol HC1 through Hairless Mouse Skin
The cumulative amount of propranolol HC1 in the receptor 
compartment (in moles) at each sampling time was calculated, and a 
series of plots of the cumulative amount of propranolol HC1 (in
moles) in the receptor compartment versus time were obtained similar 
to figure 4.7. The permeability coefficient of propranolol HC1 was 
obtained from the linear portion of the plots as described in section 
1.5.3. The mean value of the permeability coefficients was 2.92 x
10-3 cm h-1 with a standard error of 2.78 x 10-4.
4.3.2 Effect of Penetration Enhancers on the Permeation of
Propranolol HC1 through Hairless Mouse Skin
4.3.2.1 Sodium Dodecyl Sulphate (SDDS) as an Ion-Pairing Agent
4.3.2.1.1 Determination of the Apparent Solubility Product of the
Complex Between SDDS and Propranolol HC1 
The changes in apparent absorbance and conductivity with changes 
in the concentration of SDDS for the system with a propranolol HC1 
concentration of 7.96 x 10_4M  are shown in figure 4.8. The appearance 
of turbidity (end-point) was associated with a change in the slope of 
the conductivity curve. The two other systems in double distilled
water showed similar behaviour with the appearance of turbidity in 
the solutions associated with a change in the slope of the 
conductivity curve. This appearance of an insoluble phase may be 














[SDDS] (X 104 mol dm"3)
Figure 4.8. Changes in conductivity (#) and apparent absorbance (■) 
with SDDS concentration in the presence of 7.96 x 10-4M propranolol 












equilibrium between the insoluble phase and the ions in solution may
be written as follows :
xPropranolol+ + yDDS- v  Propranololx DDSy(insoluble)
The equilibrium may be defined by the apparent solubility product,
K'Sp, as follows :
K'sp = [Propranolol+(aq)]x.[DDS-(aq)]y
This equation may be rearranged to give the following :
log10 [DDS-(aq)] = 1 log10 K'sp - X  log10 [Propranolol* (aq} ]
Y Y
Figure 4.9 shows a plot of [Propranolol HC1] versus [SDDS]-1
determined from the complexation end-point. For a 1:1 complex between 
SDDS and propranolol HC1 this plot should be linear with slope K'sp 
and pass through the origin. Linear regression analysis of the data 
from figure 4.9 yielded the following statistics :
Number of points : 3
0.9911 
5.30 x 10-8 (5.02 x 10-9)
-2.83 x 10-5 (5.50 x 10-5)
Figure 4.10 shows a double log plot of [SDDS] versus [Propranolol
HC1]. For a 1:1 complex between SDDS and propranolol HC1 this plot 
should be linear with a slope of unity. Linear regression analysis of 










-0.868 (9.04 x 10-2) 
-6.87 (0.305)
The results indicate a 1:1 stoichiometry for the complex between 
propranolol HC1 and SDDS with an apparent solubility product at 30°C 

















[ S DD S ]  ’ (X 10'4 mofclm3)
Figure 4.9. Relationship between propranolol HC1 concentration and 














Log [Propranolol HCl] (mol dm 3)
Figure 4.10. Relationship between the logarithm of SDDS concentration 
at complexation end-point and the logarithm of propranolol HC1 
concentration at 30°C.
- 219 -
The NMR spectrum of the anhydrous ion-pair complex in deuterated 
chloroform (CDC13) showed the complex to have a 1:1 stoichiometry 
(appendix 5), which is in agreement with the results obtained from 
conductivity and turbidity experiments.
Figure 4.11 shows a plot of apparent absorbance versus [SDDS] 
for the series of solutions containing 7.98 x 10-4M  propranolol HC1 
in acetate buffer. The complexation end-point was estimated as 
occurring at an SDDS concentration of 1.01 x 10~4M, and the apparent 
solubility product estimated as 8.08 x 10-8 mol2 dm-6 at 30°C in 
acetate buffer.
4.3.2.1.2 Determination of the Concentration of SDDS Required to
Solubilise the Complex between SDDS and Propranolol HC1 
Figure 4.12 shows the effect of increasing the concentration of 
SDDS on the apparent absorbance of solutions containing 8.45 x 10_3M  
propranolol HC1 in acetate buffer at 30°C. The concentration of SDDS 
required to solubilise the complex between SDDS and propranolol HC1 
was estimated as 2.69 x 10-2M.
4.3.2.1.3 Effect of SDDS on the Permeation of Propranolol HC1
through Hairless Mouse Skin 
The permeability coefficients of propranolol HC1 were determined 
as described in section 4.3.1.3, figure 4.13 shows the cumulative 
amount of propranolol HC1 in the receptor compartment versus time and 
shows the effect of SDDS. The permeability coefficient of propranolol 
HC1 in the presence of 9.4 x 10_6M  SDDS in acetate buffer was 5.26 x 
10~3 cm h-1 with a standard error of 2.09 x 10-3. This is a small 
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Figure 4.11. Change in apparent absorbance with SDDS concentration in 
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Figure 4.12. Change in apparent absorbance with SDDS concentration in 




Figure 4.13. Relationship between cumulative amount of propranolol 
HC1 in the receptor compartment versus time for a donor concentration 
of 8.4 m M  propranolol HC1 in the presence of a) 9.40 x 10"6M SDDS in 
acetate buffer (-*-), b) acetate buffer (— A-), c) 2.69 x 10-2M 
SDDS in acetate buffer (— # — ).
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permeability coefficient determined in buffer alone. The ion-pairing 
of propranolol HC1 was thus not successful in enhancing the 
permeation through hairless mouse skin. This is probably partly due 
to the large size of the ion-pair, but mainly due to the fact that 
the actual ion-pair concentration is very low. The concentration of 
ion-pair in solution is limited by the solubility product of the 
ion-pair, which has been shown to be low for propranolol dodecyl 
sulphate (section 4.3.2.1.1). It is perhaps surprising that a greater 
effect was not seen since surfactants such as SDDS have a direct 
enhancing effect on the skin [26]. The permeability coefficient of 
propranolol HC1 in the presence of 2.69 x 10~2M  SDDS in acetate 
buffer was 1.71 x 10-4 cm h-1 with a standard error of 6.91 x 10-6. 
Thus by solubilising the complex between SDDS and propranolol HC1 a 
significant decrease (P<0.05) in the permeability of propranolol HC1 
through hairless mouse skin occurs. This may be explained by the fact 
that the thermodynamic activity of propranolol HC1 is decreased in
i
!the presence of SDDS micelles.
4.3.2.2 Effect of Azone on the Permeation of Propranolol HC1 
through Hairless Mouse Skin 
The permeability coefficients of propranolol HC1 were determined 
as described in section 4.3.1.3 and are shown in table 4.2. Figure 
4.14 is a plot of the cumulative amount of propranolol HC1 in the 
receptor compartment versus time and shows the effect of the various 
formulations. The values of the permeability coefficients, together 
with those determined from sections 4.3.1.3 and 4.3.2.1 are compared 

























Figure 4.14. Relationship between cumulative amount of propranolol 
HC1 in the receptor compartment versus time for a donor concentration 
of 8.4 m M  propranolol HC1 in the presence of i) acetate buffer (7), 
ii) 0.11% Tween 20 in acetate buffer (8), iii) 2% Azone in acetate 
buffer (6), iv) 0.11% Tween 20 in acetate buffer plus the following 
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Figure 4.15. Effect of various formulations on the permeability 
coefficient of propranolol HC1 through hairless mouse skin (see table 
4.3 for key to formulations).
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Table 4.3 Key to figure 4.15 showing the nature of the various
formulations of propranolol HCl added to the donor canpartment in the 
skin diffusion cell (each formulation is based on 8.4 iriM propranolol 
HCl in acetate buffer).
Formulation Number Formulation
1 -
2 9.40 X  10“6M SDDS
3 2.69 x 10“2M SDDS
4 0.11% Tween 20
5 2% Azone
6 1% Azone + 0.11% Tween 20
7 2% Azone + 0.11% Tween 20
8 3% Azone + 0.11% Itoeen 20
9 4% Azone + 0.11% Tween 20
10 5% Azone + 0.11% Tween 20
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alone cause any significant increase (P<0.05) in the transport of
propranolol HCl across hairless mouse skin. It can however be seen
that when Azone is applied as an emulsion, enhancement in the
transport of propranolol HCl does occur, and a significant increase
(P<0.05) in the permeability coefficient is found. An emulsion of
propranolol HCl and 2% Azone in buffer (with Tween 20) is found to
have a permeability coefficient approximately 7.8 times greater than
propranolol HCl in buffer alone. The data indicates that an emulsion
of 1% Azone is as effective in enhancing the transport of propranolol
HCl in comparison with higher concentrations of Azone, with a
decrease in enhancer activity occurring in the presence of 3, 5 and
j 10% Azone, which may be due to changes in the thermodynamic activity 
I of propranolol HCl in the donor phase at higher concentrations of 
[Azone.
Table 4.2 Effect of Azone on the transport of propranolol HCl through 
hairless mouse skin.
Formulation Permeability Coefficient (cm h-1) Standard Error
A 4.73 X 10-3 1.58 X 10-3
B 1.84 X
CO1o1 3.84 X l-» o 1
C 2.25 X 10-2 1.62 X 10-3
D 2.29 X 10-2 1.50 X o 1 u
>
E 1.72 X 10-2 1.21 X IQ"3
F 1.89 X 10-2 3.80 X o 1
G 1.41 X 10-2 1.66 X IQ-3
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4.3.3 In Vitro Model of a Transdermal Electrophoretic Device
Figure 4.16 shows a continuous plot of the change in measured 
concentration of propranolol HCl in the receptor compartment versus 
time. The control experiment, together with the experiment with 
buffer alone in the cathode compartment indicate that the hairless 
mouse skin yields u.v. absorbing materials into solution which 
interfered with the assay. Therefore the true concentration of 
propranolol HCl at any given time can not be accurately determined by 
the analytical method employed. The control experiment indicates that 
the amount of u.v. absorbing material leached by the skin increased 
slowly and continuously after an initial burst; the release of these 
materials being unaffected by the application of an electrophoretic 
current of 2 mA. Thus the plots may give an indication of the changes 
in the concentration of propranolol HCl in the receptor compartment. 
The results indicate that Azone has an enhancing effect on the 
transport of propranolol HCl into the receptor compartment and that 
the application of an electric current across the electrodes 
increased the delivery rate of propranolol HCl into the receptor 
compartment after a lag period. The increase in the delivery rate 
produced by an electrophoretic current appears to be irreversible. 
This may be explained by the fact that the skin is the rate limiting 
step for drug delivery into the receptor compartment. During 
application of an electrophoretic current the concentration of 
propranolol HCl in the cathode compartment probably increases, thus 
the driving force of diffusion-controlled transport across the skin 
would be expected to increase, which is reflected by an increase in 
the delivery rate of propranolol HCl into the receptor compartment 

















Figure 4.16. Electrophoretically modulated transdermal delivery of 
propranolol HCl showing the change in apparent propranolol HCl 
concentration with time in the receptor compartment for (1) control,
(2) acetate buffer in cathode compartment, (3) 1% Azone + 0.11% Tween 
20 in cathode compartment.
Note : On = electrophoretic current switched on.
Off = electrophoretic current switched off.
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rate into the receptor compartment could be to apply an 
electrophoretic current with the polarity of the electrodes reversed 
instead of simply switching off the current, in an attempt to 
decrease the concentration of propranolol HCl in the cathode 
compartment.
Assessment of the performance of the model investigated is 
limited by the analytical technique, however it would be useful to 
re-examine the system with another continual assay method that is 
unaffected by interfering substances. One possible method would be to 





High pressure liquid chromatography of propranolol HCl (PHC) in 
aqueous solution indicated that PHC is stable in solution for at 
least one month at 25°C and at a pH below 5.3.
Homogeneous crosslinked PHEMA was prepared by chemically 
initiated solution polymerization, whereas uniform polymerization by 
gamma irradiation in the conditions available was unsuccessful. The 
equilibrium water content and the swelling behaviour of PHEMA when 
stored in water was found to be comparable with previously reported 
studies. However in acetate buffer PHEMA showed complex swelling 
behaviour. Scanning electron microscopy of PHEMA did not reveal any 
porous ultrastructure at a magnification of X5000 - the polymer 
surface appeared to be smooth and regular.
PHC was found to interact with PHEMA in solution, this
interaction could only be partly explained by the presence of 
negatively charged binding sites shown to be present in PHEMA, the 
presence of which were thought to be related to initial monomer 
purity.
PHC showed anomalous diffusion behaviour through PHEMA with 
respect to the effect of altering crosslinker content. A decrease in 
crosslinker content resulted in an increase in the diffusion 
coefficient which was consistent with a change in diffusion 
mechanism from a predominantly partition mechanism to a pore
mechanism, however the changes in diffusion coefficient at lower 
crosslinker content were anomalous with respect to the diffusion
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behaviour of previously reported solutes. Methylating PHEMA resulted 
in a small but significant decrease in the diffusion coefficient of 
propranolol HCl through PHEMA at low crosslinker content, but no 
difference was found at higher crosslinker contents.
In the model electrophoretic system examined, significant 
degradation of PHC occurred at a current of 15 mA. The presence of 
platinum black on the platinum electrodes caused degradation at lower 
currents in the range of 0 to 2.4 mA. However, by using uncoated 
platinum electrodes and currents in this range no detectable 
degradation of PHC was found during the course of experiments. No 
localized heating effects were found in the PHEMA films during 
electrophoresis. Constant current electrophoresis in the current 
range 0 to 2.4 m A  produced predictable and reproducible increases in 
the delivery rate of PHC in the model system. The effect produced by 
a current was dependent on the crosslinker content of the PHEMA 
film. Several factors affected the delivery rate of PHC during 
electrophoresis, such as ionic strength, temperature and reservoir 
PHC concentration. Reversal of electrode polarity resulted in a 
reduction of the basal drug delivery rate due to diffusion. 
Application of an electrophoretic current during the diffusion lag 
time was found to produce a different effect to that found when 
electrophoresis was carried out during steady state diffusion. 
Feedback experiments demonstrated that control over the delivery rate 
of PHC from the model electrophoretic system could be achieved by 
means of feedback control.
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The effect of the permeation enhancers sodium dodecyl sulphate 
(SDDS) and Azone on the permeation of PHC through hairless mouse skin 
was investigated. SDDS caused an insignificant increase on the 
permeation of PHC through hairless mouse skin when present at a 
concentration which did not exceed the apparent solubility product 
between PHC and SDDS. SDDS present at a concentration above that 
necessary to solubilise the complex coacervate between SDDS and PHC 
caused a significant decrease in the permeability coefficient of PHC 
through hairless mouse skin. The stoichiometry of the complex between 
SDDS and PHC was found to be 1:1. Azone significantly enhanced the 
permeation of PHC through hairless mouse skin.
A model of a transdermal electrophoretic drug delivery device 
was investigated. However, the u.v. assay used was not entirely 
satisfactory due to significant leaching of interfering substances. 
Nevertheless the model did indicate that some control over drug 
delivery could be achieved, although results from the same model 
indicated that controlled drug delivery across the skin may be 
restricted by long lag times.
The use of an electrophoretically modulated drug delivery device is 
considered to be a feasible method of providing true controlled drug 
delivery. Significant control over drug delivery is possible using 
low constant currents. The degree of control that this type of device 
potentially offers would make it suitable for use as an implant 





Measurement of Diffusion Coefficients from Permeation through 
Membranes [286-290].
The mathematical theory of passive diffusion in an isotropic
medium is based on Fick's laws of diffusion. Diffusion is the
tendency of a solute to distribute itself uniformly over the space
available to it due to the random movement of molecules and is a
probabilistic process which is spontaneous, irreversible and
thermodynamically favourable. Fick's first law of diffusion states
that the rate of transfer of a diffusing substance across a plane of
unit area, known as flux (J), is proportional to the concentration
gradient across the plane (dC/dx) as stated below :
J = -DdC (eq. 1) 
dk
where D, the diffusion coefficient, is the constant of 
proportionality. The negative sign indicates that the flux is in the 
direction of decreasing concentration. The diffusion coefficient may 
be considered a constant at a given temperature, however in some 
situations it may be concentration dependent and is best regarded as 
a mean for the concentration under consideration.
Fick's second law of diffusion states that the rate of change in
concentration in a volume element within a diffusional field (dC/dt)
is proportional to the rate of change in concentration at that point
in the field (d2C/dx2) as stated below :
dC = Dd2C (eq. 2) 
cE dx2
Fick's second law is a general equation which has many complex 
solutions depending on the boundary conditions being considered. The 
case commonly encountered is the simple zero-order flux situation.
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This solution is applicable where we have a membrane (eg. polymer or
skin) of thickness h separating two compartments, where the
concentration gradient across the membrane may be considered constant
and the receptor compartment is kept at essentially sink conditions.
The defined boundary conditions are that unidirectional diffusional
flow occurs beginning at x=0, the high concentration side of the
membrane, and continues toward the other membrane surface where x=h.
The concentration of the diffusant substance at x=0 is a constant
(CQ) at all values of time (t), also the concentration of the
diffusant (C) at x=h is zero at all values of time. The model also
assumes that at t=0, for all values of x greater than zero, C=0. The
diffusion coefficient is also assumed to be invariable. The solution
of Fick's second law for these given boundary conditions is usually
expressed in terms of the cumulative mass of diffusant (M) which
passes through unit area of the membrane in time t, as shown below :
M = DC0t - hCc - 2hCo A  (-l)n exD/-Dn2 rc2t \ (eq. 3)
h 6 ti2 2-/ n2 \ E2 J
n=l
As t approaches infinity the third term in the equation tends to zero 
and the equation can be reduced to the straight line expression shown 
below :
M = DC0/t - h2\ (eq. 4)
1 r[ 6DJ
Equation 4 applies once steady state diffusion has been attained
where dC/dt is zero at all values of x within the membrane. The
steady state flux of the diffusant (dM/dt) may be obtained by
differentiating equation 4 as shown below :
dM = DC0 (eq. 5)
Ht h
If the steady state line from equation 4 is extrapolated to the time
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axis, one may obtain the lag time (tL) as shown below :
tL = h2 (eg. 6)
6D
Steady state diffusion is not assumed to have been attained until a 
time of at least 2.7 times the lag time. It can therefore be seen 
that from a permeation experiment the diffusion coefficient may be 
estimated provided the membrane thickness is known.
In most experiments the actual value C0, the concentration of 
diffusant in the first layer of the membrane, is not known. The value 
actually measured is the concentration in the donor phase bathing the 
membrane, C\ which may be related to CQ by the partition coefficient 
(K) as follows :
Thus substituting equation 7 into equation 4 yields the following :
If the volume (V) of the receptor compartment is known then equation 
8 may be written in terms of the measured concentration of diffusant 
in the receptor compartment (Ct) as follows :




Ct = DKC'/t - h2 
"TfiTl 6D
(eq. 9)
A plot of equation 9 is sometimes termed a Barrer plot.
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APPENDIX 2
Measurement of pH and Preparation of Buffers
Calibration of the pH meters (Radiometer PHM64 research pH 
meter, V.A. Howe and Co. Ltd., London, U.K., Philips PW 9421 pH 
meter, Pye Unicam Ltd., Cambridge, U.K.) was carried out using the 
following primary standard buffer solutions [271] :
Buffer pH at 25° C
0.05M potassium hydrogen phthalate 4.005
0.01M disodium tetraborate 9.185
0.025M potassium dihydrogen orthophosphate 6.858
and 0.025M disodium hydrogen orthophosphate
The standard buffers were prepared by dissolving appropriate 
amounts of the buffer salts in freshly distilled water. Prior to 
buffer preparation all salts except for the disodium tetraborate,
were dried over phosphorous pentoxide in a vacuum oven at 80°C to
remove any traces of water.
The buffer salts used in this work were all based on the 
following systems unless otherwise stated :
pH at 25° C Buffer*
4.48 Walpole's acetate
3.03 Mcllvaine’s citric acid-phosphate
10.05 Delory and King’s carbonate-bicarbonate
*[291]
The pH of each of the buffers was measured after equilibrating 
samples of buffer in a water bath held at 25°C. All buffers were 
stored at 4°C in the dark and discarded after four weeks.
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APPENDIX 3














140PRINTTAB(2,8)"CONTINUE (C) OR CALIBRATE AGAIN (R)" 
150Z%=GET
160IF Z%=67 THEN PROCCHECK 
170IF Z%<>82 THEN150 
180CLS
190PRINTTAB(2,5)"CALIBRATION OF DETECTOR" 
200PRINTTAB(2)" "
210PRINTTAB(2,12)"How Many Points Do You Want?" 
220INPUTTAB(2,14)"? ”0%
230CLS





290PRINTTAB(2,6)"Choose Type Of Run"
300PRINTTAB(2)" "
310PRINTTAB(2,10)"(1) Auto Data Capture" 
320PRINTTAB(2,12)"(2) Auto Data Capture With Absorbances" 
330X?f GET-48
340IFX%<>1 AND X%<>2 THEN 330
350PROCCALIB
360CLS:@%=&1050A
370PRINT"" ADVAL(l) CONC "
380PRINT" "’
390FOR P%= 3 TO 0%+2 
400PRINT X1(P%) Y1(P%)
410NEXT
420PRINT”"PRESS ANY KEY TO CONTINUE"
430D=GET
























670PRINT" " CALIBRATION ANALYSIS "''
680@%=10:PRINT" No. of Points ";0%
690@%=&20508:PRINT:PRINT" Corr. Coeff. ";CC
700@%=&1050A:PRINT:PRINT" Slope Coeff ";SL'
710PRINT" S.D. of Slope M;SDS'
720PRINT" Intercept ";IN'
730PRINT" S.D. of Intercept ";SDI"





790PRINTTAB(2,8)"Have You inserted disc?"
800J%=GET




850CHAIN " GIL "
860END
870DEF PROCCALIB 
880FOR H%=3 TO 0%+2 
890CLS
900PRINTTAB(2,12)"What is Drug Concentration ";H%-2 
910INPUTTAB(2,15)"? "Y1(H%)
920IF Y1(H%)=0 THEN 900
930CLS
940@%=&1050A
950PRINTTAB(2,2)"Drug Concentration= ";Y1(H%) 
960@%=&2000A
970PRINTTAB(2,4)"(Press S When Detector is Stable)" 
980PRINTTAB(2,6)"(Must Not Exceed 2290)"' 
990PRINT"Detector Output= "'
1000FORV%=1 TO 14 
1010WT%=TIME










cn £* co 
o  o  o  
M dd >
2  M  M
O 1 1w  /^ N
H- >
cn cn cn cn cn cn cn 
co to  
o  o
X ^  O o
w  M 
* c !^
vO oo
S-^  fED hd
to  cn
5
tO M  
O  O
0 > 
>  >  
M  M  I I 
C/3 C/3
X  X




M  I-* 







O  xO 00
o  o  o  
Z  C/3 C/3
M X * !  
X  * ! 1-1 




CO Co Co 
ox cn 
o  o  o  
C/3 M U  
X  O  M 
** M M
11 *-rl
3 ^ 2X  ii M

































' ' N S
* *












to I-* o  
o  o  o  
C /3  Q  >
c > >> I I 
I I  C /3 C/3
O  X  X
>  X
> AJs
>  C /3 C /3*: x 
*  *  




to  to  
xO 00 
o  o  
Z  C/3
M X  
X  ►< 











to  to  to  
- j  ox cn 
o  o  o  
C/3 C /3  M
^ X O
I I M 
C f l C f l H  




cAO (AO U  w  cAO
C/3 C /3 t t )  
H< X  
►< X  
'I II C/3 C/3
* !  X
to  to
M  CO
o  o  






M hd cA° 0\o
t * " *>  X  
03 P
'm <M o\o cA°
to  to  





















tO M  





























M  2  
X  c jcAO K 
I cAO c o Y
H >
M  dP
2  m  
o  






M  M  M  O  
CO M  O  xO O O O O
M  <  H  
X  <*° M cAO
H •! M I












1610PRINTTAB(2,8)"Have You inserted disc?"
1620J%=GET
1630IF J%<>89 THEN1620 
1640CHAIN"GIL"
1650ENDPROC
Data Collecting Program for Diffusion and Electrophoresis Experiments
10REM A  D'Emanuele 
























260@%=10:PRINT" No. of Points ";0%
270@%=&20508:PRINT:PRINT" Corr. Coeff. ";g







390PRINTTAB(4,6)"What is the Power Supply Scale ?" 
400PRINTTAB(4,10)"(1) 0-25 mA"
410PRINTTAB(4,12)"(2) 0-2.5 mA" 











S.D. of Slope 
Intercept
S.D. of Intercept ";iii • m i
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510PRINTTAB(12,2)"Electrophoresis/Diffusion Cell Programs (210ml 
Cell)”
520PRINTTAB(11,3)"--------------------------------------------_______ i
530PRINTTAB(25,5)"Choose Type of Experiment”
540PRINTTAB(24,6)"--------------------------”
550PRINTTAB(4,10)"Keyboard Control of Power Supply at any Time. 
(Check PROCv) (1)"
560PRINTTAB(4,13)”Power Supply Turned On and Off at Fixed Times.
(2) ”
570PRINTTAB(4,16)”Feedback Control (Resulting in Fixed Flux from 
a Given Start Time). (3)"
580PRINTTAB(4,19)”Fixed Release Profile (Set PROCv, run program 
again) (4)”





640PRINTTAB(2,5)"What is the Title?”
650INPUTTAB(2,7)T$
660IFT$=” "THEN650
670PRINTTAB(2,9)"Enter Sample Interval (s)”
680INPUTTAB(2,ll)o%
690IFo%=0THEN680












































1130PRINTTAB(4,8)"Read Current and Voltage (3)" 
1140PRINTTAB(4,10)"Read Cone, and Absorbance (4)" 
1150PRINTTAB(4,12)"Read Drug Delivery Rate (5)" 













1290PRINTTAB(4,4)"Number of Points Available = ";349-Y% 
1300PRINTTAB(4,6)"How Many Points Do You Want ?" 
1310INPUTTAB(4,8)Z%
1320IFZ%<10RZ%>(349-Y%)THEN1600
1330PRINTTAB(4,10)"What Time Intervals Do You Want Samples 















































































































































































































3310PRINTTAB(2,3)"Time = n;INT(TIME/100);" Secs)” 
3320PRINTTAB(2,5)"( ";TIME/360000;" Hours)" 
3330@%=&0002010A
3340PRINTTAB(2,8)”Current = ";?&FDFB/1;" mA" 
3350PRINTTAB(2,10)" Voltage = ";?&FDFC/10;" V" 










3460PRINTTAB(2,3)”Time = ";INT(TIME/100);" Secs)" 
3470PRINTTAB(2,5)"( ";TIME/360000;" Hours)" 
3480@%=&0001040A
3490PRINTTAB(2,8)"Concentration = "ap 
3500@%=&0002040A
3510PRINTTAB(2,10)" Absorbance = ";ao 
































3830PRINTTAB(2,5)"What is the title of worksheet"
3840INPUTTAB(2,7)T$
3850IFT$=" "THEN3840
3860PRINTTAB(2,10)"What is worksheet name"
3870INPUTTAB(2,12)bo$
3880IFbo$=""THEN3870






















4110INPUTTAB(2,8)"What DDR do you require for Steady State Line 
(mg/h) ? "s
4120INPUTTAB(2,12)"What Time Do You Wish to Start Feedback Control
(Hours) ? "as
4130as=as*360000












4240PRINTTAB(2,3)"Time = f';INT(TIME/100);" Secs)"
4250PRINTTAB(2,5)"( ";TIME/360000;" Hours)"
4260@%=&0001040A
4270PRINTTAB(2,8)"Slope = ";be;" (%w/v/s)"
4280@%=&0002040A
4290PRINTTAB(2,10)"DDR = ";ae;" mg/h"
4300PRINTTAB(2,12)"r = ";bg
4310PRINTTAB(2,15)"(Data Based on Ten Samples Over The Last 30 
Minutes)"





















4530INPUTTAB(2,9)"What Time Do you want the Power Supply Turned On 
(Hours) ? "as



























4790PRINTTAB(18,5)"Current = ";?&FDFB/1;" mA"
4800GOTO 4820
4810PRINTTAB(18,5)" "






4880PRINTTAB(2,10)"Polarity is Currently Driving Flux, Do 





4930PRINTTAB(2,10)"Polarity is Currently Opposing Flux, 







5000REM ALTER ROUTINE FOR RELEASE PROFILE
5010REM GOTO ENDPROC (5450) IF NO PROFILE
5020REM ALTER a%,C%,P%,w%,?&FDF9













































5470REM DELETE 5480 TO RUN ROUTINE 
5480GOTO5550









Controlled Transport of Propranolol HC1 through Crosslinked PHEMA 
Films Using Constant Current Electrophoresis
The following pages contain examples of the concentration 
against time profiles obtained from electrophoresis experiments. The 
figures are screen dumps from the statistics package which was used 
to analyse the data (INSTAT). The examples demonstrate the effect 
of applying a constant current for a period of four hours. In all the 








Applied Current of 0.40 mA between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.090 cm.
Initial Donor Propranolol HC1 Concentration = 14.5 mM. 
Temperature = 25°C.







Applied Current of 0.90 mA between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.091 cm.
Initial Donor Propranolol HC1 Concentration = 14.7 mM. 
Temperature = 25°C.







Applied Current of 1.40 mA  between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.101 cm.
Initial Donor Propranolol HC1 Concentration = 14.7 mM. 
Temperature = 25°C.
Buffer Ionic Strength = 0.039.
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-18
e 18 28 38 t8 58
0 CONC
E x p e rim e n ta l C o n d it io n s  :
A p p lie d  C u r re n t  o f  1.90 mA b e tw e e n  35 and 39 H ou rs . 
1%C PHEMA F ilm  T h ic k n e s s  = 0.105 cm.
I n i t i a l  D o n o r P ro p ra n o lo l HC1 C o n c e n tra t io n  = 14.9 mM. 
T e m p e ra tu re  = 25°C.






E x p e rim e n ta l C o n d it io n s  :
A p p lie d  C u r re n t o f  2.30 mA b e tw e e n  35 and  39 H ou rs . 
1%C PHEMA F ilm  T h ic k n e s s  = 0.107 cm.
I n i t i a l  D o n o r P ro p ra n o lo l HC1 C o n c e n tra t io n  = 14.9 mM. 
T e m p e ra tu re  = 25°C.
B u f fe r  Io n ic  S tre n g th  = 0.039.
- 260 -
351
e le 20 30
° CONC
E x p e r im e n ta l C o n d it io n s  :
A p p lie d  C u r re n t  o f  1.90 mA be tw e e n  28 and 32 H o u rs . 
0.1%C PHEMA F ilm  T h ic k n e s s  = 0.110 cm.
I n i t i a l  D o n o r P ro p ra n o lo l HC1 C o n c e n tra t io n  = 14.7 mM. 
T e m p e ra tu re  = 25°C.






Applied Current of 1.90 mA between 70 and 74 Hours. 
7%C PHEMA Film Thickness = 0.092 cm.
Initial Donor Propranolol HC1 Concentration = 14.7 mM. 
Temperature = 25°C.





5 15 25 35
0 CONC
Experimental Conditions :
Applied Current of 2.40 mA  between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.089 cm.
Initial Donor Propranolol HC1 Concentration = 14.7 mM. 
Temperature = 25°C.





Applied Current of 2.40 mA between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.104 cm.
Initial Donor Propranolol HC1 Concentration = 14.4 mM. 
Temperature = 25°C.




0 le 20 30 V0 50
0 CONC
Experimental Conditions :
Applied Current of 1.00 mA between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.097 cm.
Initial Donor Propranolol HC1 Concentration = 1.46 mM. 
Temperature = 25°C.








Applied Current of 1.00 mA between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.096 cm.
Initial Donor Propranolol HC1 Concentration = 14.7 mM. 
Temperature = 25°C.





5 15 25 35 5^
° CONC
Experimental Conditions :
Applied Current of 1.00 mA between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.097 cm.
Initial Donor Propranolol HC1 Concentration = 36.9 mM. 
Temperature = 25°C.






Applied Current of 1.90 mA between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.090 cm.
Initial Donor Propranolol HC1 Concentration = 14.6 mM. 
Temperature = 31°C.





Applied Current of 1.90 mA between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.094 cm.
Initial Donor Propranolol HC1 Concentration = 14.7 mM. 
Temperature = 37°C.





10 30 50 70
n CONC
Experimental Conditions :
Applied Current of 0.90 mA  between 35 and 39 Hours. 
1%C PHEMA Film Thickness = 0.099 cm.
Initial Donor Propranolol HC1 Concentration = 14.9 mM. 
Temperature = 37°C.
Buffer Ionic Strength = 0.039.
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APPENDIX 5
Nuclear Magnetic Resonance Analysis of the Complex between SDDS and 
Propranolol HC1
XH NMR spectroscopy at an operating temperature of 25°C (270MHz, 
JEOL JNM 270 FT NMR Spectrometer) was used to characterise 
propranolol HC1 (D20), SDDS (D20), and solid ion-pair (CDC13). 
Analysis of the integrals for the solid ion-pair revealed a complex 
of 1:1 ratio. The following figures show respectively the interpreted 
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